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Abstract 
 
Respiratory (Lung and head and neck) cancers contribute highly to the burden of cancer-
related deaths. Taxanes are microtubule-targeting agents used to treat a variety of human 
cancers. Paclitaxel and Docetaxel represent the most prominent members of the taxane 
family, demonstrating significant activity mainly as part of complex chemotherapeutic 
regimens. Mitotic spindle formation and spindle checkpoint are critical for the 
maintenance of cell division and chromosome segregation. Many of mitotic spindle 
associated members, including AURKA, AURKB, AURKC, CKAP5, DLGAP5, KIF11, TPX2, 
TUBB, TUBB3, and TTK are implicated in several malignancies including lung cancer due to 
their frequent deregulation and may be associated with response to taxanes based therapy 
in NSCLC.  
The aims of this project were to  
1) Explore the association between the expression profiles of ten genes listed above and 
clinicopathological characteristics in human non-small cell lung carcinoma and  
2) Investigate the potential of some of these genes to predict response to taxane involving 
regimens in lung and head and neck cancerous cells.  
qPCR-based RNA gene expression profiles of 132 non-small cell lung carcinomas (NSCLC) 
and 44 adjacent normal tissues were generated and Cox proportional hazard regression 
was used to examine associations. Associations between mitotic spindle gene expression 
and resistance to both taxanes were established in 23 cancer cell lines of respiratory tract 
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origin. AURKA mRNA expression (Hazard Ratio (HR)= 1.81; 95%CI 1.16-2.84, P= 0.009) was 
the only molecular independent predictor of poor prognosis in patients with NSCLC. Poor 
prognosis of those patients with high AURKA expression suggests they may benefit from 
combined therapy with AURKA inhibitors. Furthermore, in LUDLU1, SKLU1 and SK-MES1 
cell lines, shRNA driven AURKA down-regulation sensitized cells to docetaxel. Inhibition of 
Aurora A kinase activity using the selective inhibitor alisertib augmented docetaxel 
efficiency in the above mentioned cell lines.  
AURKB overexpression in NSCLC cell lines strongly correlated with resistance to both 
docetaxel (p=0.0016) and paclitaxel (p=0.0096). Conversely, AURKB knock down derivatives 
of two cell lines consistently showed a dose-dependent association between AURKB mRNA 
expression and resistance to paclitaxel. Inhibition of Aurora B activity by barasertib also 
demonstrated a strong dose-dependent efficiency in triggering paclitaxel resistance in all 
the cell lines tested.  
This study clearly demonstrated that AURKA mRNA over-expression could prognosticate 
the clinical outcome in NSCLC patients suggesting that patients bearing tumours with high 
AURKA expression may benefit from combined use of AURKA inhibitors. The present study 
has also clearly uncovered a role for AURKB in the response of NSCLC cells to paclitaxel and 
provided unique evidence for a dose-dependent association. Given the large extent of 
AURKB deregulation in NSCLC, these findings suggest that assessing the levels of AURKB 
protein in surgical samples could become a determinant in the clinical decision tree for 
managing patients and have potential for development as a predictive biomarker. 
 
 
 
  11 
 
Abbreviation table 
AAH Atypical Adenomatous Hyperplasias 
ABC ATP-Binding Cassette 
AdC Adenocarcinoma 
AIS Adenocarcinoma In Situ 
APC Anaphase-Promoting Complex 
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CT Conversion Conversion of unmethylated Cytosine to Thymine  
DLGAP5 Disks Large-Associated Protein 5 
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EBUS Endobronchial Ultrasound 
Eg5 Kinesin-related motor protein 
EGFR Epidermal Growth Factor Receptor 
ESCC Esophageal Squamous cell carcinoma  
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G2 phase Gap two phase 
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HURP Hepatoma Up Regulated Protein 
INCENP Inner Centromere Protein 
KRAS Kirsten Rat Sarcoma viral gene 
LCNEC Large Cell Neuroendocrine cancer 
LCT Lung Carcinoid Tumours 
LD-CT Low-Dose Computed Tomography 
M phase Mitotic phase 
mC methylated Cytosine 
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MDR Multi-Drug Resistance 
MIA Minimally Invasive Adenocarcinoma 
MSC Mitotic Spindle Checkpoint 
MTR Malignant Transformation Rate 
MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide 
NLST National Lung Screening Trial 
NSCLC Non-Small Cell Lung Carcinoma 
OED Oral Epithelial Dysplasia 
OPSCC Oropharyngeal Squamous Cell Carcinoma 
OS Overall Survival 
PFS Progression-Free Survival 
PPi Pyrophosphate 
PSQ Pyrosequencing 
qMSP Quantitative Methylation Specific PCR 
RCC Renal Cell Carcinoma 
RFS Relapse-Free Survival 
RQ Relative Quantity 
RTCs Respiratory Tract Cancers 
S phase DNA synthesis phase 
SABR Stereotactic Ablative Body Radiotherapy 
SAC Spindle Assembly Checkpoint 
SBRT Stereotactic Body Radiation Therapy 
shRNA short hairpin RNA 
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TACC3 Transforming Acidic Coiled-Coil-containing protein 3 
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TPX2 Targeting Protein for Xenopus kinesin-like protein 2 
TUBB Tubulin Beta class I 
TUBB3 Tubulin Beta class III 
VAST Video Assisted Thoracoscopic Surgery 
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Glossary table 
 
Aneuploidy 
Aneuploidy 
An abnormal number of chromosomes per cell, differing from the 
normal karyotype (somatic number 2n, or n in gametes) by loss or gain 
of pairs of chromosomes, whole chromosomes or chromosome 
fragments. Chromosome missegregation in mitosis or meiosis can 
produce aneuploid cells or organisms respectively (Extracted from 
www.nature.com). 
 
Cancer 
incidence rate 
The number of new cancers of a specific site/type occurring in a 
specified population during a year, usually expressed as the number of 
cancers per 100,000 population at risk. That is, 
Incidence rate = (New cancers / Population) × 100,000. 
 (Extracted from surveillance.cancer.gov). 
 
Cancer 
mortality rate  
The number of deaths, with cancer as the underlying cause of death, 
occurring in a specified population during a year. Cancer mortality is 
usually expressed as the number of deaths due to cancer per 100,000 
population. That is, 
Mortality Rate = (Cancer Deaths / Population) × 100,000. 
(Extracted from surveillance.cancer.gov). 
 
Centrosome The centrosome is the major microtubule-organising centre of the cell 
and consists of two centrioles surrounded by pericentriolar material. 
The centrosome is duplicated during the cell cycle and in mitosis the 
two centrosomes form the poles of the mitotic spindle, which 
segregates the chromosomes into two daughter cells (Extracted from 
www.nature.com). 
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DNA 
methylation 
The covalent addition of methyl groups to DNA bases, typically the 
cytosine of CpG dinucleotides. It is catalyzed by methyltransferase 
enzymes using a S-adenosyl methionine donor and can lead to mitotic 
propagation of the modified sequence with consequences for the 
binding of regulatory proteins such as transcription factors (Extracted 
from www.nature.com). 
Extra-capsular 
spread 
Extension of the tumour through the capsule of the lymph node into 
the perinodal tissues (Extracted from (1)). 
 
Hazard Ratio A measure of how often a particular event happens in one group 
compared to how often it happens in another group, over time. In 
cancer research, hazard ratios are often used in clinical trials to 
measure survival at any point in time in a group of patients who have 
been given a specific treatment compared to a control group given 
another treatment or a placebo. A hazard ratio of one means that 
there is no difference in survival between the two groups. A hazard 
ratio of greater than one or less than one means that survival was 
better in one of the groups (Extracted from www.cancer.gov). 
 
Kinetochore Kinetochores are large protein complexes that assemble at the 
centromere of a chromosome, and function to connect the 
chromosome to microtubules in the mitotic spindle (Extracted from 
www.nature.com). 
 
Microtubule Microtubules are cylindrical polymers composed of alpha and beta 
tubulin. They are a major component of the cytoskeleton and mediate 
crucial cellular functions including formation of the mitotic spindle that 
segregates chromosomes during cell division and intracellular 
trafficking. (Extracted from www.nature.com). 
 
Mitotic spindle The mitotic spindle is the microtubule-based bipolar structure that 
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segregates the chromosomes in mitosis. The poles of the mitotic 
spindle are made up of centrosomes and the chromosomes are lined 
up at the spindle equator to ensure their correct bi-orientation and 
segregation (Extracted from www.nature.com). 
 
Multivariate 
analysis 
Exploring the association between one outcome variable (referred to 
as the dependent variable) and one or more predictor variables 
(referred to as independent variables). Multivariate techniques 
concern the statistical analysis of relationships among a set of 
variables, particularly when at least three variables are involved. 
Regression analysis one example of a multivariable technique 
(Extracted from practice.sph.umich.edu). 
 
 
Overall survival The percentage of people in a study or treatment group who are still 
alive for a certain period of time after they were diagnosed with or 
started treatment for a disease, such as cancer. The overall survival 
rate is often stated as a five-year survival rate, which is the percentage 
of people in a study or treatment group who are alive five years after 
their diagnosis or the start of treatment. Also called survival rate 
(Extracted from surveillance.cancer.gov). 
 
Phase I trials Small dose-finding studies designed to rapidly identify the optimal dose 
of a new agent, which is administered on one or more dosing schedules 
that were shown to be effective in preclinical models of human cancer 
(Extracted from (2)). 
 
Phase II trials The primary objective of phase II trials is to define the spectrum of 
antitumor activity for a new agent administered at the optimal dose 
and schedule from phase I trials (Extracted from (2)). 
Phase III trials Designed to determine efficacy or clinical benefit. They are typically 
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large cooperative group trials that randomize patients to new regimens 
versus standard therapy (Extracted from (2)).  
 
Polyploidy The presence of more than two homologous sets of chromosomes in a 
cell or organism. It occurs as a result of genome duplication due to 
nondisjunction during meiosis (Extracted from www.nature.com). 
 
Pyrosequencing Pyrosequencing is a sequencing-by-synthesis method that 
quantitatively monitors the real-time incorporation of nucleotides 
through the enzymatic conversion of released pyrophosphate into a 
proportional light signal (Extracted from (3)). 
 
Univariate 
analysis 
Exploring one variable at a time in a data set. It investigates each 
variable in a data set separately and looks at the range of values, as 
well as the central tendency of the values. For this type of analysis, 
researchers look at the range, mean, median and mode of each 
variable as well as describe any apparent patterns (Extracted from 
practice.sph.umich.edu). 
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Chapter 1 - Introduction 
 
Respiratory Tract Cancers (RTCs), which include malignancies of lung, upper respiratory 
tract and head/neck affect almost 2.5 million people world-wide and represent the first 
cause of cancer-death (Figure 1) (4). 
 
Figure 1: Incidence and mortality rates for the most frequently diagnosed malignancies for 
both sexes worldwide/ 2012. Respiratory Tract Cancers are the most frequent cancer types 
with 2,511,029 cases. This bar chart has been plotted based on the data obtained on 15th May 
2015from the GLOBCAN 2012 website.  
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The proportion of all reported RTCs cases are approximately 18% worldwide and 15% 
within the UK among diagnosed cancer cases. Overall incidence of RTCs in men is two times 
higher than that in women, whereas the difference between the genders in the UK is less. 
The mortality due to RTCs represents quarter of all reported cancer deaths. The proportion 
of men who die from RTCs is twice as high as that of women across the world although this 
difference is smaller in both British genders (Table 1). 
Table 1: (%) Estimated incidence & mortality of respiratory tract cancers in comparison of all 
cancers excluding non-melanoma skin cancer. The data obtained from GLOBCAN 2012 and 
NCRI 2013/4 data base.  
  
 
WORLDWIDE 
 
UNITED KINGDOM 
 Cancer 
 
Incidence  
 
Mortality  
 
Incidence 
 
Mortality 
 Number (%)  Number (%)  Number (%)  Number (%) 
Both sexes 
           
  
 Lip, oral cavity 
 
300373 2.1 
 
145353 1.8 
 
4986 1.5 
 
1296 0.8 
 Nasopharynx 
 
86691 0.6 
 
50831 0.6 
 
309 0.1 
 
117 0.1 
 Other pharynx 
 
142387 1 
 
96105 1.2 
 
2200 0.7 
 
846 0.5 
 Larynx 
 
156877 1.1 
 
83376 1 
 
2201 0.7 
 
765 0.5 
 Lung 
 
1824701 13 
 
1589925 19.4 
 
40382 12.3 
 
35581 22.5 
Women 
           
  
 Lip, oral cavity 
 
101398 1.5 
 
47413 1.3 
 
1848 1.1 
 
497 0.7 
 Nasopharynx 
 
25795 0.4 
 
15075 0.4 
 
94 0.1 
 
37 0 
 Other pharynx 
 
27256 0.4 
 
18507 0.5 
 
553 0.3 
 
229 0.3 
 Larynx 
 
18775 0.3 
 
10115 0.3 
 
390 0.2 
 
142 0.2 
 Lung 
 
583100 8.8 
 
491223 13.8 
 
18537 11.4 
 
16186 21.6 
Men 
           
  
 Lip, oral cavity 
 
198975 2.7 
 
97940 2.1 
 
3138 1.9 
 
799 1 
 Nasopharynx 
 
60896 0.8 
 
35756 0.8 
 
215 0.1 
 
80 0.1 
 Other pharynx 
 
115131 1.6 
 
77598 1.7 
 
1647 1 
 
617 0.7 
 Larynx 
 
138102 1.9 
 
73261 1.6 
 
1811 1.1 
 
623 0.8 
 Lung  1241601 16.7  1098702 23.6  21845 13.2  19395 23.4 
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1.1 Lung cancer 
Lung malignancies represent a serious medical problem worldwide. According to the 
GLOBCAN 2012 database, Lung cancer, which is almost close to colorectum cancer 
incidence, ranks as the second most common malignant disease after breast cancer in 
females and prostate cancer in males in the UK (Figure 1.1).  
 
 
 
Figure 1.1: Bar chart demonstrating the estimated incidence and mortality rates for both 
sexes in the UK. This chart has been plotted using data obtained on 15th May 2015 from 
GLOBCAN 2012 website. 
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1.1.1 Histological description 
Lung cancers include three main different histological types; Non-Small Cell Lung 
Carcinoma (NSCLC), accounting for over 85%, Small Cell Lung Carcinoma (SCLC), which 
accounts for less than 10-15%, and Lung Carcinoid Tumours (LCT) which represent fewer 
than 5% of lung cancers. NSCLC is subdivided into Squamous Cell lung Carcinoma (SqCLC), 
lung adenocarcinoma (LAdC) and large-cell lung carcinoma. LAdC is the most common 
histological subtype of NSCLC (~44%) followed by SqCLC (~20%) (csg.ncri.org.uk), (5).  
The lung is a complex organ, which is anatomically sectioned into central and peripheral 
airway compartments. As these compartments have entirely different histological 
structures, each one develops distinct histologic subtypes of NSCLC. Whereas SqCLC and 
SCLC widely emerge from the central airways, most if not all of adenocarcinomas emerges 
from the peripheral ones. In general, SqCLC and LAdC are the most common histologic 
subtypes of NSCLC (6). 
Recently, the formerly restricted term “bronchioloalveolar carcinoma (BAC)” has been 
reclassified into wider spectrum of subtypes e.g. adenocarcinoma in situ (AIS), minimally 
invasive adenocarcinoma (MIA), lepidic-predominant adenocarcinoma, major invasive 
adenocarcinoma with a lepidic component, and invasive mucinous adenocarcinoma (Figure 
1.2) (7). According this new classification, Adenocarcinoma is developed from preinvasive 
lesions, through minimally invasive adenocarcinoma (MIA), to invasiveness stage which 
could be either invasive adenocarcinoma or mucinous adenocarcinoma. Preinvasive lesions 
include AIS and atypical adenomatous hyperplasia. AIS is described as a localised small (≤3 
cm) adenocarcinoma which is mainly non-mucinous composing of pneumocytes and/or 
Clara cells but rarely to be mucinous AIS (6). MIA is known as a small, solitary 
adenocarcinoma (≤3 cm), with maximum dimension of invasion in any one focus measuring 
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≤5 mm expect lymphatics, blood vessels, or pleura. Similar to AIS, MIA is typically non-
mucinous, but rare cases of mucinous MIA occur (8) ,(9).  Instead of AIS or MIA, Lepidic-
predominant adenocarcinoma diagnosis is made if the invasiveness includes lymphatics, 
blood vessels or pleura, or if the tumour contains necrosis. Invasive adenocarcinomas are 
suspected when the invasiveness is more than 3 cm and measuring higher than 5 mm 
dimension in at least one focus where the invasive predominant components/lesions are 
included. Invasive adenocarcinomas accounts for higher than 70% to 90% of surgically 
resected LAdC due to the rarity of AIS and MIA. It has been recently classified as 
predominant pattern and subtyped with lepidic, acinar, papillary, solid patterns, and newly 
added histologic subtype “micropapillary”. Variants of invasive adenocarcinoma include 
colloid, fetal, enteric and invasive mucinous adenocarcinoma, which previously categorised 
as mucinous BAC. Invasive mucinous adenocarcinoma shows a high level of KRAS mutation 
but lack of EGFR mutation (7).  
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Figure 1.2: (A) Non-mucinous AIS (B) Mucinous AIS (C) Nonmucinous minimally invasive 
adenocarcinoma (D) Invasive mucinous adenocarcinoma. Adapted from (6), (7), (10). 
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Squamous cell carcinomas are thought to arise after a series of sequential events. Mucosal 
pathological changes in the central lung compartments, which may give rise to invasive 
squamous cell carcinoma, progress from normal to carcinoma in situ (CIS), through 
metaplasia for lung and dysplastic steps of increasing severity (Figure 1.3) (11). In the 
classification of preinvasive lesions, squamous dysplasia is the counterpart to AAH, which 
proliferate mildly to moderately, and squamous cell CIS the counterpart to AIS (Figure 1.4: 
A- C) (6). 
SCLC is microscopically defined as small sized and round-to-fusiform shaped tumour cells. 
Despite of the small size of its cancerous cells, it is the most aggressive form of lung 
malignancies due high mitotic rate. The most prominent morphological diagnostic 
characteristic of SCLC is the presence of neuroendocrine morphology (Figure 1.4.A) (12) , 
(13). 
Finally, the rest of lung carcinomas specified as neuroendocrine tumours are lung carcinoid 
tumours (Figure 1.4.B) large cell neuroendocrine cancer (LCNEC) (Figure 1.4.C).  Lung 
carcinoid malignancies are ranged from the low-grade typical carcinoid to intermediate-
grade atypical carcinoid, while LCNEC represents the high-grade large cell neuroendocrine 
cancer (14). 
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Figure 1.3: Histological changes through the pathogenesis of lung squamous cell carcinoma. Adapted from (13). 
 
 
Figure 1.4: Histological preparations of representative examples of (A) Small-cell carcinoma, (B) Carcinoid tumour, (C) Large-cell 
neuroendocrine carcinoma. Adapted from (15). 
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1.1.2 Preneoplastic precursors 
As with other malignancies, lung cancers arise through a series of preneoplastic changes 
constituting a multistage pathogenesis of these carcinomas. The accumulative precursors’ 
lesions are crucial to develop respiratory tract malignancies including lung cancer. Long-
term observations elucidate that not all lung tumours pursue a particular histological trend, 
and it is undoubtedly difficult to predict the clinical course particularly for early lesions. 
Such preinvasive lesions may offer opportunities for predicting risk of cancer progression 
(16). 
1.1.2.1 Squamous preneoplasia: 
Epithelial dysplastic squamous lesions of central lung airway vary in degree from mild to 
severe (17). Nonetheless, a continuous histologic irregular alteration is the feature of the 
dysplastic lesions that may result in some overlapping between stages. Less histological 
irregularity is shown in mild squamous dysplasia in comparison of that of moderate 
dysplasia or even for that of severe dysplasia (18). CIS demonstrate severe cytological 
aberrations which is disorganised histologically, it has, however, non-damaged basement 
membrane with free invasion stroma (11), (19). It is also of note that the molecular events 
involved in the squamous carcinogenesis present an accumulation of genetic & epigenetic 
changes such as loss of heterozygosity on the same hotspots (of the 3p, 9p & 17p 
chromosomes), p53 mutations, p16 methylation and many more (11). 
1.1.2.2 Adenomatous preneoplasia 
The atypical adenomatous hyperplasias (AAH) feature has been represented as the main 
precursor lesion of adenocarcinoma for long term beside Clara cells or type 2 pneumocytes 
(20). However, recent evidence has generated other categories being determine as 
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additional pre-invasive lesions (adenocarcinoma in situ/AIS, minimally invasive 
adenocarcinoma/MIA, lepidic predominant growth pat-tern, and invasive adenocarcinomas 
or predominant non-lepidic growth (6). However, the pathogenesis of many peripheral 
adenocarcinomas remains to be fully understood (21). The genetic abnormalities arising 
adenocarcinoma are categorised into two pathways depending on the smoking status of 
adenocarcinomas patients. While the main genetic aberration pathway in non-smokers is 
EGFR mutation and ⁄ or up-regulation, KRAS mutation, p16 methylation and p53 
inactivation are the main abnormalities engaged in progressing the pre-invasive lesions in 
smoking NSCLC patients (20). 
1.1.3 Epidemiology 
Lung cancer is regarded as an age related disease. More than 50% of individuals diagnosed 
with lung cancer occur over the age of 65 years and about one third of all cases are 
diagnosed in those aged (70-79) (22), (23). By 2030, it is expected that two thirds of total 
lung cancer patients will be age 65 years and over (24). Moreover, there is a dramatic 
increase in mortality rates of lung cancer cases in elderly females in comparison of that in 
elderly men, which may lag behind improvement observed in younger NSCLC patients (25). 
Regarding the patient gender, global rates of Incidence and mortality are half in women in 
comparison of those in men. However, these rates of lung carcinoma for British women are 
only lower to those for British men respectively (Table 1). 
1.1.3.1 Genetic predisposition 
Lung cancer is a typical example of disease evolving through the interaction of environment 
on the human genetic background. Over the last decade there have been comprehensive 
genome-wide association studies (GWAS) in an effort to identify genetic polymorphisms 
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that are potentially associated with higher risk. GWAS on lung cancer were carried out 
utilising case-control designs that included thousands of recruits across Europe. Conclusive 
evidence was provided on the association of SNPs in a region at 15q25 to lung cancer. 
However, their contribution to the overall risk estimation was 14% of 2,513 lung cancer 
cases irrespective of smoking status (26), (27). Additional GWAS analyses have also 
confirmed the strong link between genetic variants at 15q and Respiratory Tract Cancers 
(RTCs) even when adjusted for smoking (28), (29). The five variants reported in the latter 
study have close proximity to genes previously shown to be related to lung cancer 
development (29). The most recent comprehensive GWAS has indicated etiological 
heterogeneity to lung malignancy development affected by genetic variation, in particular 
in squamous cell lung carcinoma (30). Despite the existing information originating from 
very high powered studies involving multinational cohorts, the identified polymorphisms 
have not been yet successfully incorporated into lung cancer risk models. 
1.1.3.2 Lifestyle factors 
The most important known risk factor that causes RTCs is tobacco. Although most lung 
malignancies are diagnosed in former or current smokers, patients diagnosed with NSCLC 
who are non-smokers account for 10%-25% of all cases. Among ethnic groups of patients, 
there is remarkable variation of non-smokers distribution, with higher proportion in 
women compared with men and in Asian patients as opposed to Caucasians (Samet 2009 , 
Scagliotti 2009 ). Approximately two third of Asian women diagnosed with lung 
malignancies are never-smokers (31). This variation may result from gender and geographic 
diversity in smoking environments [WHO Report on the Global Tobacco Epidemic, 2008]. 
Whilst smoking proportions in few developed countries decrease, the proportion of NSCLC 
patients who are non-smokers is probably to increase in such countries (32). The reason 
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why those non-smokers are diagnosed with NSCLC remains to be fully understood. 
However, the environmental factors such as passive smoking, genetic factors, and history 
of lung illness could be contributors (33). 
In many respects, genetic instability features of NSCLC in never-smokers are different from 
those in smokers. For instance, mutations of epidermal growth factor receptor (EGFR) 
seem to be two fold higher in never-smokers than that in smokers In contrast, KRAS 
mutations are 4 fold more prevalent in smokers than in never-smoked NCLC patients (34). 
These findings are comparable with what has been proved in previous study (35). 
Regardless of their treatment setting or genetic variation, Never-smoked NSCLC patients 
have predominantly higher survival rates than smokers (36), (37).  Taken together, these 
reported data may suggest that the smoking status could confer prognostic and predict 
values for NCLC treatment.   
The differences in socio-economic status among lung patients groups during the period 
from diagnosis to therapy are important to determine systematically. The socio-economic 
inequalities, if existence could be useful to inform the development interventions to 
minimise the diagnostic-to- treatment time intervals, eventually reducing inequalities in 
survival rate (38). Malnutrition is an additional risk factor that significantly reduces survival 
among cancer patient after surgery (39), (40). 
1.1.4 Diagnosis 
The main reason behind the high mortality of lung cancer, (4) can be attributed to the fact 
that less than 25% of the lung malignancies are diagnosed at early stages (41). This 
appalling prognosis for lung malignancies warranted the improvement of lung cancer 
screening by under taking many clinical trials that would decrease the mortality rates of 
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lung cancer by diagnosing this malignancy at early stages, long before it would reach 
advance stage or become incurable. The early attempts of reducing lung cancer deaths 
employing chest radiographs were carried out since 1950s. This technique resulted in an 
augmented diagnosis of lung carcinoma at earlier stages in comparison of control cohorts. 
However, reducing the mortality of lung cancer was not reached the desired aim (42), (43). 
A higher sensitivity imaging for lung cancer diagnosis had become available with 
developing the volumetric computed tomography (CT) (Figure 1.5). CT allows measuring 
pulmonary nodules with diameter less than 3mm with high accuracy (44). Screening with 
low-dose CT (LD-CT) reduces lung cancer mortality by 20% in the national lung screening 
trial (NLST) study (41). Endobronchial ultrasound (EBUS) probes were initially developed to 
assess the invasion depth of malignancies in the bronchi and also for lymph node screening 
in lung cancer patients.  New techniques of EBUS, EBUS-TBNA (Figure 1.5) and EUS-FNA, as 
well as video assisted thoracoscopic surgery (VAST) were introduced for staging NSCLC with 
higher than 84% sensitivity for malignancy (45) (46), (47). 
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Figure 1.5: (A) Chest CT demonstrates Right middle lobe (RML) mass diagnosed as lung adenocarcinoma. (B) Representative case of EBUS-TBNA, (C) 
Histological diagnosis. The figures were adapted from (45). 
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1.1.5 Therapy 
1.1.5.1 Surgery  
The outcomes of surgical therapy applied on lung cancer patients have been improved by 
early diagnosis and accurate surgical procedures. However, patients with advanced lung 
cancer encounter recurrence, even postoperative treatment. Moreover, about 70% of 
patients diagnosed with NSCLC have unresectable advanced cancer (48), (49). Recently, it 
has been strongly approved that the same short term surgical outcome could be obtained 
by either thoracoscopic lobectomy or segmentectomy, therefore thoracoscopic 
segmentectomy is the choice to minimise the postoperative respiratory malfunction (50). 
1.1.5.2 Chemotherapy 
Many chemotherapeutic schemes are utilised in NSCLC treatment either as preoperative 
(neoadjuvant) or post-operative (adjuvant) regimens. Whether to apply neoadjuvant or 
adjuvant treatment in cancer therapeutic setting remains a debatable topic. However, 
postoperative chemotherapy is still the regimen of choice in NSCLC treatment. (51). 
Chemotherapy is also classified as first-line (initial) or second line (subsequent, if first line 
fails). If both these lines have not improved the outcome, the third line therapy would be 
the choice. The most commonly used chemotherapeutic agents in aforementioned NSCLC 
therapeutic regimes are organometalics, such as cisplatin, carboplatin and oxaliplatin (52), 
and anti-mitotics, for instance paclitaxel, docetaxel, and vinorelbine (53) as well as 
antimetabolites like pemetrexed (54) (Table 1.1). 
Recent advances in targeted therapies for lung cancer have witnessed discovering new 
generations of drugs used for NSCLC treatment by targeting the epidermal growth factor
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 Table 1.1  : The most commonly used chemotherapeutic agents in NSCLC therapy 
 
 
 Agent Target Molecular mechanism Reference  
 Organometalics     
 Cisplatin, 
Carboplatin &  
Oxaliplatin 
Target DNA producing intrastrand 
cross-links with the purine bases. 
Interfering with DNA 
repair mechanisms, 
causing DNA damage, 
and inducing apoptosis. 
(52) 
 Antimitotics     
  Vinca alkaloids 
(Vinorelbine) 
Binds to Beta-tubulin of 
microtubules disrupting their 
interactions resulting in 
microtubule depolymerisation. 
Mitotic arrest and 
apoptosis induction by 
bcl-2 phosphorylation 
and the elevations of p53 
and p21.  
(55) 
 Taxanes  
(Paclitaxel & 
Docetaxel) 
Stabilise the microtubules 
resulting in blockage of cell 
mitosis and induces apoptotic and 
non-apoptotic cell death. 
Apoptosis induction by 
activating mitotic spindle 
checkpoint. 
(56) 
 
Antimetabolites 
    
 Pemetrexed & 
Methotrixate  
Deactivate folate-dependent 
enzymes required for nucleotide 
synthesis during DNA replication. 
Cause DNA damage, 
arresting cell cycle at S-
phase, and inducing 
caspase- dependent and 
independent apoptosis. 
(57) 
 Gemcitabine  Targets of ribonucleotide 
reductase (RNR) blocking DNA 
replication and repair. 
Induces apoptosis via 
replacing cytidine, during 
DNA replication and then 
arrests cancerous cell 
growth. 
(58) 
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 receptor (EGFR) pathways using small molecule tyrosine kinase inhibitors (EGFR-TKIs) and 
anti-EGFR monoclonal antibodies. They have evolved from single receptor 1st-generation 
inhibitors, such as Erlotinib (59)and Gefitinib (60), in random population of patients to 
biomarker-driven clinical trials of more powerful 2nd and 3rd- generation irreversible 
multi-targeted EGFR-TKIs, e.g. Afatinib (61) and AZ9291 respectively, as well as  anti-EGFR 
monoclonal antibodies (62). There are about 11 clinical trials recruiting in the UK 
administrating taxanes either as a monotherapy or in combination with other 
chemotherapeutic agents [UK clinical trials].   
1.1.5.3 Radiotherapy 
Radiotherapy can be given with the aim of curing cancer or preventing recurrence post 
operation. Many approaches of having radiotherapy, such as conventional external 
radiotherapy, Continuous Hyper fractionated Accelerated Radiotherapy (CHART) and 
Stereotactic Body Radiation Therapy (SBRT), may vary from daily application to shorter 
interval. They can be used to treat NSCLC tumours as an alternative to surgery for patient 
who can’t have surgery, or where the tumour is in a difficult area to operate on (63). For 
instance, accumulative evidence has proved that Stereotactic ablative body radiotherapy 
(SABR), which is ordinarily applied for shorter interval than conventional external 
radiotherapy, can accomplish superior therapeutic outcomes (64). Therefore, SABR has 
been accepted as the standard radiotherapy for treating patients diagnosed with early 
stage NSCLC in few nations for example the UK and Netherlands (65). 
 1.1.6 Prognosis 
In the chemotherapeutic setting of NSCLC, the two main targets are to prolong survival 
duration and to reduce the symptoms related to the disease and therapy (66). As 
aforementioned, several therapeutic options are currently available for advanced NSCLC 
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including organometalics, antimitotics and antimetabolites (Table 1.1), in addition to 
molecular/targeted therapies (e.g. erlotinib and bevacizumab). However, the prognosis is 
still to be improved (67). Despite the advance in molecular medicine of lung cancer, 
survival in both early and advanced NSCLC stages is still low (68). Many areas of research, 
such as genetics , epigenetics (69), (70), proteomics (71), (72), circulating tumour cells (73), 
and others, have made significant progress in identifying genes, or their encoded proteins, 
as prognostic or predictive biomarkers for lung cancer therapy. However, the prognosis is 
still poor. Very recent phase III clinical study using pooled analysis of mature overall 
survival (OS) data, among 631 Asian patients with advanced NSCLC carried common EGFR 
mutations, has proved  that including afatinib in chemotherapeutic regimen improved OS 
(median 27.3 months) compared with afatinib-free chemotherapy (median 24.3 months). 
This is the real benefit of survival was not observe in previous clinical study with erlotinib 
or gefitinib (61). 
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1.2 Head and Neck Squamous Cell carcinoma (HNSCC) 
The majority of head and neck tumours, which constitute a heterogeneous group of 
malignancies, are squamous cell carcinomas. They include the malignancies of the lip, oral 
cavity, pharynx, and larynx which arise from the mucosal tissue of the upper aerodigestive 
tract. HNSCC develops over a long period of time, which may span 20 years or more (74), 
(4).  Among all cancer types reported over the world, excluding non-melanoma skin 
cancer, head and neck cancers represent the seventh most commonly occurring 
malignancy (incidence of 686,328 in 2012) and ranks as the seventh most common cause 
of cancer-related death (375665 cases in 2012). While in the UK, it has rank eight of 
incidence with (9516 cases in 2013/14), and the fifteenth most common cause of cancer 
related death with (3033 cases in 2013/14) (NCRI HNSCC CSG Annual Repeport 2013/2014) 
(Table 1 and Figure 1.1). On the other hand, Amit et al 2013 data shows that during the 
last decades the disease-specific survival DSS associated with surgical therapy has 
improved significantly from 69%, during the period between 1990 and 2000, to 81% at the 
period between 2001 and 2011 in the UK (75). Although OS is usually around 55% at 5 
years, the risk factors for HNSCC also predispose to lung cancer, COPD, heart disease, 
stroke etc. The mortality, therefore, in cured individuals remains high. In addition, the 
HNSCC cases were slightly higher in males than females, while worldwide, this difference 
in men is almost twice as high as in women which is related to risk factors such as smoking 
and the gender difference is reducing (Table 1). Taken together, these reported data may 
indicate the improvement in HNSCCs prognosis in the UK, of particular in women, in 
comparison of that around the globe.  
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1.2.1 Histological description 
Squamous carcinogenesis has very similar histopathological stages in both lung and HNSCC 
Carcinomas. It progresses from normal to carcinoma, through hyperplasia (instead of 
metaplasia for lung) and dysplastic steps of increasing severity (76) (Figure 1.6). 
1.2.1.1 Preneoplastic precursors 
HNSCC may require many years to develop from pre-neoplastic cells, evolving through 
accumulation of genetic and epigenetic changes in epithelial cells that result in histological 
abnormalities (77). This frequently occurs in so called field cancerization (Figure 1.7). This 
concept was first referred to more than 60 years ago in an HNSCC clinical study in which a 
correlation was established between non-visible molecular or cellular abnormalities and 
HNSCC recurrence (78). Pre-neoplastic cells expand in a distinct cancer field owing to the 
early genetic events. Some clones of these cells undergo subsequent genetic alterations 
that transform them to cancerous phenotype. A meta-analysis of 14 non-randomized 
studies reporting a malignant transformation rate (MTR) included 992 oral dysplasia 
patients and found an overall MTR for surgical resected oral dysplastic lesions to be 5.4% 
(341 patients) in comparison to 14.6% of 651 patients who didn’t undergo surgery (p = 
0.003) (79). Overall, the population of pre-neoplastic daughter cells, with or without 
histological abnormalities, represent the field cancerization (77). Cancer-related genetic 
alterations are the main characteristics of pre-neoplastic cells, particularly loss of 17p 
(p53), 9p (CDKN2A) and 3p, leading to either up or down regulation of the indicated 
tumour suppressor genes or oncogens (80). While these alterations occur in dysplasia and 
may reflect early carcinogenesis, alterations at chromosomes 8, 4q and 11q may associate 
with late stage of carcinogenesis (81). These molecular markers, in addition to p53 
inactivation, show that above one third of the HNSCC tumours are surrounded by 
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genetically altered mucosal epithelium, which has a macroscopically normal morphology, 
but histologically could be dysplastic fields (82). These fields are usually overlapped with 
the surgical margins during tumour resection and may remain in the patient causing the 
local recurrences or developing second primary tumours (80). 
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Figure 1.6: Histological changes through the pathogenesis of Head and Neck squamous cell carcinoma. The figures extracted from (76). 
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Figure 1.7: Field cancerization and local relapse. The figure was extracted from (80). 
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1.2.2 Epidemiology (risk factors) 
The traditional risk factors for HNSCC are tobacco smoking and excessive alcohol 
consumption, while infection with high-risk human papillomaviruses (HPV) is mostly related 
to non-smoking HNSCC patients with cancers at the oropharyngeal subsite (83), (84). 
1.2.2.1 Smoking and alcohol 
It is well known that smoking and excessive consumption of alcohol are the most common 
risk factors for head and neck malignancies. These factors act independently and, when 
combined, they exhibit a synergistic effect (85). In a study of 1303 head and neck cancer 
patients, however, a marked number (172) had never smoked or drunk (i.e. 13%) (86). In 
addition, the role of tobacco smoking and alcohol as risk factors is implicated in oral 
epithelial dysplasia (OED), which is a preneoplastic lesion that gives rise to HNSCC at a rate of 
12.1% (79). However, this perception of risk in OED remains to be fully understood. In a 
recent study, particular factors in non-smoking patients such as non-homogeneous 
appearance, large size and lesion position, specifically lateral tongue, may increase the rate 
of malignant transformation even in patients with mild or moderate dysplasia (87). In study 
on 291 Israeli patients with oral tongue squamous cell carcinoma, the outcome was similar 
regardless the risk factors (smoking and alcohol) (88). However, the oral cancer prognosis 
was worse in those younger patients under 40 and without risk factors. 
1.2.2.2 Human Papilloma Viruses (HPV) 
Human Papilloma Viruses (HPV) is an important risk factor in oropharyngeal squamous cell 
carcinoma (OPSCC). Decreasing in smoking has been related with decline in the incidence of 
all HNSCCs types (89) except HPV-positive oropharyngeal cancers (base of tongue and 
tonsils) which have risen in incidence (90). In contrast to tobacco smoking and alcohol 
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consumption, HPV infection is believed to be an etiologic factor in oropharyngeal cancers 
but not in oral, laryngeal or hypopharyngeal cancer (91), (84), (92). HPV-positive Head and 
Neck cancer, which has recently witnessed increasing incidence in many countries including 
the UK, seems to be linked with oral sexual behaviour and non-related with smoking (83). 
1.2.2.3 Age 
HNSCC cases are most frequently diagnosed in individuals who are older than 50 years. 
Nevertheless, oral squamous cell carcinoma among young generations is currently increasing 
around the globe (93). The role of age in HNSCC prognosis is not fully understood. However, 
it was demonstrated as criterion to prognosticate a therapeutic regime outcome since 
findings showed that disease-specific survival was significantly influenced by age in elderly 
patients (94). Cases that are above 70 are considered a preclusion to use of concomitant 
chemoradiotherapy (95). Recently, it has been reported that the younger non-smoker 
HNSCC patients, which are mainly HPV-positive HNSCCs, have a mean value of genetic 
aberrations 50% lower than that in those older smoker ones, where the age cut off was 40 
years old. In particular, losses in 3p and 9p21 are not frequent molecular events in young 
patients, while they remain detectable in the entire older cases (96). Very recent studies 
reported an increased incidence of young patients with HPV positive Oropharyngeal 
Squamous Cell Carcinomas, who are overwhelmingly non-smoking (93). 
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1.2.3 Diagnosis  
Early diagnosis of oral malignancies is essential for improving prognosis. There are a variety 
of diagnostic tools using in early detection of oral cancers that allow the delivery of timely 
treatment intervention to minimise the evolution of oral potentially malignant disorders to 
cancer. Two of these important approaches are the following:  
1.2.3.1 Optical diagnosis 
Auto-fluorescence based imaging system (VELscope™) has been suggested to visualise and 
manage oral malignancies (97). However, despite its high sensitivity in detection of oral 
mucosal disorders (84%), this technique has low specificity (15%) in discriminating high risk 
dysplasia from low risk or benign lesions. A combination of NIR optical imaging and real-time 
fluorescence imaging during surgery is one of recent successful strategies used during the 
surgery to target specific hallmarks of head and neck cancer to facilitate assessing tumour 
margins to optimise radical resection avoiding unwanted damage to the healthy tissues (98). 
1.2.3.2 Molecular diagnosis 
Diagnosis of oral malignancies at their earliest stages could markedly affect patient 
prognosis, therapeutic intervention, disease-specific survival, and recurrence. The discovery 
of body fluids-based molecular biomarkers delivers unique accessible tool to bypass painful 
invasive methods like biopsies that add excessive stress to an already disturbing experience. 
Utilizing plasma, serum, saliva and urine in detection of oral cancers including distant 
metastases is being evaluated. Determining promoter hypermethylation of tumour 
suppressor genes or LOH of 3p and 9p, and HPV and microRNA using these body fluids is an 
attractive target for early detection of OSCC (99), (100), (101). In a cohort of HNSCC patients 
collocated and evaluated at diagnosis, frequent hyper-methylation was identified in a panel 
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of 6 gene promoters (CDH1, CDKN2A/p16, DAPK, MGMT, RASSF1A and TIMP3) at very close 
levels of 82% and 78% in paired tumour and saliva samples respectively. The detection of 
promoter hyper-methylation in this small number of genes was sensitive enough to early 
diagnosis of neoplastic exfoliated cells in saliva months prior to clinical diagnosis of relapse 
(102). The problem, however, is that patients at risk from recurrence have usually received 
radiotherapy, therefore have xerostomia and cannot expectorate saliva. Frequent promoter 
hyper-methylation of KIF1A (103), EDNRB and DCC (104) has also recently been employed as 
molecular diagnostic tool of oral dysplasia/cancer in salivary rinses. Very recently, 40 pairs of 
oral cavity squamous cell carcinomas (OSCCs) and saliva samples collected from healthy 
individuals have been evaluated by Quantitative Methylation Specific PCR (qMSP) and 
identified a combination of 4 gene panel (CCNA1, DAPK, DCC and TIMP3) with high 
frequency of hypermethylation with sensitivity and specificity up to 92.5% (105). This panel 
of hyper-methylated genes may offer a feasible tool for diagnosing early stages of OSCC in 
clinical practice if pursued. 
1.2.4 Therapy 
Surgical resection and radiation therapy are the cornerstone of HNSCC treatment. However, 
recent years have witnessed increasing incorporation of systematic chemotherapy into 
therapeutic regimens of HNSCC patients either before surgery as an induction or 
neoadjuvant chemotherapy or during radiotherapy as a concomitant chemo-radiotherapy 
(106).  
1.2.4.1 Surgery  
Approximately, one-third of HNSCC patients are diagnosed at early stage cancer (stage I and 
II), and those patients are subjected to surgery or radiotherapy. The remaining patients, who 
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diagnosed with advanced stage cancer, are subjected to a combination of surgery, 
radiotherapy, chemotherapy or all. In order to prevent malignancy recurrence, 
postoperative chemo-radiotherapy is highly recommended, in particular, to high risk 
patients of recurrence, for instance cases with positive resection margin or extra-capsular 
metastatic invasion of cervical lymph nodes (107).  
1.2.4.2 Concurrent chemoradiotherapy (CRT) 
Up until 2000, radiotherapy was almost only the non-surgical therapy administrated to the 
HNCC patients. After several phase III clinical trials showed a survival benefit of combining 
chemotherapy with radiotherapy vs radiotherapy alone, concurrent chemoradiotherapy 
(CRT) was introduced to treat patients with advanced HNSCC (108), (109), (110). Eighty-
seven clinical trials, reported by Pignon et al on 16485 HNSCC patients, demonstrated a 
range survival benefit for chemotherapeutic regimens of 4.5% at 5 years as well as for 
concurrent chemo-radiotherapy of 6.5% (95). However, no significant benefit was shown 
either for induction chemotherapeutic regimen in the total HNSCC patient cohort. This meta-
analysis showed the superiority of concomitant chemotherapy over induction 
chemotherapy. Despite the prognostic improvement in locally advanced HNSCC patients 
treated with concurrent chemo-radio therapeutic regimen compared with radiotherapy 
alone, increasing toxicity remains the issue (108). However, induction chemotherapy with 
docetaxel, cisplatin, and fluorouracil (TPF) (111) is recommended for patients with N3 locally 
advanced HNSCC (112) prior to concurrent chemo-radiotherapy. 
1.2.4.3 Targeted therapy 
Although multiple EGFR tyrosine kinase inhibitors (TKIs) have been tested in HNSCCs clinical 
trials, the outcome in most cases was disappointing.  Erlotinib has been used as a single 
agent in phase II clinical trials in recurrent or metastatic HNSCC patients. The response rate, 
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however, was 4.3% with a 38% stable disease rate (113).  Although the response was slightly 
higher when used as combination with cisplatin, the prognosis of using this Erlotinib 
involving regimen remained disappointing (114). Gefitinib also has not shown a prognostic 
improvement in recurrent or metastatic head and neck cancer patients in phase III 
randomized trial when combined with docetaxel compared with using docetaxel alone (115). 
Recently, one encouraging phase II trial of using dacomitinib as first-line chemotherapy in 
recurrent/metastatic HNSCC has shown favourable disease control and improved overall 
survival (116). The presence of HPV DNA is not related with response to EGFR inhibitors in 
HNSCC patients with recurrence or metastatic spread (117). Regarding locally advanced 
HNSCC, although combining cetuximab to conventional chemo-radiotherapy with cisplatin 
has not been encouraging so far, outcome of the ongoing monotheraputic comparison of 
ceutaximab vs cisplatin given with radiotherapy may change the care standard of this 
disease in the future (118). 
1.2.5 Prognosis 
As with other head and neck cancers, good prognosis in HNSCC is associated with early 
detection of stage of disease (stage I or II) with favourable outcome of up to 90% after 
surgery or radiotherapy (119). In a retrospective cohort study performed in the North-West 
of England on oral cancer patients who were relatively elderly, the value of oral cancer-
specific survival (CSS) has been emphasised as an indicator of a successful therapeutic 
regimen since the overall survival is influenced by age, poor socioeconomic circumstances 
and comorbidity. Extra-capsular spread and pathological node status are the main 
pathological characteristics of the tumour that were reported as the most powerful 
prognostic markers of oral cancer-specific survival in addition to the age, clinical appearance 
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of the oral tumour and its differentiation, pattern of invasion, pathological stage and 
perineural invasion (94), (120). HPV appears to have a prognostic value for both disease-
specific survival (P = 0.005) and overall survival (P = 0.003); HPV negative status is 
significantly correlated with poor prognosis in OPSCC patients, while good prognosis is 
related with those who are HPV positive even if presenting with late stage disease. p16 
association with both disease-specific survival and overall survival shows similar significant 
prognostic trend as that for HPV status either separately or collectively (121). 
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1.3 Taxanes and mitotic spindle in cancer therapeutics 
1.3.1 History of taxanes 
In 1962, Arthur Barclay, who was a botanist at U.S. Department of Agriculture (USDA), 
obtained crude extract of from of bark of Pacific yew tree, Taxus brevifolia, and found it to 
have cytotoxic activity. Taxol (paclitaxel) (Figure 1.8) was then isolated from the bark 
extract of Taxus brevifolia by Wani group 1970 [Wani 1970] and reported to possess anti-
tumourgenic activity and was the first type of taxanes that had been isolated. In 1979, 
Schiff gruop investigated the depolymerising action of paclitaxel on mitotic spindle 
microtubules in cancerous HeLa cell line (122). This mitotic stabilising activity resulted in 
forming a paralyzed cytoskeleton that restrains the mitotic cell division. Eight years later 
paclitaxel was extensively utilised in a number of phase I clinical trials to treat patients 
with a variety of malignancies, including NSCLC, along with pharmacokinetic studies (123), 
(124), (125), (126), (127). Although these trials were run and encountered several 
difficulties such as weak response to paclitaxel therapy of most studied cancer cases, 
except few such as ovarian cancer (123), in addition to undesirable side effects, 
particularly hypersensitivity reactions and Neutropenia. These difficulties were about to 
threaten the prospects for administrating paclitaxel in further. The findings, however, led 
to further investigation of paclitaxel efficacy in treating cancer patients. In 1992, paclitaxel 
has been approved by the Food and Drug Administration for treating females with ovarian 
cancer as a marked response was already established as either a complete or a 50% partial 
response (128). In 1993, two different phase II clinical trials that administrated paclitaxel 
on patients with advanced NSCLC showed more efficacy and favourable outcome as single 
agent or in comparison of other therapies (Merbarone and piroxantrone) were used to 
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treat lung cancer (129), (130). In the same year, paclitaxel evaluation in phase II study 
administrated on untreated patients with metastatic head and neck squamous-cell 
carcinoma, also demonstrated promising results in favour of patient response to this agent 
(131).  
Docetaxel (Figure 1.8), which is a paclitaxel analogue, was derived from the European Yew 
tree Taxus baccata by a semisynthetic process [Denis 1990]. Similar to paclitaxel, docetaxel 
acts as microtubule stabilising agent that disrupts microtubule dynamics leading to mitotic 
arrest of cell cycle (132). Docetaxel demonstrated a marked significant efficacy in treating 
different types of cancers including lung and head and lung cancers. In 1994, the outcomes 
of very early phase II clinical studies that had been conducted on advanced NSCLC cases 
using docetaxel based therapy showed a significant anti-tumour activity in those patients 
(133), (134). These finding led to involve docetaxel in chemotherapeutic setting of 
respiratory tract cancers in later clinical studies.  
 
Figure 1.8: Three dimension chemical structures of taxanes (paclitaxel and docetaxel) and 
their common names (taxol and taxotere). 
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1.3.2 Therapeutic schemes using taxanes in lung and HN cancers: 
Taxanes are used to treat a variety of human cancers (135), (136), (137) including 
carcinomas of lung (138) as well as head and neck (139). Paclitaxel and Docetaxel, which 
represent the most prominent members of the taxane family, have manifested significant 
activity in treating lung tumours used either as part of complex chemotherapeutic 
regimens (140), (141) or less frequently as monotherapy if the complex regimens have 
undesirable effects (142), (143). Regarding head and neck cancers treatment, Several 
randomized clinical trials have shown that including taxanes in induction regimens 
comprising of cis-platin and fluorouracil could be superior to that of excluding taxanes 
(144), (145), (146), (147), (111), (139). Most of these clinical trials have demonstrated a 
marked improvement in overall survival (OS) and progression-free survival (PFS) with less 
toxicity in the taxane containing regimens. 
1.3.2.1 Taxane resistance in RTC cancers 
There are many factors are implicated in cellular response to taxanes of respiratory tract 
cancers. ATP-binding cassette (ABC) transporter superfamily members are responsible for 
extruding substrates of a variety of chemotherapeutic agents including taxanes (148). This 
efflux mechanism accordingly results in augmentation of cellular resistance of NSCLC. In 
vitro studies reported that Overexpression of ABCC10 is correlated with resistance to 
paclitaxel (r = 0.574; P < 0.05) in 17 NSCLC cell lines (149). mRNA expression of MRP5 and 
MRP8 (the MDR-related pump members which also belong to ABC superfamily) in 49 
NSCLC tissue specimens was correlated with docetaxel response (150). In ex vivo study, 
although the authors reported that ABCC3 overexpression is predictive of poor prognosis 
and resistance in NSCLC to chemotherapeutic setting of five drugs including paclitaxel and 
docetaxel,  the data in their paper does not clearly demonstrate the degree of ABCC3-
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induced chemoresistance in each individual drugs (151). Thus far, the range of relevant 
interactions is not clear and the mechanisms related to taxane resistance acquisition are 
still largely unexplored, in spite of their long clinical use in cancer therapeutics (152). 
1.3.3 Molecular predictive biomarkers of taxanes: 
A number of genes have been implicated in taxane resistance in NSCLC (Table 1.2). In vitro 
studies demonstrate that functional p53 induces sensitivity to docetaxel (153) and 
paclitaxel (154) in NSCLC cell lines. High expression levels of Bax and low expression levels 
of Cyclin E were reported to predict sensitivity paclitaxel in HNSCC cells (155). A phase-III 
randomized trial showed that KRAS mutations decrease NSCLC cells response to therapy 
involving paclitaxel, carboplatin and erlotinib (156) However, in vitro studies demonstrate 
KRAS independency when using docetaxel as a single agent or in combination with 
erlotinib (157) or gefitinib (158). Several studies attempted to investigate whether the 
expression of genes involved in mitotic spindle formation may be predictors of sensitivity 
to taxanes. Tubulin bIII mutations have been associated with resistance to docetaxel in 
NSCLC patients (159) as well as paclitaxel in cultured lung cancer cells (160). However, the 
inclusion of TUBB3 expression levels in the prediction model for docetaxel sensitivity 
shows no improvement (150). In fact, the latter study demonstrated a correlation between 
docetaxel activity mainly with the expression of certain drug pump genes (MRP5 and MVP) 
and genes involved in the detoxification process. In retrospective clinical study on locally 
advanced HNSCC, TUBB3 expression was suggested as a predictor of resistance to 
docetaxel involving induction chemotherapy (161). Another study pointed to the 
expression of the Checkpoint with Forkhead and Ringfinger domains (CHFR) gene as a 
potential predictor of response of NSCLC patients to first-line therapy with carboplatin and 
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paclitaxel (162). Nevertheless, the available information on taxane efficacy predictors does 
not provide conclusive evidence. Although an increasing number of targeted therapeutic 
agents have come into clinical use (163), it is estimated that taxanes will still be used in 
chemotherapy regimens for lung cancer treatment for the foreseeable future (164). 
Therefore, the identification of relevant response predictors will highly benefit clinical 
practice by stratifying patients into suitable currently available schemes (165). 
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Table 1.2: Potential molecular predictors of taxane-based thereby 
Gene Therapeutic type RTC type Study type Reference 
p53 Docetaxel & Paclitaxel NSCLC In vitro functional (153), (154) 
Bax Paclitaxel HNSCC In vitro study (155) 
Cyclin E Paclitaxel HNSCC In vitro study (155) 
KRAS paclitaxel, carboplatin and erlotinib NSCLC phase-III trial (156) 
KRAS docetaxel alone or in combination NSCLC In vitro study (157), (158) 
TUBB3 docetaxel NSCLC Clinical cohort (159) 
TUBB3 paclitaxel NSCLC In vitro study (160) 
TUBB3 Docetaxel-involving induction chemotherapy HNSCC Clinical retrospective (161) 
CHFR Paclitaxel-based First Line Therapy NSCLC Clinical cohort (162) 
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1.3.4 Mechanism of taxane action: 
The classic cytotoxic action of these compounds is mediated mainly through their binding 
of β tubulin monomers, leading to microtubule stabilization (Figure 1.9), thus blocking 
their depolymerisation and subsequently triggering cell cycle arrest at the G2/M phase 
(166), (167). In addition, there are a number of other well-known molecular mechanisms 
of action. One mechanism is activation of kinase activity of cdc-2 (cell division control-2 
kinase) (168), which leads to apoptosis due to cytosolic accumulation of cytochrome c and 
caspase 3 activation. Paclitaxel induces mitotic arrest due to activation of spindle assembly 
checkpoint in the presence of Aurora b activity which maintains a dynamic equilibrium 
between attached kinetochore with those unattached (169), (170). Therefore, a functional 
spindle assembly checkpoint is required for efficient paclitaxel-induced mitotic arrest and 
thus cell death. Taxanes also induced apoptosis due to B-cell lymphoma2 (Bcl-2) 
phosphorylation (171), (52). However, many other pathways may also be involved in 
modulating their therapeutic effect such as causing cancerous cell death due to affecting 
interphase cells or inducing multipolar divisions (172). However, no any of these notions 
has been clearly established.  
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Figure 1.9: Figure depicting the classic mechanism of Taxol-β tubulin interaction promoting assembly of αβ-tubulin heterodimers that mimic 
that of GTP binding effect. However, Taxol binds β-tubulin while GTP binds the tubulin heterodimer forming a protofilament, which 
subsequently configures the microtubule. GTP hydrolysis allows microtubule depolymerisation, while tubulin dimerization promoting by 
paclitaxel is irreversible activation and thus results in microtubule stabilisation. 
Chapter 1 
 57 
1.3.4.1 Molecular differentiation between response to Paclitaxel and Docetaxel  
The two microtubule stabiliser taxanes, paclitaxel and docetaxel, are clinically approved to 
treat advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (106), as well as Non-
Small Cell Lung Cancer (NSCLC) (173), (174). However, the exact molecular action of these 
drugs is not fully understood, therefore they are still under comprehensive investigation to 
predict response of respiratory carcinomas to their chemotherapeutic action. Despite the 
fact that both taxanes are mainly implicated in apoptosis by causing microtubule 
catastrophe leading to cell arrest at the G2/M phase (175), they are not identical in their 
substantial clinical (176) and molecular (175) action. Therefore, cancer cells respond 
differently to these taxanes (177). This variance in cancerous cell response to paclitaxel 
and docetaxel was first described by Hanauske et al (1992) (178) and this led to the 
investigation of  the unique mechanisms underlying differences in sensitivity to these 
taxanes in in vitro and in vivo experiments together with preclinical and clinical studies. It 
has been reported that docetaxel induces Bcl-2 and apoptosis at 100 fold lower 
concentrations than that of paclitaxel (179). Comparatively, docetaxel has almost twice as 
much affinity for β-tubulin as paclitaxel (180), with broader cell cycle effectiveness in three 
phases (S/G2/M) compared with two (G2/M) for paclitaxel. Furthermore, the retention 
time of docetaxel in tumour cells is longer than that of paclitaxel due to higher uptake and 
lower efflux (181). However, the efficacy of docetaxel and paclitaxel noted in preclinical 
and clinical studies cannot be explained merely based on molecular determination or even 
pharmacokinetics. Despite the evidence that docetaxel has superior activity in comparison 
of paclitaxel in terms of treating cancer cells (docetaxel IC50 is ten folds less than that of 
paclitaxel) (175), Paclitaxel, occasionally, exhibits more inhibitory effect against cancer cell 
lines than that of docetaxel (177). Although a phase III clinical study demonstrated that 
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docetaxel-based therapy was significantly associated with good prognosis in metastatic 
breast cancer patients (P< 0.0001) compared with paclitaxel, there was no significant 
difference in overall response rate in treating those patients (176). Docetaxel mainly 
targets centrosome organization leading to incomplete mitosis and cell damage in S phase 
with partial toxic effect during mitosis, whereas paclitaxel affects the mitotic spindle 
causing cell death (182). This difference in site of action may explain some difference in 
their efficacy in killing cancer cells. 
1.3.5 Spindle assembly and cancer therapy 
In order to understand the mechanism of therapeutic action of taxane, it is important 
to consider the role of mitotic spindle formation and spindle assembly checkpoint  
1.3.5.1 Mitosis and Bipolar Spindle formation 
Accurate sharing of genetic material during cell division is accomplished after assembling 
of a bipolar microtubule-based structure called the bipolar spindle. This spindle is a 
dynamic structure that drives the congregation and segregation of chromosomes during 
mitosis and is monitored by so called mitotic spindle checkpoint (MSC), it is also known as 
spindle assembly checkpoint (SAC), which is the important cell cycle surveillance 
mechanism that ensure faithful distribution of DNA content between the daughter cells 
(183), (184). The normal process of assembling the bipolar spindle is mediated within very 
well-known distinct subsequent mitotic stages (Figure 1.10). The first stage in mitosis 
(prophase) can begin once the DNA is duplicated and matured centrosomes are separated. 
At this stage, the cylindrical polymers “microtubules” are nucleated from these 
centrosomes utilising α/β-tubulin heterodimers. These mitotic filaments have a fast-
polymerising plus end and a slow polymerising minus end that capped by a ring-like 
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microtubule nucleator called γ-tubulin ring complex (185). Next, pro-metaphase is begins 
once the nuclear membrane is decomposed. Some of polymerised microtubules attach to 
kinetochores (Kinetochores microtubules) at their plus-end. These attached kinetochores 
attach, in turn, to the centromeres of each sister chromatid forming what so called 
“Amphitelic attachment” which represents a proper dynamic form of attachment for 
bipolar spindle assembly that results in accurate chromosomal segregation (Figure 1.11) 
(186). Non-kinetochore microtubules represent another microtubule bundles that 
antiparallel overlapped at their plus ends without chromosomal attachment. The third 
array is called astral microtubules. They are polymerising apart of chromosomes and their 
plus ends anchor to the cell cortex mediating the position of the bipolar spindle (187). 
Metaphase is the next stage where the sister chromatids align along the central plate of 
the mitotic spindle enabling these chromatids to be separated at the next stage. The 
correct chromosomal alignment and their proper attachment to the microtubules are 
ensured by the spindle checkpoint prior chromosome segregation can progress (188) 
Through this stage, the kinetochore fibres are pulled towards the poles of the cell those in 
turn move farther apart. Anaphase is the penultimate stage where the sister chromatids 
are moved apart toward the cell poles resulted in accurate chromosomal segregation 
microtubule disassembly at this phase (189). During the final stage of mitosis (Telophase) 
the cellular compartments begin to appear and, simultaneously, the microtubules are 
depolymerising. At this point, a new nuclear membrane appears surrounding the uncoiled 
chromosomes that eventually return to uncondensed phase. The cell then divided into two 
daughter cells by cytokinesis. 
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Figure 1.10: Mitotic stages of normal cells. The figure was adapted from figures extracted from websites (study.com) & (Cummings 2003) 
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Figure 1.11: This figure shows the chromosome orientation at metaphase to the left column, chromosome segregation at anaphase in the 
middle and the divided daughter nuclei at telophase to the right. Four different types of kinetochore–microtubule attachments lead to 
chromosomal segregation; Amphitelic orientation (a) represents accurate segregation. Syntelic (b), monotelic (c) and merotelic (d) orientations 
which represent continuous kinetochore mis-orientation produce mis-segregated chromosomes at anaphase accordingly aneuploid daughter 
cells. The figure was reproduced from (190). 
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1.3.5.2 Mitotic Spindle Assembly and its checkpoint in cancer cells  
Characterizing the molecular components involved in mitotic events during the cell cycle, 
and exploring differences in their expression signature between normal and malignant 
cells, could help to facilitate discovering and developing predictors for chemotherapeutic 
compounds that personalised cancer patient for treatment (188). Bipolarity of mitotic 
spindle, which is contributed by several molecular pathways, is the most obvious and 
preserved aspects. The chromosomal congregation and segregation during mitosis is firmly 
regulated either by a mechanism of correction of improper kinetochore-microtubule 
attachment or by the mitotic spindle checkpoint members (191). There are three types of 
improper attachments could accrue in the mitotic spindle. They happen when sister 
kinetochores are not be able of binding to microtubules accurately to form the proper 
amphitelic attachment (Figure 1.11).  Sister kinetochores may be mono-oriented when 
they both attach to microtubules from the same pole forming what so called “syntelic 
attachments” but  when only one of the them attaches they form monotelic. If multiple 
microtubules from both spindle poles attach with individual kinetochores they form 
merotelic attachment (190). This checkpoint ensures that the genetic contents pass 
properly to the daughter cells during mitosis until this process has correctly completed 
(192). Defects in the aforementioned mechanisms, that control the accurate chromosome 
segregation, predispose cells to death in most cases because of chromosome miss-
segregation, chromosome instability or subsequently aneuploidy. In some cases, however, 
aneuploidy cell is triggered for cancerous transformation and transformed to a neoplastic 
cell (191), (188), (193). Therefore, activating the mitotic spindle checkpoint and targeting 
the progression of the oncogenic mitotic process are extremely successful strategies for 
cancer chemotherapy (54). Nevertheless, the greatest challenges of following these 
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strategies are the emergence of drug resistance and dose-related toxicity of anti-mitotic 
agents (194). 
1.3.5.3 Spindle assembly associated members 
Mitotic spindle formation and spindle checkpoint are critical for the maintenance of cell 
division and chromosome segregation (195). Many of the mitotic spindle associated 
members are implicated in several malignancies including lung and head and neck cancers 
(196), (197) due to their frequent overexpression. Overexpression and gene amplification 
have been reported to contribute to the development and progression of malignant 
tumours for a number of mitotic spindle associated genes. These genes include those 
involved in centrosome maturation (e.g. AURKA, TPX2, and KIF11) (198) , (199), 
microtubule formation (e.g. AURKA, CKAP5, TUBB  and TUBB3) (200), (201), (202) and 
chromosomal alignment and segregation (e.g. AURKA, AURKB, AURKC, DLGAP and TTK) 
(203), (204), (205).  Aurora A plays a central role in recruiting other mitotic spindle 
members (196). Several studies conducted to date have investigated the prognostic value 
of some of the aforementioned genes in lung cancer such as AURKA (206), AURKB (207) 
and TPX2 (208). However, the information relevant to lung cancer prognosis remains to be 
fully understood. No such information has been provided to date for DLGAP5, CKAP5 and 
TTK, while the prognostic value of AURKA (209), (210), (206) and AURKB (211), (207), (212), 
(213) in human NSCLC is still debated. 
1.3.5.3.1 AURKA 
Aurora kinase A, which is the gene product of AURKA (20q13.31) (Figure 1.12), is a 
member of the Aurora kinase subfamily of conserved Serine/Threonine kinases, which also 
includes Aurora B and Aurora C. Deregulation of Aurora kinases leads to impairment of 
mitotic spindle checkpoints causing abnormal spindle assembly (196). Overexpression of 
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AURKA is known to play an important role in cancer aggressiveness through a range of 
mechanisms. Elevated levels of AURKA perturb mitotic spindle formation and thus 
cytokinesis due to centrosome amplification, aneuploidy and chromosomal instability 
(214), (196). When overexpressed, AURKA also inactivates the activity of several tumour 
suppressor genes including p53 (215).  The association between AURKA overexpression 
and p53 mutation with high tumour grade and high cancer stage was also reported in 
patients with hepatocellular carcinoma (216) and with clinically aggressive disease and 
reduced survival in ovarian cancer (217). The perturbation of spindle formation and 
inactivation of tumour suppressor genes by elevated AURKA may explain the association 
between up-regulated AURKA and poor outcome of aforementioned cancer patients. 
Nonetheless, the notion that up-regulated AURKA contributes to a poor outcome in lung 
cancer has been debated, presumably because NSCLC represents a set of heterogeneous 
malignancies (218), with differing outcomes, even amongst those with the same 
clinicopathological features. 
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Figure 1.12: Genomic regions and transcripts of AURKA. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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1.3.5.3.2 AURKB 
Aurora kinase B, which is encoded by the AURKB gene (17p13.1) (Figure 1.13), plays a key 
role during mitosis by regulating chromosomal alignment, segregation and cytokinesis, as 
the catalytic protein of the Chromosomal Passenger Complex (CPC). Activation of Aurora B 
by the inner centromere protein (INCENP) is required for promoting transfer of the CPC 
sub-complex (INCENP–Survivin–Borealin subcomplex) to the spindle midzone during 
mitotic exit (219). Here it is localised to centromere and is required for the kinetochore 
localization and chromosome attachment to the mitotic spindle (169), as well as 
establishing the SAC to correct anomalous chromosome-kinetochore microtubule 
attachment before the cell enters anaphase (220). AURKB is frequently overexpressed in 
NSCLC (211) and is associated with genetic instability (212), aneuploidy and poor patient 
prognosis (221), (207). However, high Aurora B kinase expression has been associated with 
improved relapse-free survival (RFS) in ovarian cancer patients on taxane-based therapy 
(222). 
1.3.5.3.3 AURKC 
Aurora kinase C, which is encoded by AURKC (19q13.43) (Figure 1.14), represents the third 
member identified in the Aurora kinase family. It is very similar to Aurora kinase B in both 
molecular structural and subcellular localization (223), (224). Aurora kinase C also conducts 
similar functions as Aurora kinase B supporting mitotic progression through cell cycle in 
the absence of Aurora kinase B (205). Although it was originally detected in reproductive 
organs testes (225), AURKC deregulation has been reported in numerous malignancies 
(226), (227). Upregulated Aurora kinase C has been associated with promoting oncogenic 
activity of cancerous cells (228). 
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1.3.5.3.4 CKAP5 
Aurora kinase A recruits the interaction between the CKAP5 (11p11.2) (Figure 1.15) 
encoded protein, colonic and hepatic Tumour Over-expressed Gene (ch-TOG), and TACC3 
to centrosomes and proximal spindle microtubules (229). ch-TOG up regulation in cancer 
was first demonstrated by Charrasse et al 1995 in liver and colon tumours compared with 
the corresponding normal tissues (230). However, up to now, there is no available data 
could show such association between CKAP5 expression and survival in cancer patients 
that could potentially prognosticate the disease outcome. This may need more exploration 
of CKAP5 role in predicting survival in cancer patient including lung cases.  
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Figure 1.13: Genomic regions and transcripts of AURKB. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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Figure 1.14: Genomic regions and transcripts of AURKC. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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Figure 1.15: Genomic regions and transcripts of CKAP5. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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1.3.5.3.5 DLGAP5 
DLGAP5 (14q22.3) (Figure 1.16), whose encoded protein is regulated by AURKA (231), was 
first described by Tsou et al as an up-regulated transcript in hepatocellular cancer called 
Hepatoma Up Regulated Protein (HURP) (232). HURP is a kinetochore microtubule-
associated protein that mediates Ran-GTP-dependent mitotic spindle assembly, promoting 
microtubule polymerization and spindle formation, activating chromosome congregation 
and alignment during mitosis in normal and cancer cells (233). Increased expression levels 
of DLGAP5 are related to tumour aggressiveness in several cancers such as hepatocellular 
carcinoma (234), adrenocortical tumours (235), and meningioma (236). Up-regulation of 
DLGAP5 is correlated with bad prognosis in liver (237) and prostate (238) cancers.  
1.3.5.3.6 KIF11 
KIF11 (10q24.1) (Figure 1.17) encodes kinesin-5 motors Eg5, a microtubule motor, which 
localizes in centrosomes and asters of antiparallel microtubules moving them apart. 
Recently, it has been reported that defects in specific mitotic spindle members have been 
indicated to induce the aberrant spindles assembly with monopolar form or with poor 
centrosomes’ separation. Monopolar spindles formation is induced by Eg5 suppression 
leading to mitotic arrest (239). This Induction could be employed as a feasible strategy for 
cancer treatment, where cell death often caused by aberrant mitotic machinery. 
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Figure 1.16: Genomic regions and transcripts of DLGAP5. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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Figure 1.17: Genomic regions and transcripts of KIF11. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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1.3.5.3.7 TPX2 
The kinase activity of Aurora kinase A is regulated by TPX2, Targeting Protein for Xenopus 
kinesin-like protein 2, (20q11.21) (Figure 1.18) through their interaction during mitosis 
(240). At the end of mitotic cell division, both Aurora A (241) and TPX2 (242) are degraded 
by the anaphase promoting cyclosome/complex E3 ubiquitin ligase. TPX2 expression was 
differentially detected in cancerous lung tissues and not in normal lung tissue (243). 
Investigation of the distinctively higher expression of TPX2 in mitotic phases of cell cycle 
led to the suggestion it may serve as a biomarker for cancer prognosis (244). several 
studies on TPX2 expression have demonstrated the potential prognostic value of this gene 
when overexpressed in lung cancer using different approaches either as independent 
marker by immunohistochemistry (245), or as a part of 5 gene cluster/ panel signature (P < 
0.001, HR = 2.84) employing lung adenocarcinoma microarray data sets (69), (208). 
Nevertheless, TPX2 mRNA involvement in NSCLC prognosis has not been previously 
investigated independently in lung cancer cases. 
1.3.5.3.8 TTK 
TTK (6q14.1) (Figure 1.19) encodes protein MPS1 which plays important role, as a 
substrate to Aurora B kinase, in recruitments the MSC entities particularly Mad2 to 
deactivate APC until all the chromosomes biorientated properly at the middle plate of 
mitotic spindle so the microtubules attached accurately to the kinetochores (246). 
Activating MSC by TTK in existence of unattached kinetochores is enhanced by AURKB, 
which is necessary for TTK to accomplish rapid activation once cells enter mitosis, and thus 
rescues mitotic checkpoint function (247). Breast cancer is the only malignancy that TTK 
has been reported to be deregulated and that is associated with high histologic grade 
(248). 
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Figure 1.18: Genomic regions and transcripts of TPX2. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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Figure 1.19: Genomic regions and transcripts of TTK. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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1.3.5.3.9 TUBB and TUBB3  
TUBB (6p21.33) (Figure 1.20) and TUBB3 (16q24.3) (Figure 1.21) encode class I β-tubulin 
and class III β-tubulin respectively. These tubulins are members of β-tubulin family that 
represents one of two core protein families along with β-tubulin family. The 
heterodimerised tubulin is the leading target for taxanes. β tubulins are heterodimerised 
with  tubulins to assemble the microtubules, the key components of the mitotic spindle 
as mentioned above (249). Tubulin bIII mutations has been reported to be associated with 
resistance to taxanes in NSCLC patients (159) also lung cancer cells (160). This is not 
confirmed in a study where the addition of TUBB3 expression in the prediction model for 
docetaxel sensitivity shows no improvement (150). The same study demonstrates 
correlation of docetaxel activity in NSCLC cells mainly with the expression of drug pump 
genes, MRP5 and MVP, and detoxification process.  
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Figure 1.20: Genomic regions and transcripts of TUBB. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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Figure 1.21: Genomic regions and transcripts of TUBB3. The figure was adapted based on figures extracted from (genecards.org) & 
(ncbi.nlm.nih.gov) 
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1.4 Hypothesis 
Expression of mitotic spindle members may predict outcome and modifies the response to 
taxane-based therapy in respiratory tract carcinomas. 
1.5 Aims and Objectives  
This study aims to identify genes involved in the spindle assembly checkpoint process 
(AURKA, AURKB, AURKC, CKAP5, DLGAP5, KIF11, TPX2, TTK, TUBB and TUBB3) that may 
modulate taxane resistance in the human airways carcinomas. 
Specific objectives include:  
1. Explore the association between the expression profiles of these ten genes and clinico-
pathological characteristics and survival in human non-small cell lung carcinoma. 
2. Investigate the sensitization of cancer cells to taxanes by modifying the 
expression/activity of certain targets. 
3. Examine the potential sensitisation of lung and oral cancer cells to paclitaxel by 
epigenetic modifiers. 
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Chapter 2: Materials and methods  
2.1 Primary NSCLC tumour samples:   
This study was undertaken in association with Liverpool Lung Project. Appropriate Ethical 
approval has been acquired from Liverpool Research Ethics Committee (Reference number 
97/141) and all patients have provided written informed consent. One hundred and thirty 
three frozen surgical tumour samples were included in the study; fifty-six from 
adenocarcinomas (AdC) and seventy six from squamous cell carcinomas (SqCCL). In 
addition, 44 non-tumour adjacent paired surgical tissues (20 from adenocarcinoma and 24 
from SqCCL patients) were available for analysis. Most specimens were of the pT2 stage 
group (n=102)   while pT1 and pT3/4 group comprised 19 and 12 patients respectively. The 
clinicopathological characteristics of this cohort are provided in (Appendix 2). The median 
age of those patients was 67 (45-82); fifty-six of the patients were females and 77 were 
males. 
2.1.1 Cryosectioning  
Snap frozen biopsies were cryo-sectioned using OCT embedding matrix (CellPath-UK) to 
embed frozen blocks for cryosectioning using Cryostat (Thermo Scientific Shandon-UK). 
Two thicknesses of sections were obtained from each sample; 1st) five m sections which 
fixed in 10% buffered formalin (Catalogue no. UN 2209 - AnalaR) and stained using 
haematoxylin (Catalogue no. 6765003 Thermo Scientific) and eosin (Catalogue no.  
6766007 - Thermo Scientific) staining for histopathological examination. 2nd) 10 m 
sections utilised for DNA, RNA and protein extractions.  
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2.2 Cell lines & Growth conditions: 
Nine NSCLC cell lines (A549, Calu-3, CALU6, CRL5802, COR-L23, H358, LUDLU-1, SK-LU-1 & 
SK-MES1) and twelve HNSCC cell lines (BHY, HN5, PE/CA-PJ15, PE/CA-PJ41, UM-SCC-104, 
UM-SCC-12, UM-SCC-17as, UM-SCC-19, UM-SCC-4, UM-SCC-47, UM-SCC-5, UM-SCC-81b, 
UPCI-SCC-090 & LIV-7K) (Table 2.1) were tested in this study. They were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s Nutrient Mixture F-12 (1:1) 
containing 5% Fetal Bovine Serum (Sigma-Aldrich). Non-tumourigenic immortalised human 
bronchial epithelial cells (HBEC-3KT) along with their isogenic derivatives; p53 knockouts 
(HBEC-3KT-53), KRAS mutants (HBEC-3KT-R) and cells with both aberrations (HBEC-3KT-
R53) were also employed in this study. HBECs were maintaining in Keratinocyte-SFM 
medium supplemented with 50μg/mL Bovine Pituitary Extract (BPE) and 5 ng/ml human 
recombinant Epidermal Growth Factor (rEGF) (Life Technologies). All cell lines were 
maintained at 37ᵒC, 5% CO2. Cell line authentication was carried out utilising the 
GenePrint 10 System (Catalogue no. B9510 - Promega) to amplify 10 ng DNA of each cell 
line. The amplification product was mixed with internal lane standard 600 allele ladder and 
analysed on a 3130 Genetic Analyzer (Life Technologies) using GeneMapper ID-X Software 
(Appendex 3). Cell lines were also verified as free from mycoplasma utilising the e-
MycoTM plus Mycoplasma PCR Detection Kit (Catalogue no. 17341 - Intron Biotechnology).  
2.2.1 Cell growth curves 
 For growth curve estimation, 103 cells were seeded in each well of flat-bottomed 48-well 
plates in six replicates and cultured in 500 μl of medium. MTT assessments were 
performed every 24 hrs for 5 subsequent days. The average proliferation rate was 
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  Table 2.1: Cells lines utilised in this study and their histological subtype     
  Cell Line   Histological origin          
  NSCLC 
      
  
  A549 
 
Adenocarcinoma 
   
  
  Calu-3 
 
Adenocarcinoma 
   
  
  CALU6 
 
Adenocarcinoma 
   
  
  COR-L23 
 
large cell carcenoma 
  
  
  CRL5802 
 
SCC 
    
  
  H358 
 
Bronchioloalveolar adenocarcinoma 
 
  
  LUDLU-1 
 
SCC 
    
  
  SK-LU-1 
 
Adenocarcinoma 
   
  
  SK-MES-1  
 
SCC 
    
  
  HNSCC 
      
  
  BHY 
 
Oral SCC 
    
  
  HN5 
 
SCC 
    
  
  PE/CA-PJ15 
 
Oral SCC 
    
  
  PE/CA-PJ41  
 
Oral SCC 
    
  
  UM SCC-104 
 
SCC 
    
  
  UM SCC-19 
 
SCC 
    
  
  UM SCC-4 
 
SCC 
    
  
  UM-SCC- 47 
 
SCC 
    
  
  UM-SCC-12 
 
Laryngeal SCC 
   
  
  UM-SCC-17as 
 
Supraglottic SCC 
   
  
  UM-SCC-5 
 
Supraglottic SCC 
   
  
  UM-SCC-81B 
 
Laryngeal SCC 
   
  
  UPCI-SCC-090 OPSCC          
 HBEC       
 HBEC-3KT Non tumourigenic human bronchial epithelial      
 HBEC-3KT-53 Non tumourigenic human bronchial epithelial      
 HBEC-3KT-R Non tumourigenic human bronchial epithelial      
 HBEC-3KT-R53 Non tumourigenic human bronchial epithelial      
 LIV-7K Primary oral SCC (obtained from Dr Janet Risk)      
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deducted from six independent replicates. This experimental setting was followed according 
the preliminary results of previous pilot experiments. 
2.3 Examination of cell growth 
2.3.1 Cellular phenotypic characteristics 
 EVOS digital inverted microscope (AMG-USA) was used for phenotypic examination of cell 
lines in addition to monitoring cell growth, confluence and clonal colonies formation. 
2.3.2 Exposure to therapeutic agents  
Depending on the growth rate of each cell line, (5-8) × 104 cells were seeded in each well 
of flat-bottomed 48-well plates in six replicates and cultured in 500 μl of medium. After 
overnight incubation, the medium was replaced with media contained a range of 
concentrations (0-35nM) of Paclitaxel (Catalogue no. T7191 - Sigma-Aldrich), Docetaxel 
(Catalogue no. 01885 - FLUKA), either separately or synchronously with Alisertib 
(Catalogue No. S1147 - Selleck Chemicals) (0-11.1 nM), 0-3.2 nM Barasertib-AZD1152 
(Catalogue No. S1147 - Selleck Chemicals), 50-200 nM Decitabine (5-Aza-2′-deoxycytidine) 
(Catalogue No. A3656 - Sigma), or 0.5-8 mM Valproic acid (VPA) (Catalogue No. P4543 - 
Sigma) and pretreated with 0.5-1 mM VPA. Cells were incubated for 72 hours with 
replenishment of medium with drug at 36 hours.  
2.3.2 MTT proliferation assay  
The drug toxicity and viability of the cell lines and knockdown derivative clones were 
measured using the MTT proliferation assay. Cells already seeded and/or exposed to the 
chemotherapeutic compounds in 48 well plates, for required time course, were washed 
with PBS and incubated with fresh medium containing 0.75 mg/ml of MTT (3-(4,5-
dimethy1–2-thioazoyl) 2,5-diphenyltetrazolium bromide) (Catalogue No. M5655 - Sigma-
Chapter 2 
 85 
Aldrich) for 3 hours at 37ᵒC supplemented with 5% CO2. The medium was subsequently 
discarded and the converted formazan was solubilised by lysing the cells by addition 200 ul 
of 0.04 M HCl in isopropyl alcohol. After five minutes, viability of the cells was determined 
by measuring the optical density (O.D.) at 590nm with 630nm as reference in a GENios 
plate reader (Tecan Austria GmBH).  
2.4 mRNA expression analyses 
2.4.1 RNA extraction 
Total RNA was extracted using Direct-zol™ RNA MiniPrep Kit (Zymo Research). Quality and 
quantity of DNA and RNA were determined using a NanoDrop 2000 Spectrophotometer 
(Thermo Scientific). RNA extraction from primary tumour tissues was undertaken utilising 
10 μm thick sections obtained by cryosectioning. The sections were collected in Precellys 
ceramic beads prefilled tubes (Catalogue No. KT03961-1-003.2 - Bertin Technologies) 500 
μl TRIzol Reagent was added per about 50 mg tissue. The suspension was homogenized 
using Precellys 24 homogenizer (Bertin Technologies). RNA extraction from cell lines was 
performed by lysing the cells directly in the culture container by removing liquid medium, 
washing cells with Dulbecco PBS and replacing with 600 μl TRIzol Reagent. To remove 
particulates, the mixture was centrifuged at 12,000 x g for 1 minute. One volume ethanol 
(95-100%) was added directly to one volume sample homogenate (1:1) in TRI Reagent and 
mixed well by vortexing. The mixture was then loaded into a Zymo-Spin™ IIC Column in a 
collection tube and centrifuged at 10,000-16,000 x g for 1 minute. The column was 
transferred into a new collection tube and the collection tube containing the flow-through 
was discarded. 400 μl Direct-zol™ RNA PreWash reagent was added to the column and 
centrifuged at aforementioned speed for 1 minute. The flow-through was then discarded. 
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The previous stage was repeated twice. After that, 700 μl RNA Wash Buffer was added to 
the column and centrifuged as mentioned above and the flow-through was discarded. To 
ensure complete removal of the wash buffer, the column was centrifuged for an additional 
4 minutes in an emptied collection tube. The column was carefully transferred into an 
RNase-free tube then 40 μl of DNase/RNase-Free Water was directly added to the column 
matrix and centrifuged at max speed for 1 minute. Finally, an aliquot of each RNA sample 
was used for Agilent chip analysis in order to check its quality and quantity while the 
remaining RNA was stored at -80°C for future use. 
2.4.2 Agilent RNA 6000 Nano kit 
RNA quality and quantity was assessed by capillary electrophoresis on an Agilent 2100 
Bioanalyser (Agilent Technologies). In brief 550 μl of Agilent RNA 6000 Nano gel matrix 
were placed into the top receptacle of a spin filter. The spin filter was centrifuged for 10 
minutes at 1500 g ± 20 % and 65 μl filtered gel were used per each chip. RNA 6000 Nano 
dye concentrate was vortexed and 1 μl of RNA 6000 Nano dye concentrate was added to a 
65 μl aliquot of filtered gel.  The gel and dye mix was vortexed thoroughly and spun for 10 
minutes at room temperature at 13000 g. 9.0 μl of the gel-dye mix were pipetted at the 
bottom of the well-marked in a RNA Nano chip. The gel and dye mix was spread 
throughout the chip under air pressure using a syringe for 30 seconds. After 5 seconds, the 
plunger of the syringe was slowly pulled back, the chip priming station was opened and 9.0 
μl of the gel-dye mix were pipetted in each of the marked wells. Subsequently 5 μl of the 
RNA 6000 Nano marker were pipetted into the well-marked with the ladder symbol and 
each of the 12 sample wells. To minimize secondary structure, RNA ladder and samples 
were heat denatured at 70°C for 2 minutes before loading on the chip. 1 μl of the RNA 
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ladder was pipetted into the well-marked with the ladder symbol and 1 µl of each sample 
into each of the 12 sample wells. The chip was placed horizontally in the adapter of the IKA 
vortex mixer and was vortexed for 60 seconds at 100 g. Finally the chip was inserted in the 
Agilent 2100 Bioanalyzer and the run started in the following five minutes. 
2.4.3 Reverse transcription 
RNA was Reverse Transcribed using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies). This kit was utilised following the manufacturer’s protocol. Briefly (200-300) 
ng of RNA (10 µl) was heated at 70 ᵒC for 5min then cooled down at 0 0C for 2 minutes. 
After that, it mixed with 2 µl of 10x RT Buffer, 0.8 µl of dNTP Mix (100 mM), 2 µl of RT 
Random Primers, 1 µl of MultiScribe™ Reverse Transcriptase and 4.2 µl of Nuclease-free 
deionised H2O. After mixing by pippeting and centrifugation, the reaction of the reverse 
transcription took place using a thermal cycler and performing the following steps: 10 min 
at 25 0C, 120 min at 370C and a last step of 5 sec at 85 0C. cDNAs were diluted five times 
and 2 μl or 1.5 µl were used for the Quantitative PCR reactions. 
2.4.4 Quantitative Real-Time PCR expression assays 
The selection of targets among the mitotic spindle genes in this study was based on 
existing unpublished data; more specifically an expression microarray analysis (ALMAC 
platform) had been performed on about 4000 genes. Therefore, the mitotic spindle - 
associated genes demonstrating significant mRNA deregulation were selected for this 
study (Table 2.2: A: AdC, B: SqCC).  
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Table 2.2: A: Microarray mRNA expression analysis (ALMAC platform) of mitotic spindle-associated genes  
A. Adeno vs normal           
Affy Probe ID's Gene 
Name 
Normal 
Intensity 
SqCCL 
Intensity 
Log 
(Ratio) 
Log 
(Error) 
Fold 
Change 
P-value GenBank Orientation 
LC3P.5565C1_s_at AURKA 0.8558 3.2300 0.5624 0.1539 3.6506 0.00026 NM_198437 Sense 
LCHP.1058-22_s_at AURKA 0.7636 3.0911 0.5928 0.1440 3.9156 0.00004 NM_198437 Sense 
LCHP.1130-22_s_at AURKB 0.1183 0.6151 0.7015 0.2249 5.0292 0.00181 NM_004217 Sense 
LC3P.9707C1_s_at AURKB 0.1209 0.6866 0.7400 0.2363 5.4953 0.00174 NM_004217 Sense 
LC3P.9713C1_at DLGAP5 0.0950 0.5764 0.7684 0.2464 5.8668 0.00181 NM_014750 Sense 
LCADNH.6892_at KIF11 0.3177 0.6134 0.2713 0.0983 1.8678 0.00576 AL356128 AntiSense 
LCRS.2611_at KIF11 0.4543 1.6643 0.5495 0.1263 3.5436 0.00001 NM_004523 Sense 
LCMXR.18640C1_at KIF11 0.2840 1.2394 0.6255 0.1543 4.2216 0.00005 NM_004523 AntiSense 
LCHP.701-22_s_at TPX2 0.2574 1.8723 0.8474 0.2065 7.0373 0.00004 NM_012112 Sense 
LCHP.1160-22_s_at TPX2 0.0953 0.9198 0.9701 0.2437 9.3342 0.00007 NM_012112 Sense 
LCADA.4890_s_at TPX2 0.1198 1.1900 0.9826 0.2369 9.6081 0.00003 NM_012112 Sense 
LC3P.10122C1_s_at TPX2 0.1935 1.9712 0.9936 0.2076 9.8547 1.69E-06 NM_012112 Sense 
LCHP.442_s_at TTK 0.1420 0.8482 0.7619 0.2174 5.7794 0.00046 NM_003318 Sense 
LCHP.442-22_s_at TTK 0.1258 0.7674 0.7710 0.2171 5.9020 0.00038 NM_003318 Sense 
LC3P.846C3_at TUBB 1.4783 2.1457 0.1473 0.0473 1.4039 0.00184 NM_178014 Sense 
LC3SNG.2461a55_at TUBB1 0.3620 0.1640 -0.3583 0.1045 -2.2821 0.00061 NM_030773 Sense 
LC3P.846C4_at TUBB3 0.1577 0.9819 0.7797 0.2270 6.0218 0.00059 NM_006086 Sense 
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Table 2.2: B: Microarray mRNA expression analysis (ALMAC platform) of mitotic spindle-associated genes  
B. Squamous vs normal         
Affy Probe ID's Gene 
Name 
Normal 
Intensity 
SqCCL 
Intensity 
Log 
(Ratio) 
Log 
(Error) 
Fold 
Change 
P-value GenBank Orientation 
LC3P.5565C1_s_at AURKA 0.8558 4.0941 0.6627 0.1434 4.5998 2.51E-08 NM_198437 Sense 
LCHP.1058-22_s_at AURKA 0.7636 3.8997 0.6911 0.1337 4.9106 2.18E-08 NM_198437 Sense 
LCHP.1130-22_s_at AURKB 0.1183 0.8528 0.8408 0.1960 6.9307 1.81E-07 NM_004217 Sense 
LC3P.9707C1_s_at AURKB 0.1209 0.9830 0.8932 0.2076 7.8205 2.17E-07 NM_004217 Sense 
LC3P.9713C1_at DLGAP5 0.0950 0.9467 0.9813 0.2083 9.5793 5.46E-07 NM_014750 Sense 
LCRS.2611_at KIF11 0.4543 2.6259 0.7449 0.1190 5.5580 8.15E-09 NM_004523 Sense 
LCMXR.18640C1_at KIF11 0.2840 2.0164 0.8343 0.1429 6.8273 4.71E-08 NM_004523 AntiSense 
LCHP.701-22_s_at TPX2 0.2574 2.5100 0.9721 0.1945 9.3781 7.24E-08 NM_012112 Sense 
LC3P.10122C1_s_at TPX2 0.1935 2.9047 1.1594 0.1893 14.4353 8.43E-08 NM_012112 Sense 
LCHP.1160-22_s_at TPX2 0.0953 1.6204 1.2134 0.2095 16.3461 6.6E-08 NM_012112 Sense 
LCADA.4890_s_at TPX2 0.1198 2.0565 1.2176 0.2066 16.5052 8.43E-08 NM_012112 Sense 
LCHP.442-22_s_at TTK 0.1258 1.3821 1.0239 0.1887 10.5665 9.5E-07 NM_003318 Sense 
LCHP.442_s_at TTK 0.1420 1.5762 1.0284 0.1885 10.6752 1.02E-06 NM_003318 Sense 
LC3P.846C3_at TUBB 1.4783 2.5113 0.2131 0.0450 1.6333 2.24E-08 NM_178014 Sense 
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For qPCR validation, predesigned FAM-MGB labelled Taqman expression assays were 
utilised in this study (Table 2.3). 
 
Table 2.3: predesigned FAM-MGB labelled Taqman expression assays 
Gene name 
Catalogue 
number   
AURKA Hs01582072_m1 
AURKB Hs00945858_g1 
AURKC Hs00152930_m1 
CKAP5 Hs01120723_m1 
DLGAP5 Hs00207323_m1 
KIF11 Hs00189698_m1   
TPX2 Hs00201616_m1 
TTK Hs01009870_m1 
TUBB Hs00962419_g1 
TUBB3 Hs00964962_g1    
 
 
A customised expression assay was designed for ACTB gene expression in order to be used 
as an endogenous control. RT-qPCR primers and probe (labelled with TAMRA-BHQ2 
reporter/quencher) were designed using the Primer Express v 3.0 software (Life 
technologies) (Table 2.4).  
Table 2.4: Primers designed for the detection of ACTB RNA sequences. 
Targe
t 
Forward primer  
(5’→3’) 
Reverse primer 
(5’→3’) 
probe (TAMRA 
labelled) 
ACTB 
GGCACCCAGCACAAT
GAAG 
 (58.7ᵒC) 
CATACTCCTGCTTGC
TGATCCA  
(58.9ᵒC) 
CTCCTCCTGAGCGCAA
GTACTCCGTG 
(68.8ᵒC) 
 
The different dyes between my targets (FAM) and endogenous control (TAMRA) enabled 
multiplexing of the target and endogenous control expression in the same reaction tube. 
Assays were performed in a final reaction volume of 20 μl containing 10 μl of 2x TaqMan 
Gene Expression Master Mix (Life Technologies), 900 nM of each primer and 250 nM probe 
(my targets), 900 nM of each primer and 250 nM probe of the endogenous control ACTB-
VIC (Life Technologies). 3 l of cDNA was then added to the premix (described in section 
2.4.3) following the universal (life Technologies term) conditions: [2 min at 50ᵒC (UNG 
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action), 95ᵒC for 10 min (activation), 45 cycles of 95ᵒC for 15 sec (denaturation), 60ᵒC for 
1min (annealing and extension)] on a Life Technologies StepOnePlus Real-Time PCR 
System. The assays’ efficiency regarding reproducibility and robustness was tested over 5-
logs of cDNA concentration. The StepOnePlus Software v2.0.1 (Life Technologies) was used 
for data analysis. RNA levels were expressed as relative quantification values (RQ) which 
were calculated as: RQ=2-ΔΔCt, where the mRNA expression of HBEC-3KT cells was used as 
a calibrator in each run. All assays were run in duplicate and the mean values were used for 
the analysis. 
2.5 DNA methylation analysis  
2.5.1 DNA extraction 
DNA extraction from cell lines and primary lung tumours was performed using DNeasy® 
Blood and Tissue Kit (QIAGEN) using DNeasy 96 protocol for purification of total DNA from 
tissues and spin-column protocol for purification of total DNA from cell lines. Quality and 
quantity of DNA were determined using a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific). 
DNA extraction from primary tumour tissues was undertaken utilising 20 μm thick sections 
obtained by cryosectioning. The first and last sections underwent pathological review to 
ensure an at least 80% tumour cell content.  DNA extraction of the samples was performed 
following the manufacturer’s protocol.  Briefly, tissue was lysed with 360 μl of ATL reagent 
and 40 μl of Proteinase K solution (Qiagen) and incubated at 55°C overnight in an orbital 
shaking incubator at 200rpm. 820 μl of premixed AL buffer with ethanol were added and 
after mixing, lysates were transferred in two “twin” 96-well plates with silica based 
membranes. The samples were then centrifuged at 4,000 g for 10min and washed once 
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with 500μl buffer AW1. After centrifugation at 4,000 g the samples were washed again 
with 500μl buffer AW2. After centrifugation at 4,000 g, 55μl of AE buffer pre-warmed at 
60°C were added to each sample and DNA was recovered by centrifugation at 4,000 g for 5 
min.  
For the DNA extraction from cell lines, a maximum of 5x106 cells were pelleted at 300 x g 
for 5 minutes and the pellet was re-suspended in 200 μl PBS. 20 μl proteinase K and 4 μl of  
RNase A (100 mg/ml) (Qiagen) were added, the lysate was then mixed by vortexing and 
incubated at room temperature for 10 minutes. Subsequently 200 μl Buffer AL were added 
and the lysate was mixed thoroughly by vortexing and incubated at 56°C for 10 min. 200 μl 
of ethanol (96–100%) were added to the sample which was mixed thoroughly by vortexing. 
The mixture was transferred into the DNeasy Mini spin column (which carries a silica based 
membrane) placed in a 2 ml collection tube, and was centrifuged at 6000 x g for 1 min. 500 
μl of Buffer AW1 were added, and the sample was centrifuged  for 1 min at 6000 x g . 500 
μl of Buffer AW2 were then added and the sample was centrifuged for 3 min at 20,000 x g 
to dry the DNeasy membrane. The DNeasy mini spin column was then placed in a 1.5 ml 
microcentrifuge tube and the DNA was recovered into 200 μl Buffer AE with centrifuging at 
6000 x g for 1 min. DNA quality and quantity was assessed by spectrophotometry at 
260/280 nm wavelength.  
2.5.2 DNA methylation  
In order to generate positive control for methylation-specific PCR or bisulfate sequencing, 
reaction of four units SssI per g of unmethylated DNA for 2 hours was prepared according 
the modified manufacturing protocol. Briefly, 5l nuclease free water, 3l of 10x NEB 
buffer, 1l of 1600μM S-adenosylmethionine (SAM), 20l WBC DNA and 1l of 4U/1l SssI 
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methylase were added in order and mixed properly by pipetting then incubated for 2 hours 
at 37ᵒC. the reaction was stopped by heating at 65°C for 20 minutes. Standard curve of 
20l two-fold methylated DNA dilutions (5%, 10%, 20%, 40%, and 80%) was prepared by 
diluting in unmethylated DNA. 
2.5.3 Bisulphite treatment of DNA 
To investigate the methylation status of the different gene promoters tested in this study, 
500 ng DNA from primary tissues was bisulphite treated utilising the EZ-96 DNA 
Methylation-Gold™ Kit (ZymoResearch) following the manufacturer’s protocol.  
The CT Conversion Reagent was prepared prior to use by adding 900 μl of water, 50 μl of 
M-Dissolving Buffer, and 300 μl of M-Dilution buffer. It was then mixed by shaking for 10 
minutes at room temperature. The M-Wash Buffer was prepared by adding 144 ml of 100% 
ethanol to the 36 ml M-Wash Buffer concentrate. 130 μl of the CT Conversion Reagent 
were added to 20 μl (500 ng) of each DNA tissue sample or 1000 ng DNA from cell lines in a 
12 PCR tube strip and samples were mixed by pipetting up and down. The PCR tube strip 
was locked and transferred to a thermal cycler and the following steps were performed: 
98°C for 10 minutes, 64°C for 2.5 hours. The samples from the Conversion step were 
transferred to Eppendorf tubes containing 600 μl M-Binding Buffer and samples were then 
mixed by pipetting up and down. Zymo-Spin™ IC Column was placed onto an assembly 
onto a vacuum manifold and loaded with the sample then the vacuum was turn on the 
until all of the liquid had passed completely through the column. 1000 μl of M-Wash Buffer 
were added to each column. Each column was placed into a collection tube and centrifuged 
at full speed (>10,000 x g) for 30 seconds to eliminate any residue Wash Buffer from the 
column. 200 μl of M-Desulphonation Buffer were then added to each well and the plate 
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was left at room temperature (20°C–30°C) for 20 minutes. After the incubation, it was 
centrifuged at full speed for 30 seconds, and the flow-through was discarded. 800 μl of M-
Wash Buffer were added to the column, which was then centrifuged at full speed for 30 
seconds, and the flow-through was discarded. Another 800 μl of M-Wash Buffer were 
added to the column, which was then was spun at full speed for 2 minutes to ensure 
complete removal of alcohol traces. Finally 10 μl of M-Elution Buffer were added directly to 
the column matrix, the column was placed into a 1.5 ml tube and spun briefly at full speed 
to elute the DNA. 3 µl of bisulphite treated DNA was used for each PCR reaction. 
2.5.4 Pyrosequencing Methylation Analysis (PMA). 
Pyrosequencing (PSQ) is a method that can identify the sequence from small DNAs 
efficiently and with high fidelity. The procedure of the technique divided into two parts. 
The first part was the preparation of the samples for pyrosequencing. The targeted DNA 
sequence was amplified by PCR using forward biontinylated (Fb), reverse (R) and 
Sequencing (S) primers (Table 2.5). The primers were designed by the PyroMark assay 
design 2.0 software (Appendix 4). One of the two primers is biotinylated. After the 
examination of the product’s quality in an agarose gel, the PCR products were mixed with 
the binding buffer, which contained sepharose streptavidin beads and buffer, and then 
were transferred into a 96 well PSQ plate.  
With the help of a tool that used vacuum, the beads, in which the PCR product was bound, 
were held against a filter. The beads were then washed successively with ethanol, NaOH 
and wash buffer. NaOH denatured and separated the strands, while the wash buffer 
neutralised the immobilised strand. As a result, at the end of the above procedure, in the 
tool remained only the streptavidin beads with the biotinylated strand of the PCR products. 
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Table 2.5: Pyrosequencing primers of the targeted sequence in the promoter regions of the examined genes.   
Gene Forward biontinylated primer (Fb) Reverse primer (R) Sequencing primer (S) 
AURKB 5-TTTTTTATTGGGTTTTTATGA 3’ 5-ACTTTTCAAATCTCCCCCCC 3’ 5-ACCCCATTAAACAAACT 3’ 
CKAP5 5-GTTTGGTTTAGAGGGAAAT 3’ 5-CCATTTAAAAAACCTATAAACA3’ 5-TGGTTTAGAGGGAAATA 3’ 
KIF11 5-TATGGGATGTAGTATTTTTATTGG 3’ 5-ACAAACAAACAAACCACCTC 3’ 5-AAACAAACCACCTCTTTA 3’ 
TPX2 5-ATTTTTGTATTATTGGGAAGG 3’ 5-TCTCCTTATAATTATACATTATCCC 3’ 5-AAATTCAAAAAATTCACTTC 3’ 
TUBB 5-GAGGGAAAGTAGGTTGGG 3’ 5-CCACTAATCAAAACCAAACTC 3’ 5-ATAAAACTTTATCTCCCTA 3’ 
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The beads were then released in a new 96 well PSQ plate together with the annealing 
buffer, which contained the sequencing primers. The first of the four triphosphates (dNTPs) 
was injected into the reaction. DNA polymerase catalyses the incorporation of the first 
dNTP into the DNA strand if it was complementary to the base in the template strand. Each 
incorporation event was accompanied by release of pyrophosphate (PPi) in a quantity 
equimolar to the amount of incorporated nucleotide. ATP sulfurylase converted PPi to ATP 
in the presence of Adenosine 5′-phosphosulfate (APS). This ATP drived the lusiferin to 
oxyluciferin that generated visible light in amounts that were proportional to the amount 
of the ATP. The light produced in the luciferase- catalysed reaction was detected by a 
charge coupled device (CCD) camera and seen as a peak in a pyrogram. The height of each 
peak (light signal) is proportional to the number of nucleotides incorporated (Figure 2.1). 
Apyrase, a nucleotide degrading enzyme, continuously degrades ATP and unincorporated 
dNTPs. This switches off the light and regenerates the reaction solution. The next dNTP is 
then added. The dNTPs are added one at a time. As the process continuous, the 
complementary DNA strand is built up and the nucleotide sequence is determined from the 
signal peaks in the pyrogram. Using the standard treatment of genomic DNA with 
bisulphite (described in the previous paragraph), unmethylated Cytosine (C) is converted to 
Uracil (U), whereas methylated Cytosine (mC) remains unchanged. Using PCR, Uracil (U) is 
amplified to Thymine (T), whereas mC is amplified to Cytosine (C). Discrimination between 
mC and C is thereby achieved by transforming mC and C to appear as a C/T SNP. 
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Figure 2.1: Nucleotide incorporation generates light seen as peak in the program. The figure extracted from 
(Petrosino 2009). 
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2.5.5 Decitabine efficiency 
The previous protocol on Decitabine efficiency in lung cancer cells (Daskalos 2009) was 
confirmed by assessing global DNA methylation following the cells’ treatment. A549 cells were 
treated with 50, 100, 200 nM 5-aza-20-deoxycytidine (Decitabine; Sigma-Aldrich, cat no11390) 
for 48 hours. Following a wash with PBS, DNA was extracted as described in section (2.5.1). 
Decitabine efficiency was determined by measuring global DNA methylation. This was 
achieved by pyrosequencing-methylation analysis of the LINE-1.2 (Genebank accession no 
M80343) retrotransposon (Daskalos 2009). Sodium bisulfite conversion as described in section 
(2.5.3).  The primers used were the following:  
Promoter Forward primer  (5’→3’) Reverse primer (5’→3’) Sequencing primer  (5’→3’) 
LINE-1 Bio-TAGGGAGTGTTAGATAGTGG AACTCCCTAACCCCTTAC CAAATAAAACAATACCTC 
 
PCR amplification was performed using Qiagen HotStarTaq Plus Master Mix Kit, 5μΜ 
biotinylated primer, 10 μΜ non-biotinylated primer and 3 μl (approximately 60ng) of 
bisulphite treated DNA. The thermal profile for LINE-1 amplification is shown in Table 2.6. 
Table 2.6: Thermal profile for LINE-1 amplification PCR reactions 
Step Temperature (oC) Time No of cycles 
Taq Activation 95 5 min  
Denaturation 94 30 sec  
Annealing 58 45 sec 40 cycle  
Extension 72 45 sec  
Final extension 72 10 min  
 
The PCR product quality and quantity was confirmed by agarose gel (2%) electrophoresis UV 
visualisation on a UVP VisionWorks LS instrument prior to clean up and Pyrosequencing 
analysis. For the latter the SQA kit was used following the suppliers protocol (Qiagen) and the 
reaction was performed on a 96MA Pyrosequencer (Qiagen). 
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2.6 Transfection  
2.6.1 AURKA, AURKB and TPX2 mRNA downregulation 
Five different constructs were used to target AURKA, AURKB or TPX2 mRNA expression 
(Catalogue no. SHC202 - Sigma-Aldrich (Table 2.7) that belong to type TRC2-pLKO-puro Vector 
(Figure 2.2: A) along with a scrambled control construct which is MISSION TRC2 pLKO.5-puro 
Non-Mammalian shRNA Control Plasmid DNA (Catalogue no. SHC202 - Sigma-Aldrich) (Figure 
2.2: B). 
2.6.1.1 Propagation of MISSION short hairpin RNA (shRNA) constructs in E. coli 
One Shot TOP10 Chemically Competent E. coli (Catalogue no. C4040-03 – Life technologies) 
were transformed with MISSION shRNA constructs utilised in this study. The transformation 
was followed the Life technologies protocol. Briefly, 2 μl of the DNA was added (100 ng) into a 
vial of One Shot cells and incubated on ice for 30 minutes. The cells then exposed to Heat-
shock for 30 seconds at 42°C without shaking. The vial subsequently placed them on ice for 2 
minutes.  Aseptically, 500 μl of pre-warmed S.O.C. Medium was added to the vial and then 
incubated at 37°C for 1 hour at 225 rpm in a shaking incubator. Subsequently, 200 μl from 
transformation was spread on a pre-warmed selective plate (Luria-Bertani medium contained 
100 μg/ml) and incubated overnight at 37°C. After the incubation period, single colonies were 
selected and analysed by plasmid isolation. 
2.6.1.2  shRNA constructs DNA isolation 
MISSION shRNA constructs plasmid were isolated utilising Zyppy Plasmid Midiprep Kit 
(Catalogue no. D4025 - Zymo Research) according to the manufacture protocol. In brief, Six ml 
of bacterial culture in LB medium was centrifuge at at ≥3,400 x g for 10 minutes. 6 ml of TE 
was added to the bacterial cell pellet and completely re-suspended by vortexing. 1 ml of 7X 
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Table 2.7 : shRNA constructs from MISSION library (SIGMA) 
matching gene transcripts of AURKA, AURKB & TPX2 
Clone ID Target Sequence Target Region 
AURKA 
  TRCN0000000655 ACGAGAATTGTGCTACTTATA 3UTR 
TRCN0000000656 CCTGTCTTACTGTCATTCGAA CDS 
TRCN0000000657 GAGTCTACCTAATTCTGGAAT CDS 
TRCN0000000658 AGGCCACTGAATAACACCCAA CDS 
TRCN0000010533 CACATACCAAGAGACCTACAA CDS 
AURKB 
  TRCN0000000776 CTACCTCCTCCTTTGTTTAAT 3UTR 
TRCN0000000777 CCTGCGTCTCTACAACTATTT CDS 
TRCN0000000778 TGATGGAGAATAGCAGTGGGA CDS 
TRCN0000010547 GCATCACACAACGAGACCTAT CDS 
TRCN0000000779 GAAGAGCTGCACATTTGACGA CDS 
TPX2 
  TRCN0000074533 CCATGTAGTTACTTCCTTTAA 3UTR 
TRCN0000074534 CCGAGCCTATTGGCTTTGATT CDS 
TRCN0000074535 CGAGCCTATTGGCTTTGATTT CDS 
TRCN0000074536 CCTTTGAGAAAGGCTAATCTT CDS 
TRCN0000074537 CGTGAACTTGATCCCAGAATA CDS 
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Lysis Buffer (Blue) was then added to the sample and mixed by gently inverting the tube 2-4 
times. 3.5 ml of cold Neutralization Buffer (Yellow) was added and inverted 4-6 times to mix 
thoroughly until the sample will turned yellow when the neutralization is completed and a 
yellowish precipitate formed. Zymo-Midi Filter/Zymo-Spin V-E column assembly was placed 
onto a vacuum manifold, the entire mixture was then added into the Zymo-Midi Filter column, 
and the vacuum was then turned on until all of the liquid has passed completely through both 
columns. The Zymo-Spin V-E column was then transferred to a collection tube and centrifuged 
at ≥11,000 x g for 30 seconds to remove any retained lysate. Subsequently, 400 μl of Endo-
Wash Buffer was added to the Zymo-Spin V-E column and centrifuged at ≥11,000 x g for 30 
seconds. 400 μl of Zyppy Wash Buffer was added and centrifuged at ≥11,000 x g for 30 
seconds. The Zymo-Spin V-E column was finally transferred into a clean 1.5 ml microcentrifuge 
tube and then plasmid DNA was eluted by adding 150 μl of Zyppy Elution Buffer at ≥11,000 x g 
centrifugation for 1 minute. 
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2.6.1.3 Knock-down of AURKA, AURKB and TPX2 mRNA expression by shRNA 
Knock-down of AURKA, AURKB and TPX2 by short hairpin RNA (shRNA); A549, LUDLU1, SKLU1 
and SK-MES1 cell lines were transfected with aforementioned shRNA constructs utilising 
Attractene Transfection Reagent (Catalogue no.  301007 - Qiagen) according the 
manufacturing protocol. Briefly, 100 mm tissue culture dish was seeded with 5x105 cell/ml 
and incubated at 37ᵒC overnight. 20 μl of 100 ng/μl plasmid DNA was added to 280 μl free-
serum DMEM medium supplemented with 7.5 μl Attractene Transfection Reagent. The 
mixture was then incubated for 15minute at room temperature to allow transfection complex 
formation. Meanwhile, the medium of pre-incubated cells was replaced by 2ml of new 
medium. The transfection complex mixture was added and the cells re-incubated at 37ᵒC 
overnight. Subsequently, the medium was replaced with new medium containing 4 nM 
Puromycin. Stable clones were selected by subsequent exposure to 4 nM Puromycin and 
knockdown efficiency was confirmed by qPCR and western blotting. 
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Figure 2.2: (A) TRC2-pLKO-puro plasmid map with shRNA insert, the length is 7,518 bp. (B) 
MISSION TRC2 pLKO.5-puro Non-mammalian shRNA Control Plasmid DNA map. The figures 
extracted from (Sigma-Aldrich). 
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2.6.2 AURKB overexpression by constructed pCMV6-XL4-AURKB/Bsd plasmid 
2.6.2.1 pCMV6-XL4 Vector preparation  
PCMV6-XL4 plasmid (Catalogue no. PCMV6XL4 – OriGene) (Figure 2.3) which carries human 
AURKB cDNA was used to construct plasmid DNA express AURKA-mRNA in mammalian cells 
and carry Blasticidin resistant gene as a selective marker of successful transfection. PCMV6-
XL4 was transformed into One Shot TOP10 Chemically Competent E. coli (as mentioned in 
section (2.6.1.1). The vector was then isolated utilising Zyppy Plasmid Midiprep Kit (as 
mentioned in section (2.6.1.2).   
  
 
Figure 2.3: SC117526 NM_004217 AURKB, Homo sapiens Aurora kinase B as transfection-
ready. The figure extracted from (OriGene). 
 
2.6.2.2 pCMV6-XL4 Vector digestion 
20 µl of 75ng/µl pCMV6-XL4 Vector was digested with 3 µl of 5 units/µl PsiI (Catalogue no. 
R0657S - New England Biolabs) in 30 µl restriction buffer2 and incubated at 37ᵒC for 
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overnight. The digested DNA vector was then cleaned up utilising QIAquick PCR Purification 
Kit (Catalogue no. 28104 - QIAGENE). The manufacture protocol was followed. Briefly, 250 μl 
Buffer PB was added to the DNA sample (5:1) until the colour of the mixture turned yellow. 
The sample was then applied to the QIAquick column and centrifuged at 15000 x g for 60 
sec. 750 μl Buffer PE was added to the column and centrifuged at at 15000 x g for 60 sec. 
the column was placed in a clean 1.5 ml microcentrifuge tube. The ultra-pure DNA was 
eluted with 30 μl DNA Elution buffer at 15000 x g centrifugation for 30 sec. The purified DNA 
was analysed by gel electrophoresis. 
2.6.2.3 5`-T overhang preparation and 5`- PO4 group removal of pCMV6-XL4 Vector 
In order to avoid vector recircularization and to follow TA overhang cloning strategy, the 
vector was T overhung and PO4 group was removed (Figure 2.4). PCR amplification step was 
undertaken on 30 µl DNA vector utilising 1 µl of 100mM dTTP (BIOLINE) and 1 µl of 5U/µl 
Hot Star Taq Plus DNA polymerase (QIAGEN) in 50 ml reaction volume. The mixture was 
then incubated for 70ᵒC for 2hr. 50 µl of T-overhung vector was treated with 1 µl of 10U/µl 
Alkaline Phosphatase, Calf Intestinal (CIP) (Catalogue no. M0290S - New England Biolabs) in 
100 µl reaction buffer3. The mixture was then incubated at 37ᵒCfor 1hr. Final clean-up was 
performed as mentioned in previous section. 
2.6.2.4 pCMV/Bsd plasmid preparation 
The pCMV/Bsd plasmid (Catalogue no. V510-20 - Life Technologies), which carries the 
blasticidin resistance gene under the regulation of a CMV and EM7 promoters followed by 
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Figure 2.4: This figure demonstrates the TA overhang cloning strategy 
 
an SV40 polyA tail (Figure 2.5), was restricted to obtain the fragment carrying the blasticidin 
resistance gene and its regulatory sequences flanked by polylinker sequences enabling the 
excision of the desired fragment using different restriction enzymes. pCMV/Bsd plasmid was 
transformed into One Shot TOP10 Chemically Competent E. coli based on the procedure 
described in section (2.6.1.1). The vector was then isolated utilising Zyppy Plasmid Midiprep 
Kit as mentioned in section (2.6.1.2).    
2.6.2.4.1 Sequential digestion of the pCMV/Bsd vector to obtain Blasticidin DNA insert 
Sequential digestion method was followed to obtain the Blasticidin DNA insert. Briefly, 50 µl 
of 180 ng/µl pCMV/Bsd vector DNA was digested in 100 µl restriction buffer4 contained 10 
µl SmaI and incubated at 30ᵒC for 6hr followed by NH4-acetate/Ethanol purification step 
with -20ᵒC overnight incubation. Next day, the linear vector DNA was restricted with 10 µl  
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Figure 2.5: Genetic map of the pCMV/Bsd vector, which carries the Blasticidin resistance 
gene as a selectable marker. The figure extracted from (Invitrogen- Life Technologies). 
 
EcoRV and incubated for 37ᵒC for overnight. Next morning, Ethanol purification step was 
performed. 
Isolation and purification of Blasticidin DNA fragment from low-melt agarose gel was 
undertaken using QIAquick gel extraction kit (Catalogue no. 28704 – QIAGEN). Gel 
electrophoresis separated two fragments; the desired fragment carrying the Blasticidin gene 
(1286 bp) and the rest of pCMV vector. The desired DNA insert was cut out from the gel 
using a scalpel under low power UV illuminator and obtained using the Qiaquick gel 
extraction kit according the manufacture protocol. In brief, Blasticidin DNA insert-contained 
gel was sliced after electrophoresis and three volume of binding buffer was added. The 
mixture was then incubated at 50ᵒC for 10 min until the gel slice has completely dissolved. 
The sample was subsequently applied to QIAquick column and centrifuged for 1min at high 
speed. The binding DNA was washed with buffer PE and the column then centrifuged at 
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14000 xg for 1 min. finally, the DNA was eluted by 50 µl of buffer EB and then 5 µl was 
analysed on gel electrophoresis and the rest was stored at 6ᵒC for further use.   
2.6.2.4.2 Preparation of 3`-A overhang Blasticidin DNA insert 
PCR amplification step was undertaken on 30 µl DNA insert utilising 1 µl of 100mM dATP 
(BIOLINE) and 1 µl of 5U/µl Hot Star Taq Plus DNA polymerase (QIAGEN) in 50 ml reaction 
volume. The mixture was then incubated for 70ᵒC for 2hr. 
2.6.2.5: Vector construction 
TA overhang cloning strategy was followed and pCMV6-XL4-AURKB/Bsd recombinant 
plasmid was constructed accordingly. 
2.6.2.5.1 DNA quantification 
Quant-iT™ dsDNA Assay Kit, broad range (Catalog no. Q-33130 – Life technologies) was 
utilised to quantify the restricted DNA of pCMV6-XL4-AURKB vector and Blasticidin insert 
according the manufacture protocol. In brief, The Quant-iT working solution was prepared 
by diluting Quant-iT dsDNA BR reagent 1:200 in Quant-iT dsDNA BR buffer. 200 μl of the 
working solution was load into each microplate well. 10 μL of each λ DNA standard 
(Component C) was added to separate wells and mix well as duplicates. 20 μl of each 
unknown DNA sample was added to separate wells and mix well. The fluorescence 
measured using a microplate reader. A standard curve was plotted to determine the DNA 
amounts for the λ DNA standards, plot amount vs. fluorescence, and a straight line was fit to 
the data points. 
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2.6.2.5.2 Ligation 
The ligation reaction was set up according the 1:3 molar ratio of vector insert. 3 μl pCMV6-
XL4 DNA, 7 μl Blasticidin insert DNA and 1 μl T4 DNA ligase was mixed in 20 μl ligation 
reaction. The mixture was incubated at 16ᵒC for overnight.  
2.6.2.5.3 Transformation of E. coli with pCMV6-XL4-AURKB/Bsd recombinant plasmid 
In order to propagate the genetically engineered plasmid pCMV6-XL4-AURKB/Bsd, One Shot 
TOP10 Chemically Competent E. coli cells were transformed with this plasmid based on the 
procedure mentioned in section (2.6.1.1).     
2.6.2.5.4 Restriction mapping of pCMV6-XL4-AURKB/Bsd recombinant plasmid 
The sequence of pCMV6-XL4-AURKB/Bsd recombinant plasmid was predicted according the 
sequences of pCMV6-XL4 DNA and Blasticidin insert DNA. The suitable restriction enzymes 
were selected using NEBcutter V2.0 software. NdeI and XmaI were used to confirm the 
recombination success. 8 μl of 50ng/μl recombinant DNA was double digested by 1 μl NdeI 
and 1 μl XmaI in 20 μl reaction buffer4. The mixture was incubated at 37ᵒC for overnight. 
The reaction was deactivated by heating for 20min at 65ᵒC.  
2.6.2.5.5 Sequencing of pCMV6-XL4-AURKB/Bsd recombinant plasmid  
BigDye Terminator v1.1 Cycle Sequencing Kit (Catalog no. Q-4337449– Life technologies) 
was utilised for Sequencing of pCMV6-XL4-AURKB/Bsd recombinant plasmid.  
2.6.2.5.5.1 Cycle Sequencing 
Sequencing reaction mix was prepared in 4 tubes of recombinant DNA plasmid sequencing 
primers. The primers were designed using Primer Express Software v3.0: 
1. pCMV-xl4/5 bsd insert -sequencing F-primer    5`-TCGCCCTTTGACGTTGGA-3` 
2. pCMV-xl4/5 bsd insert -sequencing R-primer    5`-ATGGAAATTGTAAGCGTTAATA-3` 
3. pCMV-xl4/5 AURKB insert-sequencing F-primer   5`-ACGGTGGGAGGTCTATATAA-3` 
4. pCMV-xl4/5 AURKB insert-sequencing R-primer   5`-TATTAGGACAAGGCTGGTGG-3` 
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4 μl Ready Reaction Premix, 2 μl BigDye Sequencing, 2 μl Sequencing Primer and 6 μl DNA 
Template/recombinant plasmid was prepared in total volume of 20 μl. The tubes were then 
placed in a thermal cycler and the volume was set to 20 μl. Cycle Sequencing was 
performing as shown in Table 2.8. 
Table 2.8: Thermal profile for LINE-1 amplification PCR reactions 
Step Temperature (ᵒC) Time No of cycles 
Taq Activation 95 5 min  
Denaturation 95 30 sec  
Annealing 53F-primer-60 R-primer 10 sec 30 cycle  
Extension 60 4 min  
Final extension 60 5 min  
 
2.6.2.5.5.2 Purifyication of extension products 
Centri-Sep™ 8-Well Strip (Catalogue no. 4367820 – Life technologies) was utilised in order to 
efficient removal of excess dye terminators from completed DNA sequencing reactions. The 
purification was undertaken following the manufacture protocol. Briefly, the strip was first 
spun down for 2 minutes at 750 x g in a swinging bucket centrifuge to remove interstitial 
fluid in either of the two ways. 20 μl of sample was added directly to the centre of each well 
of CENTRI-SEP 8 column. The loaded CENTRI-SEP 8 was placed into an 8-well PCR strip spun 
down for 2 minutes at 750 x g to collect the sample. 
2.6.2.5.5.3 Sequencing analysis 
The purified samples were vacuumed until completely dried. The pellet was then 
resuspended with 10 μl Hi-Di Formamide (Catalogue no. 4311320 – Life technologies). The 
suspension was heated at 90ᵒC for 5 min and then put in ice path for 1 min. the samples 
were then analysed by 3130 Genetic Analyzer (Catalogue no. 3130-01R Applied 
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Biosystems/HITACHI). The sequence of pCMV6-XL4-AURKB/Bsd recombinant plasmid was 
then confirmed (Appendix 5; A and B).   
2.6.2.6 Transfection of CALU3 cells with pCMV6-XL4-AURKB/Bsd recombinant plasmid 
CALU3 cell line was transfected with pCMV6-XL4-AURKB/Bsd recombinant plasmid 
according to the method mentioned in section (2.6.1.3). Clonal AURKB-mRNA 
overexpression was confirmed by qPCR (Appendix 6; A) based on method described in 
section (2.4.4). The modulation of successful clones of taxane response was then analysed 
(Appendix 6; B) as mentioned in section (2.3.2).  
2.7 Western blot 
2.7.1 Protein extraction 
The cell lines exposed to IC50 concentrations of Aurora inhibitors for (1, 2, 4, 8, 12, 24) 
hours, AURKA and AURKB knockdown clones as well as their parental cells were washed 
with DPBS and subsequently lysed by adding Protein Extraction Buffer (PEB) which prepared 
from material shown in (Table 2.9).  
Table 2.9: Protein Extraction Buffer composition 
Solution    ml Provider Cat. no. 
1M Tris-HCl pH=7.4 12.5 Fisher Scientific  BP152-1 
Glycerol 
 
12.5 Sigma-Aldrich G5516 
Deoxycholate 6.25% 5 Sigma-Aldrich D6750 
5M NaCl 
 
2.5 Sigma-Aldrich S9625 
0.5M EDTA, pH= 7.4 1 AnalaR 100935V  
Triton X-100 1.25 Sigma-Aldrich T8787 
SDS 20% 
 
0.625 Sigma-Aldrich L3771 
ddH20 
 
64.625 
  Supplements 
   Protease inhibitor cocktail  0.1 Sigma-Aldrich S8830 
Phosphatase inhibitor cocktail 0.1 Sigma-Aldrich P5726 
PMSF (0.3M in DMSO) 0.0035 Sigma-Aldrich P7626 
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For each 1 cm2 of ~80 % confluent growth, 25l PEB was added. The cell lysate was 
incubated for 15min on ice bath and then spun at 4ᵒC for 15min at 15000 g. The 
supernatant was transferred to new tube for additional lysis step by sonication using 
Bioruptor Sonication System Catalogue no. B01010001 (UCD 200 TM) - Diagenode) following 
the manufacture protocol. Briefly, 100-250 of cell lysate transferred to 1.5 ml microfuge 
tube and then placed in the tube holder. Sonication cycle conditions were 30 sec On/90sec 
off for 6 min. During the sonication time, the temperature was maintaining at 4°C by using 
ice chilled water and small amounts of crushed ice (no more than 0.5 cm). The sonicated 
lysate was the centrifuged at 12.000 g for 15 min at 4°C (optional step). The supernatant 
was stored at -20 oC until further analysis. 
2.7.2 The BicinChoninic Acid (BCA) assay for protein quantitation 
2.7.2.1 Prepration of bovine serum albumin (BSA) standard curve 
 Two fold serial dilutions (0.125, 0.25, 0.5, 1, 2, 4, and 8) mg/ml were prepared from 
20mg/ml BSA (Catalogue no. A7906 - Sigma-Aldrich) stock dissolved in PEB. A regular assay 
used a 20:1 reagent / sample volume ratio to detect the BSA concentration range 
aforementioned according V1.0 User Manual (NanoDrop 2000 Spectrophotometer/ Thermo 
Fisher Scientific). Briefly, 4 μl of each BSA dilution was mixed thoroughly with 80 μl BCA 
working reagent by vortexing (1 reagent B: 50 reagent A) (reagent A catalogue no.23228, 
reagent B catalogue no. 23224 - Thermo Fisher Scientific). The mixture was then incubated 
at 37ᵒC for 30 minute and subsequently left for 5 minute at room temperature. The BSA 
standard curve was plotted and the samples were then measured using the NanoDrop 2000 
Spectrophotometer according the manufacture instructions. 
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2.7.2.2 Protein sample preparation 
In order to prepare reduced samples for denaturing gel electrophoresis, 40 µg of total 
protein from cells or clone derivatives were mixed together with 2.5 µl of (4x) NuPAGE LDS 
Sample Buffer (Catalog no. NP0008 - Life Technologies), 1 µl of (10x) NuPAGE Reducing 
Agent (Catalog no. NP0004 - Life Technologies), and ddH20 up to a total of 10 µl reaction 
volume. The mixture was denatured by incubation at 70 0C for 10 minutes. 
2.7.2.3 Electrophoresis of NuPAGE® Gels 
 For the electrophoresing the total protein we have used the NuPAGE Novex Bis-Tris-Acetate 
(SDS-PAGE) Mini gels (Catalogue no. NP0321PK2 - Novex). Two gels were placed in the 
electrophoresis tank of XCell SureLock™ Mini-Cell (Catalogue no. EI0001 - Invitrogen). The 
upper chamber was filled with 200 ml of 1x NuPAGE Tris-Acetate SDS running buffer 
(Catalogue no. LA0041 - Invitrogen) mixed with 500 µl of NuPAGE Antioxidant (Catalogue 
no. NP0005 - Invitrogen), while the lower chamber was filled with 600 ml of 1x NuPAGE Tris-
Acetate SDS running buffer. After denaturation the samples were loaded on the gels 
together with SeeBlue® Plus2 Pre-Stained Standard (Catalogue no. LC5925 - Invitrogen). The 
gels were run at 200 V (110-125) mA/ gel for 35 minute.  
2.7.2.4 iBlot Western Detection  
For blotting of the electrophoresed proteins we have used the iBlot Dry Blotting System 
(Catalogue no. IB1001 - Invitrogen). The pre-run gels were released from cassette plates. 
The 1st gel was rinsed in ddH20 water (3x 5min), stained with the Simple Blue SafeStain 
(Catalogue no. LC6060 - Invitrogen), destained in water (3x 5 min or more) and pictures 
were captured using the UVP VisionWorks LS instrument. The 2nd gel was used for blotting 
where placed onto the PVDF blotting surface of Anode iBlot Gel Transfer Stack (Catalogue 
no. IB8010-01 - Novex) and covered with pre-soaked (in deionised water) iBlot filter paper. 
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The Cathode iBlot Gel Transfer Stack was then placed on the top of the filter paper and then 
toped over with side facing up and aligned to the right edge. The air bubbles removed using 
blotting roller. A disposable sponge with the metal contact was placed on the upper right 
corner of the lid. The lid was securely closed and the iBlot Dry Blotting System was switched 
on at program P3 for 7min.  
Subsequently, iBlot Gel Transfer Stacks were dissembled and the PVDF blotting membrane 
was then blocked in 5ml 1x iBind™ Buffer supplemented with 1x iBind™ additive for 5 
minute at room temperature. The iBind Western System (Life Technologies) was employed 
for application of binding primary and secondary antibodies (at dilution 1:1000) and 
washing steps. Mouse and rabbit monoclonal primary antibodies to Aurora A (Catalogue no. 
ab13824 - Abcam), Aurora B (Catalogue no. 3094 - Cell Signaling Technology), total Histone 
H3 (phospho S10) (Catalogue no. ab14955 - Abcam), α-Tubulin (2144- Cell Signaling 
Technology) and β-actin (Catalogue no. ab8226 - Abcam) were used, while IRDye 800CW 
Goat Anti-Mouse IgG (Catalogue no. 925-32210 - LI-COR Biosciences) and DyLight 800 
conjugate anti-rabbit IgG (Catalogue no. 5151 - Cell Signaling Technology)  antibodies served 
as secondary. The immune complexes were detected using Odyssey® CLx Infrared Imaging 
System (Odyssey®- LI-COR Biosciences). 
2.8 Data interpretation and Statistical analysis 
mRNA levels were expressed as Relative Quantification (RQ) which were calculated as: 
RQ=2-(ΔΔCt). Ct values were determined by StepOne software V1.2 (life technologies) and 
normalized by the corresponding Ct for the endogenous control ACTB, generating ΔCt values 
(ΔCt = Ct target - Ct ACTB). Sample ΔCt values were further normalised against an 
immortalised bronchial epithelium cell-line HBEC-3KT (250) calibrator using the formula: 
ΔΔCt = (ΔCt Sample (Tumour/Normal) - ΔCt HBEC-3KT). RQ was calculated for each target by 
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the aforementioned formula (RQ=2-(ΔΔCt)). Gene expression in tumour and adjacent 
normal tissues were compared using Wilcoxon’s non-parametric test for paired samples. 
Overexpression for a tumour sample was designated based on the 95% reference range of 
normal tissues (mean + 2x SD). The study characteristics were examined using descriptive 
statistics. Categorical variables were compared using chi-squared test and continuous 
variables were examined using Mann-Whitney test because of non-normality. Overall 
survival time was calculated from the date of surgery to the date of death or last follow-up 
date. Postoperative univariate survival analysis was explored using Kaplan-Meier curves for 
all the categorical predictors. Tests of equality across strata were also conducted to check 
the suitability of including potential predictors in the final multivariate model. For the 
categorical variables, log-rank test of equality across strata was used and univariate Cox 
proportional hazard regression was used to analyse continuous variables to examine the 
differences in survival rate. Variables with P value < 0.25 in the univariate analysis were 
selected for inclusion in the final multivariate model as suggested by Bursac et al. (251). 
Multivariate Cox proportional hazard model was utilised to examine the association 
between mRNA expression and other relevant prognostic factors. All statistical analyses 
were performed using IBM® SPSS® statistical software version 22.0 (Armonk, NY: IBM Corp) 
and STATA® version 13.1 (StataCorp LP, College Station, Texas). The IC50 values were 
calculated using Prism 5 (GraphPad) in comparison to untreated cells at time 0. 
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Chapter 3: AURKA involvement in 
docetaxel resistance in non-small cell 
lung cancer  
The objectives of this set of experiments were (a) to determine the extent of AURKA 
expression deregulation in primary human lung tumours and cell lines and (b) to 
investigate possible associations between AURKA expression and sensitivity to taxane 
therapy. 
The mRNA expression of AURKA in 132 cases of NSCLC and 44 normal tissues was 
determined (Appendix 2). RNA quality analysis using the Agilent Bioanalyzer revealed that 
almost all RNA samples have RIN values ≥ 7. Out of 176 RNA samples, 158 samples ≥7 and 
5≤18 samples<7, which were within the accepted range for qPCR analysis (252) (Figure 3.1). 
Expression profiling of AURKA mRNA showed a marked overexpression of the gene 
transcript in lung tumours in comparison to the adjacent normal tissues (Mann-Whitney, 
test, p=<0001) (Figure 3.2).  
The elevated AURKA mRNA expression in a panel of nine NSCLC cell lines from different 
histopathological subtypes was confirmed. The cell lines were distributed among lung 
adenocarcinoma, squamous carcinoma of the lung and large cell lung carcinoma (Figure 
3.3: A &B). AURKA mRNA expression was markedly greater than that of non-tumorigenic 
immortalised bronchial epithelial cells (HBEC-3KT) although the expression was variable in 
lung cancer cell lines. It was also of note that p53 knockout HBECs (HBEC-3KT-p53 and 
HBEC-3K-TRp53) demonstrated higher AURKA expression (p values = 0.05). LUDLU1 cell line 
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exhibited the highest mRNA expression of AURKA, while Calu-3 showed the lowest 
expressesion. Kaplan-Meier analysis demonstrates that AURKA mRNA expression is a 
predictor of overall survival (p-value = 0.0079) (Figure 3.4). The p values were derived from 
Log Rank (Mantel-Cox) test.   
 
Figure 3.1 Example electropherogram of total RNA by Agilent Bioanalyzer chip shows 
that the peaks18S and 28S are clearly visible at time 37 and 45 seconds, respectively. 
The analysed cancer lung cells and tissue RNA set was constructed only for samples 
with adequate RNA concentration and RIN number 7.7 and above. [s] on y axis 
represents integration start time. 
Chapter 3 
 118 
 
Figure 3.2: (A) Boxplots demonstrating the significantly higher mRNA expression of AURKA in primary lung tumours (n= 124) compared 
to adjacent normal lung tissues (n=44). (B)  mRNA expression of AURKA is significantly higher in  squamous cell carcinomas (SqCC) (n= 
72) compared to adenocarcinomas (AdC) (n= 52). P values are derived from Mann-Whitney tests. RQ was calculated using HBEC-3KT 
cell line RNA as a calibrator. 
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Figure 3.3: (A) AURKA mRNA expression in human bronchial epithelial cells (HBEC) and 
NSCLC cell lines. Cancer cell lines demonstrate variable AURKA expression, however, 
consistently higher than the non-tumorigenic bronchial epithelial cells (HBEC-3KT). It is 
also of note that p53 knock down derivatives of HBEC-3KT overexpress AURKA. Bars 
represent mean values for four independent repeats and error bars represent standard 
error of the mean. (B) mRNA expression of AURKA in HNSCC cell lines. The expression 
was variable among the HNSCC cell lines. Bars represent mean values for four 
independent repeats and error bars represent standard error of the mean. Human 
bronchial epithelial cell line (HBEC-3KT) was used as a technical calibrator. 
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Figure 3.4: Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer 
patients dichotomised by median AURKA mRNA expression. The p values were 
derived from Log Rank (Mantel-Cox) test. It is evident that high AURKA 
expression is associated with low survival. 
Chapter 3 
 121 
Overall survival (OS) analysis of patients in this cohort demonstrates that high expression 
of AURKA mRNA is associated with reduced survival, while worse prognosis was linked 
with cases whose tumours expressed AURKA transcripts at greatest levels (Table 3.1). 
When NSCLC histological subtypes were analysed separately, association of elevated 
AURKA transcripts with poor prognosis remains significant for both adenocarcinomas (p 
value = 0.025) and squamous carcinomas (p value = 0.029) (Table 3.1), (Figure 3.5). The 
data demonstrate that one-year prognostic outcome of 125 cases whom cancerous tissue 
expresses low levels of AURKA transcripts was 75% as opposed to 54% for those with high 
AURKA-mRNA expression based on median. Five-year survival for low expression of 
AURKA mRNA was 52% as opposed to 36% for high expression based on median. 
Similarly, ten-year survival was 30% of low expression and 17% of high expression. 
When taxane response was examined in NSCLC cell lines and HBEC derivatives, a similar 
trend was observed for paclitaxel with few differences. In general, all cancer cell lines 
except SKLU1 exhibited more response to docetaxel compared with paclitaxel (Figures 
3.6.1-7). Investigation of the half maximal inhibitory concentration (IC50) after treatment 
with (1-35 nM) of docetaxel and paclitaxel demonstrated that IC50 values in the cancer 
cell lines ranged from the more sensitive to docetaxel and paclitaxel which are CRL5807 
and CALU6 cell lines respectively, whereas  SKLU1 cell line was the most resistant to both 
taxanes (Table 3.2 ). Among HBEC isogenic derivatives, KRAS mutants showed higher 
sensitivity to both taxanes. KRAS wild types were almost twice as resistant as the KRAS 
mutants to the cytotoxic effect of both taxanes. Docetaxel IC50 values were around 4 nM 
to KRAS wild types as opposed to about 2 nM to the mutant. Similarly, paclitaxel IC50 
values were approximately 10-11 nM for wild type as opposed to 3-5 nM for mutant cells.  
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Table 3.1: Overall survival analysis in lung cancer patients in relation to AURKA mRNA expression. (a) High AURKA 
expression: >median, Low AURKA expression: ≤median. (b) Estimation is limited to the largest survival time if it is 
censored. 
 
Means and Medians for Survival Time in Months 
Histology 
AURKA 
expression 
Mean
b
 Median 
Estimate Std. Error 
95% Confidence 
Interval 
Estimate Std. Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
NSCLC 
 (both histologies) 
P value= 0.0079 
Low
a
 91.7 11.3 69.7 113.8 76.7 20.8 35.8 117.5 
High 61.3 8.6 44.5 78.1 32.0 11.0 10.4 53.6 
Adenocarcinoma 
P value= 0.025 
 
Low 81.3 13.1 55.7 107.0 52.8 19.8 14.0 91.6 
High 40.6 10.5 20.1 61.1 24.0 7.8 8.8 39.2 
SqCCL 
P value= 0.029 
Low 107.4 18.6 70.9 143.9 114.1 50.1 15.9 212.4 
High 66.6 10.4 46.3 86.9 38.8 15.6 8.3 69.4 
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Figure 3.5: Kaplan-Meier analysis of overall survival (OS) of lung cancer patients dichotomised by median AURKA mRNA expression. The 
correlation between AURKA expression and OS is significant in both adenocarcinomas (AdC) and squamous cell carcinomas (SqCCL). 
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Figure 3.6.1: Taxane response of HBEC isogenic derivative cells, HBEC-3KT (wild type 
parental) (A) and HBEC-3KT-R (K-ras mutant) (B). Both isogenic derivatives had a 
similar trend in their response to both taxanes, as both of them are more sensitive to 
docetaxel than paclitaxel. The mean and error values are for six technical replicates 
and that one of two independent experiments is shown. Error bars in both line graphs 
represent 95% confidence intervals. 
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Figure 3.6.2: Taxane response of HBEC isogenic derivative cells, HBEC-3KT-53 (p53 
knock out) (C) and HBEC-3KT-R53 with both aberrations (p53 knockout and K-ras 
mutant) (D). Both isogenic derivatives had a similar trend in their response to both 
taxanes, as both of them were more sensitive to docetaxel than paclitaxel. The mean 
and error values are for six technical replicates and that one of two independent 
experiments is shown. Error bars in both line graphs represent 95% confidence 
intervals. 
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Figure 3.6.3: Taxane response of lung cancer cell lines Calu-3 (A) and CALU6 (B). Calu-
3 cells showed more sensitivity to docetaxel than paclitaxel, while CALU6 responded 
similarly to both taxanes. The mean and error values are for six technical replicates 
and that one of two independent experiments is shown. Error bars in both line graphs 
represent 95% confidence intervals. 
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Figure 3.6.4: Taxane response of lung cancer cell lines (C) A549 and (D) CRL5807. Both 
cell lines demonstrated more sensitivity to docetaxel than paclitaxel. The mean and 
error values are for six technical replicates and that one of two independent 
experiments is shown. Error bars in both line graphs represent 95% confidence 
intervals. 
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Figure 3.6.5: Taxane response of lung cancer cell lines (E) SKLU1 and (F) SKMES1. 
SKLU1 exhibited more resistance to docetaxel than paclitaxel, while SKMES1 response 
to both taxane showed a trend of superior cytotoxicity of docetaxel, with more 
sensitivity to paclitaxel at doses above 30nM. Both cell lines demonstrated more 
sensitivity to docetaxel than paclitaxel. The mean and error values are for six 
technical replicates and that one of two independent experiments is shown. Error 
bars in both line graphs represent 95% confidence intervals. 
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Figure 3.6.6: Taxane response of lung cancer cell lines (G) CRL5082 and (H) LUDLU1. 
CRL5082 showed more sensitivity to docetaxel than paclitaxel, while LUDLU1 
responded similarly to both taxanes. The mean and error values are for six technical 
replicates and that one of two independent experiments is shown. Error bars in both 
line graphs represent 95% confidence intervals. 
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Figure 3.6.7(I): Taxane response of lung cancer cell line CORL23, which showed more 
sensitivity to docetaxel than paclitaxel. The mean and error values are for six 
technical replicates and that one of two independent experiments is shown. Error 
bars in both line graphs represent 95% confidence intervals. 
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Table 3.2: IC50 values and their respective confidence intervals (95%) in the normal and 
cancer cell lines after treatment with (1-35 nM) of docetaxel and paclitaxel. A range of 
sensitivities to both drugs were observed for NSCLC cancer cell lines. In non-
tumourigenic cell lines, there was a significant difference to docetaxel response 
between KRAS mutants and KRAS wild type cells. 
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In order to examine whether the cellular response to taxanes is related to growth rate of 
the studied NSCLC cell lines, cell growth curves were performed and exhibited variability 
in the growth rate of NSCLC cell lines (Figure 3.7). The data of the growth curves then 
were employed to calculate the growth doubling time for each cell line with their 
respective 95% confidence intervals (95%CI). The data demonstrated that the growth 
doubling time ranged the NSCLC cells from the slowest growing cell line (SKLU1) to the 
fastest growing one (CALU6) (Table 3.3). When I compared the growth rate values with 
taxane response in these cell lines using Spearman's rho analysis, the results showed that 
there was a significant correlation between growth doubling time and cellular response to 
docetaxel (Spearman's test, rho= 0.71,  p value = 0.032). Nevertheless, the growth 
doubling time was not significantly correlated with the response to paclitaxel. 
To investigate the effect of AURKA on the taxane response of NSCLC cell lines, AURKA 
mRNA expression was knocked down in three cancer cell lines (LUDLUE1, SKLU1 and 
SKMES1).  Two shRNAs (TRCN0000000656 and TRCN0000000657) effective at knocking 
down AURKA mRNA expression were identified from five different shRNA constructs by 
RT-qPCR analysis, with knockdown of AURKA transcript at different levels. LUDLU1 cell 
line was first selected based on the level of AURKA mRNA expression, which represents 
the highest overexpressing AURKA cell line, to knock down the expression of this gene. 
The knock down efficiency was about 50% (Figure 3.8.A). The knock down derivative 
clone (Aur-KD-LUD) was then exposed to docetaxel and paclitaxel along with parental 
cells. The exposure data demonstrate that AURKA down regulation leads to sensitisation 
of LUDLU1 to docetaxel and, to a lesser degree, to paclitaxel (Figure 3.8.B). This was the 
first interesting finding achieved from very beginning pilot transfection experiment. 
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Figure 3.7: Exponential line graphs demonstrating the growth curve for cells grown in 
DMEM culture medium. The growth analysis covered six days. 
 
 
 
  
Table 3.3: Doubling time values in (hr) and their respective confidence intervals 
(95%) in the normal and NSCLC cell lines calculated based on growth rate analysis 
shown in figure 3.7.  
Cell Line Doubling Time(hr) Doubling Time(hr) at 95%CI 
CALU6 30.20 27.59 to 33.36 
CRL-5807 36.77 30.77 to 45.69 
CORL-23 38.54 33.99 to 44.49 
CRL-5802 41.53 36.37 to 48.39 
A549 45.73 41.44 to 51.03 
Calu-3 92.85 69.69 to 139.1 
SKMES1 95.12 68.57 to 155.2 
LUDLU1 104.70 73.52 to 182.1 
SKLU1 136.40 96.12 to 234.9 
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Figure 3.8: AURKA mRNA expression of LUDLU1 cell line and its derivative knock down clone (A) in relation to 
their response to both taxanes (B). Error bars in both the expression bar chart and line graph represent 95% 
confidence intervals. –PAR: parental, KD: knockdown clone. 
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Although this cell line was the highest overexpressed AURKA among all of the tested cell 
lines, it was the most sensitive to both taxanes compared with other NSCLC cell lines. I, 
however, took this issue in consideration and next selected the most resistant cell line 
(SKLU1) in addition to the second most resistant cell line (SKMES1).  One of my objectives for 
this transfection experiment was to decrease the doses of the antimitotic drugs that would 
reduce the toxic therapeutic effects. The same dose range of taxanes used with LUDLU1 was, 
therefore, applied on SKLU1 and SKMES1 cell lines for this investigation. The knock down 
efficiency of AURKA transcript expression in SKLU1 cells was approximately (40-75) %. This 
result was confirmed by RT-qPCR (Figure 3.9.A). The MTT assay indicates that up to 17.5nM, 
docetaxel had lower effect on the proliferation of parental SKLU1 and its scrambled control. 
Interestingly, exposing AURKA knock down derivative clones to identical concentrations of 
docetaxel led to significant proliferative inhibition. Thus, it was possible to sensitise this cell 
line to docetaxel by reducing AURKA mRNA expression (Figure 3.9.B), while the inhibitory 
effect of exposing to paclitaxel was less significant (data not shown). Similarly, knocking 
down about (75-80) % of AURKA mRNA expression in SKMES1, confirmed by RT-qPCR 
analysis (Figure 5.10.A), resulted in marked inhibition in viability of knock down derivative 
clones in comparison of the parental and scrambled controls when exposed to identical 
concentrations of docetaxel (Figure 3.10.B). Paclitaxel exposure show only borderline 
significant difference between parental and knock down clones. Down regulation of Aurora 
kinase A in knock down derivative clones was also confirmed by western blotting analysis of 
the clones derived from SKLU1 (Figure 3.11 A) and SKMES1 (Figure 3.11.B). 
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Figure 3.9: AURKA mRNA expression of SK-MES1 cell line and its derivative knock down clones (A) in relation to its 
response to Docetaxel (B). Error bars in both the expression bar chart and line graph represent 95% confidence 
intervals. PAR: parental, -SCR: scrambled, -Bx-y: knockdown clones where x is the shRNA construct and y is the clone 
number from this transfection. 
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Figure 3.10: AURKA mRNA expression of SKLU1 cell line and its derivative knock down clones (A) in relation to its response 
to Docetaxel (B). Error bars in both the expression bar chart and line graph represent 95% confidence intervals. PAR: 
parental, -SCR: scrambled, -Bx-y: knockdown clones where x is the shRNA construct and y is the clone number from this 
transfection. 
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Figure 3.11: Western blot analysis of protein expression of Aurora kinase A and the internal control (α-tubulin) in parental and 
knockdown derivative clones for SK-MES1 and SKLU1. It is evident that scrambled construct clones (-SCR) have similar Aurora 
kinase A expression to that of parental (-PAR) cells while lower levels of expression are observed in the shRNA  knockdown 
derivative clones (SKL-A6-3, SKL-A7-2, SKM-A7-1, SKM-A6-5). 
Chapter 3 
 139 
 
In order to gain further evidence of Aurora kinase A down-regulation effect in sensitising 
NSCLC cells to docetaxel, The cellular response to Alisertib, which is a highly selective Aurora 
kinase A inhibitor, was first investigated in SKLU1 and SK-MES1 cell lines (Figure 3.12). 
Accordingly, the IC50 values of this kinase inhibitor were determined (6.3nM and 11.1nM for 
SKLU1 and SK-MES1 respectively). Expression of AURKA was then determined after treating 
SKLU1 and SK-MES1 cell lines with alisertib IC50 value of each and in different exposure time 
points. This kinase inhibitor had no significant effect on the expression level of mRNA 
transcripts in either cell line (Figure 3.13). After that, the cell lines were exposed to a range 
of docetaxel and paclitaxel concentrations (0-17.5) nM in combination with different 
concentrations of Alisertib (0, 5 and 10) nM. MTT analysis of taxane-alisertib treated cells 
illustrated that increased concentrations of Alisertib resulted in reduced resistance to 
docetaxel in both NSCLC cell lines but not paclitaxel (Figures 3.14). Although the line graph 
shows only a trend, the IC50 values docetaxel and their respective 95% CI of were 
significantly reduced in Alisertib dose-dependent manner in both cell lines (Table 3.4). 
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Figure 3.13: AURKA mRNA expression after alisertib exposure at IC50 concentrations in (A) 
SK-MES1 and (B) SKLU1 cell lines. No difference was shown in mRNA expression between 
alisertib-treated and non-treated cells. The mean and error values are for six technical 
replicates and that one of two independent experiments is shown. Error bars in both line 
graphs represent 95% confidence intervals. 
 
Figure 3.12: Alisertib response of SKLU1 and SKMES1 cell lines.  The mean and error 
values are for six technical replicates and that one of two independent experiments is 
shown. Error bars in both line graphs represent 95% confidence intervals. 
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Figure 3.14: Sensitivity of lung cancer cell lines to docetaxel in the presence of the highly 
selective Aurora kinase A inhibitor (Alisertib).  The mean and error values are for six 
technical replicates and that one of two independent experiments is shown. Error bars in 
both line graphs represent 95% confidence intervals. 
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In summary, AURKA mRNA expression in primary NSCLC tumours was up-regulated in lung 
cancer tissues in comparison to the normal adjacent lung tissue. No profile differences were 
observed in the primary NSCLCs among age, gender, stage or nodal involvement groups. 
High AURKA mRNA expression correlated with reduced survival in both adenocarcinomas 
and squamous cell carcinomas. The levels of AURKA transcripts were variable among NSCLC 
cell lines. However, they were higher than that in non-tumorigenic bronchial epithelial cell 
lines, HBEC-3KT. In HBEC isogenic derivatives, p53 knockout increases resistance to both 
drugs while KRAS mutation appears sensitize cells to treatment. In LUDLU1, SKLU1 and SK-
MES1, AURKA knock down resulted in a drop of docetaxel IC50 values. Chemical kinase 
inhibition of AURKA using the selective Aurora A kinase inhibitor, alisertib, was found to 
augment the cytotoxic efficiency of docetaxel. 
 
 
Table 3.4: IC50 values and their respective confidence intervals (95%) in SKMES1 & SKLU1 
after treatment with (0-17.5 nM) of docetaxel in presence of (0-10 nM) alisertib.  
 
Cell line Docetaxel  Alisertib (nM) IC50 IC50 (95% CI) 
 (-) 0 15.8 12.46 to 20.02 
SKMES1 (+) 5 10.08 8.304 to 12.23 
 (+) 10 6.206 5.249 to 7.338 
 (-) 0 15.81 13.92 to 17.95 
SKLU1 (+) 5 11.13 9.349 to 13.24 
 (+) 10 7.691 6.400 to 9.243 
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Chapter 4: Aurora B expression as a 
potential predictive biomarker for 
paclitaxel response in NSCLC 
The objective of this set of experiments was to test the AURKB expression in 
modulating the effectiveness of paclitaxel in NSCLC cells. Supporting evidence for this 
part of the study was based on the fact that selective inhibition of Aurora B kinase 
activity using barasertib (the highly selective Aurora B kinase inhibitor) in cancerous 
cells results in mitotic arrest, endoreplication and polyploidy leading to cell apoptosis 
(253). This kinase inhibitory effect of treated cells by barasertib may a result of failed 
mitotic cell division and endoreplication leading to polyploidy due to blocking of 
Histone H3 phosphorylation on serine 10, the most important substrate of Aurora B 
(254). Furthermore, polyploidy cells formed by Aurora B inhibition seem to develop 
cellular resistance to paclitaxel in breast cancer cell lines (255). 
mRNA expression profiling of AURKB in surgically resected human lung tissues from 
132 cases demonstrated significant overexpression of the gene transcript in tumour 
tissue compared with adjacent normal tissue (Mann-Whitney test, p<0.0001) (Figure 
4.1: A). This overexpression was more pronounced in SqCCL than AdCs (Mann-Whitney 
test, p<0.0001) (Figure 4.1: B). In addition, mRNA expression of AURKB was more 
elevated in higher pathological T stages (Figure 4.2), however this finding has to be 
treated with caution as the great majority of tumours in this sample set fall into the 
pT2 stage group (n=102), while the pT1 and pT3/4 groups comprised 19 and 12 
patients respectively. Kaplan-Meier analysis demonstrated that AURKB up-regulation 
Chapter 4 
 144 
did not incur a significant impact on overall survival (OS) in this clinical cohort, 
although a non-significant trend was demonstrated in adenocarcinoma patients (p 
value= 0.0787) (Figure 4.3). The findings show that one-year survival of lung 
adenocarcinoma patients whose tumours demonstrated decreased levels of AURKB 
mRNA was 79% as opposed to 47% for cases with elevated AURKB transcripts based on 
dichotomy at the median. 
Five-year prognostic outcome for low level of AURKA mRNA expression was 46% as 
opposed to 27% for those with high AURKA mRNA expression. Ten-year survival showed 
the worse prognosis, as tumours with low expression level of AURKA mRNA represent 
only 18% of cumulative proportion survival, while no patients were survive after this end 
of interval. No associations were found between AURKB mRNA expression and age, 
gender, clinical stage or nodal status.  
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Figure 4.1: Boxplots demonstrating AURKB mRNA expression in primary lung tumours compared to adjacent normal lung tissues (right) and in 
squamous cell carcinomas (SqCC) compared to adenocarcinomas (AdC) (left). P values are derived from Mann-Whitney tests. RQ was 
calculated using HBEC3KT cell line RNA as a calibrator. 
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Figure 4.2: AURKB mRNA expression in comparison with 
pathological T stages of lung cancer specimens. 
 
 
Figure 4.3: Kaplan-Meier analysis of overall survival (OS) of lung cancer patients 
dichotomised by median AURKB mRNA expression. AdC: adenocarcinoma; SqCC: 
squamous cell carcinoma of the lung. 
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AURKB mRNA expression profiling was also investigated in the panel of 9 lung cancer 
cell lines, along with the immortalized normal human bronchial epithelial cells (HBEC-
3KT and its isogenic p53 knockout and KRAS mutant derivatives). AURKB expression was 
variable among the lung tumourigenic cell lines, however, markedly higher in 
comparison to that of non-tumourigenic HBECs (Figure 4.4: A). It is of note that among 
HBECs, AURKB mRNA expression was higher in the p53 knockout derivatives 
(HBEC3KTp53 and HBEC3KTRp53) while a borderline reduction was seen in KRAS mutant 
cells (HBEC3KTR). Aurora B mRNA expression was also investigated in a panel of 14 
HNSCC cell lines (Figure 4.4: B). The expression was also variable among the tested cells. 
The IC50 values for paclitaxel and docetaxel toxicity among the available lung cell lines 
along with HBEC isogenic derivatives were determined following treatment with a range 
of concentrations (1 - 35 nM) of the two drugs as shown in chapter 3 (Figure 3.6.1-7) 
and (Table 3.2). As previously observed, IC50s for docetaxel were consistently lower 
than that of paclitaxel with one exception (SKLU1 cell line). Interestingly, mRNA 
expression of AURKB in NSCLC cell lines demonstrated an inverse correlation with 
resistance to both docetaxel (Spearman’s test, rho=- 0.883, p=1.6×10-3) and paclitaxel 
(rho= -0.800, p=9.6×10-3) (Figure 4.5). However, there was no association between the 
levels of AURKB transcripts in HNSCC cell lines and IC50 values of both taxanes. 
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Figure 4.4: AURKB mRNA expression in lung cancer and human bronchial epithelial 
cells (HBEC) cell lines. (A), and HNSCC cell lines (B). In general, the expression was 
variable among the examined cell lines. In NSCLC cells, the expression was higher than 
that of HBEC-3KT cells. Among HBECs, the expression was higher in the p53 knockouts 
(HBEC-3KTp53 and HBEC-3KTRp53) while a borderline reduction was seen in KRAS 
mutants (HBEC3KTR). HBEC-3KT was used as a technical calibrator in HNSCC cells. Bars 
represent mean values for four independent repeats and error bars represent standard 
error of the mean. 
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Figure 4.5: AURKB mRNA expression (RQ values) in NSCLC cell lines and sensitivity (IC50) to docetaxel and 
paclitaxel demonstrating an inverse correlation. The mean and error values are for six technical replicates 
and that one of two independent experiments is shown. Error bars represent 95% confidence intervals. 
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In order to further explore the possible modulation of taxane response by AURKB, The 
resistance of lung cancer cell lines to paclitaxel was investigated by (a) knocking down 
AURKB expression and (b) inhibiting its protein activity. Successful AURKB knock down 
clones were derived from A549 and SK-MES1 cells using five different shRNA constructs. 
Knockdown efficiency of AURKB mRNA expression was assessed by qPCR and Aurora 
kinase B down regulation was confirmed by western blotting (Figure 4.6: A and B).  The 
clones, as expected, demonstrated variable knock down efficiency. This efficiency 
ranged from 14% to 47% for SKMES1 and from 9% to 44% for A549 cell line. When I 
exposed these clones to paclitaxel, it was apparent that response to paclitaxel inversely 
correlated to the level of AURKB mRNA expression in a dose-dependent manner. This 
was true for both clones derived from A549 and 4 clones derived from SK-MES1 (p= 
0.038, rho= 0.7), while scrambled shRNA clones did not demonstrate altered response 
to paclitaxel when compared to the paternal cells (Figure 4.7).  
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Figure 4.6: AURKB mRNA expression of AURKB knock down derivative clones (designated –Bx-y, where x is the shRNA construct and y 
is the clone number from this transfection) and scrambled controls (designated –SCR) relatively to the parental lung cancer cell lines 
(A) SKMES1 and (B) A549 (designated –PAR). Bars represent mean values for four independent repeats and error bars represent 95% 
confidence intervals. 
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Figure 4.7: Paclitaxel response of lung cancer cell lines A549 and SK-MES1 and their AURKB knock down derivative clones in relation to AURKB 
mRNA expression. The figure demonstrates that cellular response to paclitaxel inversely correlated to the level of AURKB transcripts in a dose-
dependent manner in both tested cell lines. Error bars in the line graphs and expression bar charts represent 95% confidence intervals. –PAR: 
parental, -SCR: scrambled, -Bx-y: knockdown clones where B is AURKB, x is the shRNA construct and y is the clone number from this 
transfection. 
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In order to gain additional supporting evidence, selective inhibition of Aurora B protein 
activity was undertaken using a highly specific Aurora B inhibitor (Barasertib). After 
experimentally investigating barasertib response in lung cancer cell lines A549, SK-MES1 
and SKLU1 (Figure 4.8) and then determining the IC50s of this kinase inhibitor as 0.86 nM, 
1.2 nM and 2.3 nM respectively, the cell lines were simultaneously exposed to a range of 
paclitaxel concentration and different concentrations of barasertib. AURKB inhibition was 
confirmed by measuring phosphorylation of histone 3 serine 10 (H3S10), which is on one 
of its prime substrates, using different time-points of exposure (1, 2, 4, 8, 12, and 24) 
hour. The western blot analysis showed that the peak of barasertib effect was around the 
8hr exposure time of A549, while it was 12hr of SK-MES1 (Figure 4.9). In addition, I 
confirmed that barasertib exposure of A549, SK-MES1 and SKLU1 cell lines did not alter 
the mRNA expression of AURKB at the same exposure time-points (Figure 4.10). 
Barasertib-mediated AURKB inhibition clearly demonstrated a dose-dependent effect on 
paclitaxel efficiency; increased barasertib concentrations resulted in increased cellular 
resistance to paclitaxel in all of the three examined cell lines (Figure 4.11.1 and 2). 
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Figure 4.8: Barasertib response of lung cancer cell lines A549 and SK-MES1. The 
mean and error values are for six technical replicates and that one of two 
independent experiments is shown. Error bars in the line graphs represent 95% 
confidence intervals. 
 
Figure 4.9: Western blot analysis assessing phosphorylated Histone 3 Serine 10 
(H3S10P) levels after barasertib exposure for 4-24 hours in A549 (A) and SK-MES1 
(B) cell lines. “-”: untreated control; “+”:barasertib-treated cells. 
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Figure 4.11.1: Sensitivity of lung cancer cell lines (A) A549, (B) SK-MES1 and (C) SKLU1 to paclitaxel in the presence of the highly selective Aurora B 
inhibitor (Barasertib). Exposed cells simultaneously to a range of paclitaxel concentration and different doses of barasertib showed a dose-
dependent effect of barasertib-mediated AURKB inhibition on paclitaxel efficiency; increased barasertib doses led to increased paclitaxel 
resistance in all of these three cell lines . The mean and error values are for six technical replicates and that one of two independent experiments 
is shown. Error bars in the line graphs represent 95% confidence intervals. 
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Figure 4.11.2: Sensitivity of lung cancer cell lines (D) A549, (E) SK-MES1 and (F) SKLU1 to Docetaxel in the presence of the highly selective 
Aurora B inhibitor (Barasertib). Barasertib-mediated AURKB inhibition did not show a synergistic effect on paclitaxel efficiency in the tested cell 
lines except a trend of increasing SK-MES1 resistance to docetaxel at higher concentration of barasertib. The mean and error values are for six 
technical replicates and that one of two independent experiments is shown. Error bars in the line graphs represent 95% confidence intervals. 
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In summary, the present study demonstrated that frequent up-regulation of AURKB 
mRNA was observed in NSCLC tissue in comparison to normal adjacent lung tissue 
(p<0.0001), being more prominent in squamous carcinomas (p<0.0001), and higher stages 
tumors (p=0.012). AURKB overexpression in NSCLC cell lines strongly correlated with 
resistance to both docetaxel (p=0.0016) and paclitaxel (p=0.0096). AURKB knock down 
derivatives of two cell lines consistently showed a dose-dependent association between 
AURKB mRNA expression and resistance to paclitaxel. Inhibition of Aurora B activity by 
Barasertib also demonstrated a strong dose-dependent efficiency in triggering paclitaxel 
resistance in all of the cell lines tested. 
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Chapter 5: AURKA mRNA expression is 
an independent predictor of poor 
prognosis in patients with NSCLC 
 
Based on the prognostic values of AURKA and AURKB dysregulation, I analysed mRNA 
expression levels of further 8 of mitotic spindle associated genes (AURKC, CKAP5, TPX2, 
TTK, KIF11, DLGAP5, TUBB & TUBB3) in the available NSCLC tissues (56 adenocarcinomas, 
76 squamous cell carcinomas (SqCCL), and 44 adjacent normal tissues from 20 
adenocarcinoma and 24 SqCCL patients).  The role/effect of their expression status on the 
prognosis outcome was then tested in these cancer cases by preforming a univariate and 
multivariate analysis on the mRNA expression levels of all of the ten genes along with the 
clinicopathological features. In addition, the mRNA expression profiling of 
aforementioned genes was examined in the available NSCLC cancer cell lines and further 
thirteen HNSCC cell lines. The taxane response was also tested in these HNSCC cells in 
order to explore any possible correlation between mRNA expression of the gene and 
cellular response to taxanes in RTC cell lines.  
The results of mRNA expression for both NSCLC tumour samples and cell lines have 
already been given for AURKA and AURKB in chapters 3 and 4 respectively. Further qPCR 
analysis revealed that mRNA expression levels of all of the genes tested in this study 
(CKAP5, TPX2, TTK, KIF11, DLGAP5, TUBB & TUBB3) except AURKC were significantly 
overexpressed in NSCLC tissue compared to normal adjacent lung tissue (P < 0.0001) 
(Figure 5.1.1 and 2).  
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Figure 5.1.1: Box plots showing AURKC (A), CKAP5 (B), DLGAP5 (C) and KIF11 (D) mRNA expression in NSCLC tissues and adjacent normal 
tissues. Comparison between the samples showed that mRNA expression levels of the genes in NSCLC tumours are significantly higher than 
those in adjacent normal tissues, except that of AURKC. P values returned from Mann-Whitney test and adjusted for multiple comparisons by 
Bonferroni correction. 
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Figure 5.1.2: Box plots showing TPX2 (E), TTK (F), TUBB (G) and TUBB3 (H) mRNA expression in NSCLC tissues and adjacent normal tissues. 
Comparison between the samples showed that mRNA expression levels of the genes in NSCLC tumours are significantly higher than that in 
adjacent normal tissues. P values returned from Mann-Whitney test and adjusted for multiple comparisons by Bonferroni correction. 
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Comparison between histology types revealed that the mRNA expression of seven genes; 
AURKA, AURKB (already shown in chapters 3 and 4), DLGAP5, TPX2, TTK, TUBB, and KIF11 
(Figure 5.2) was more pronounced in squamous cell lung carcinoma (SqCCL) than in 
adenocarcinoma (AdCs) tissues (P < 0.0001; KIF11, p value = 0.01). 
The correlation between expression profiles of AURKA, AURKB, AURKC, CKAP5, TPX2, TTK, 
KIF11, DLGAP5, TUBB and TUBB3 and overall survival was then explored. In addition to the 
already demonstrated correlation between elevated mRNA expression of AURKA and 
AURKB with reduced survival either in whole NSCLC cases or in patients with lung 
adenocarcinomas respectively (chapters 3 and 4),  Kaplan-Meier analysis demonstrates 
that high TPX2 mRNA expression was borderline correlated with reduced overall survival in 
all of NSCLC individuals (p=0.055) ) (Figure 5.3.A). Analysis of the effect of TPX2 mRNA 
expression on proportion of patients surviving at the end of different intervals 
demonstrated that one-year survival of NSCLC cases, whose tumours showed low 
expression of TPX2 mRNA, was 74% as opposed to 58% for individuals with increased levels 
of TPX2 mRNA expression (dichotomy based on the median value). Five-year survival for 
low level of TPX2 mRNA expression was 45% as opposed to 43% for those with higher 
mRNA expression of TPX2. Similarly, ten-year survival proportion was 30% for those with 
low mRNA expression and 16% of patients survive with higher levels of TPX2 transcripts.  
Elevated levels of CKAP5 mRNA expression were significantly correlated with poor outcome 
in studied lung cancer individuals (p=0.01) (Figure 5.3.B). No correlation observed between 
the expression of the rest of the genes and overall survival (Appendix 8, A-H). The 
proportion of patients with lung adenocarcinoma that pronounced low levels of CKAP5 
transcripts surviving one year was 80%, whereas survival was 57% for those patients with 
tumours expressing high levels of these transcripts.  
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Figure 5.2: Boxplots demonstrating mRNA expressions of DLGAP5, KIF11, TPX2, TTK and TUBB genes in squamous cell carcinomas (sqCCL) and 
adenocarcinomas (AdC) of the lung.  Comparison between histology types showed that the mRNA expression levels of the genes in sqCCL tumours 
are significantly higher than that in AdC ones. P values returned from Mann-Whitney test and adjusted for multiple comparisons by Bonferroni 
correction. 
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Figure 5.3: Kaplan-Meier analysis of overall survival (OS) of lung cancer patients dichotomised by median mRNA expression of TPX2 in NSCLC 
tumours (A), CKAP5 (B) and DLGAP5(C) in adenocarcinomas of the lung. 
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Five and ten years survival were 52% and 20% respectively in of lung adenocarcinomas with 
lower CKAP5 mRNA expression, while these 5 and 10 year intervals were censored in highly 
CKAP5 mRNA expression tumours (i.e. the data about the patients survival duration is 
incomplete owing to loss to follow-up). Overexpression of DLGAP5 mRNA was marginally 
correlated with poor outcome in patients with lung adenocarcinomas (p=0.066) (Figure 
5.3.C). One and five year prognostic outcome in those patients whose cancerous tissues 
express decreased levels of DLGAP5 mRNA were 81% and 46% respectively as opposed to 
47% and 29% respectively for adenocarcinomas patients with higher levels of  DLGAP5  
mRNA expression. 
Of 132 patients analysed, only 124 had AURKA data available for analysis and this expression 
profile was the only one to show correlation with reduced survival in both adenocarcinomas 
and squamous cell carcinomas, while no significant correlation was observed of age, gender, 
tumour stage or nodal status (Table 5.1). This significant correlation with overall survival was 
observed in both univariate and multivariate analyses (Table 5.2). In univariate analysis, age 
(Hazard Ratio (HR), 1.02; 1.00-1.05, P=0.066), gender (HR, 1.23; 0.81-1.88, P = 0.326), 
pathological stages 2 (HR, 2.82; 1.35-5.86, P = 0.006), pathological stage ≥3 (HR, 3.80; 1.42-
10.15, P = 0.008), nodal status stage 1 (HR, 1.62; 1.03-2.55, P = 0.037) and nodal status stage 
2 (HR, 2.55; 1.35-4.84, P = 0.004)  were all predictors of overall survival. Multivariate analysis 
showed that AURKA mRNA expression (Hazard Ratio (HR), 1.81; 95%CI 1.16-2.84, P = 0.009), 
age (HR 1.03; 95%CI 1.00-1.06, P = 0.020), pathological stage 2 (HR 2.43; 95%CI 1.16-5.10, P 
= 0.019), and involvement of distal nodes (pN2) (HR 3.14; 95% CI 1.24-7.99, P =0.016) were 
independent predictors of poor prognosis in patients with NSCLC (Table 5.2). 
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Table 5.1: Clinicopathological characteristics of patients and AURKA mRNA expression  
Clinicopathological 
characteristics 
Total number 
of patients (%) 
High expression of  
Aurora-A  mRNA 
(n=59) 
Low expression of  
Aurora-A  mRNA 
(n=65) 
 
     P-values 
Mean Age (SD) 124(100) 65.9 (8.5) 67.5 (8.5) 0.223 
Gender 
Male 
Female 
 
70(56.5) 
54(43.5) 
 
37 (52.9) 
22 (40.7) 
 
33(47.1) 
32 (59.3) 
0.180 
Histology 
Adenocarcinoma  
Squamous cell carcinoma 
 
52(41.9) 
72(58.1) 
 
13 (25.0) 
46 (63.9) 
 
39 (75.0) 
26 (36.1) 
<0.0001 
Tumour stage 
Stage 1 
Stage 2 
≥Stage 3 
 
19(15.3) 
91(73.3) 
12(9.6) 
 
7 (36.8) 
45 (49.5) 
7(58.3) 
 
12 (63.2) 
46 (50.6) 
5(41.7) 
0.513 
Nodal status 
0 
1 
2 
 
68(54.8) 
38(30.6) 
18(14.6) 
 
32 (47.1) 
18 (47.4) 
9(50.0) 
 
36 (52.9) 
20 (52.6) 
9(50.0) 
0.975 
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Table 5.2: AURKA mRNA expression and overall survival of 124 NSCLC patients 
  
 
Univariate 
 
Multivariate 
  
  Covariates HR(95%CI)   P-values  HR(95%CI)   P-values   
  
AURKA mRNA 1.79(1.16-2.77) 
 
0.009 
 
1.81(1.16-2.84) 
 
0.009 
  
  
Age 1.02(1.00-1.05) 
 
0.066 
 
1.03(1.00-1.06) 
 
0.02 
  
  
Tumour stage 
       
  
  
Stage 1 Reference 
 
Reference 
 
Reference 
 
Reference 
  
  
Stage 2 2.82(1.35-5.86) 
 
0.006 
 
2.43(1.16-5.10) 
 
0.019 
  
  
≥Stage 3 3.80(1.42-10.15) 
 
0.008 
 
1.39(0.38-5.09) 
 
0.623 
  
  
Nodal status 
       
  
  
0 Reference 
 
Reference 
 
Reference 
 
Reference 
  
  
1 1.62(1.03-2.55) 
 
0.037 
 
1.45(0.90-2.34) 
 
0.128 
  
  
2 2.55(1.35-4.84)  0.004  3.14(1.24-7.99)  0.016 
  
  Univariate and multivariate Cox proportional Hazard regression analysis.   
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mRNA expression profiling was also tested in RTCs cell lines. The profiling of all of the 
genes investigated in a panel of 9 NSCLC cell lines from different histological origins 
(AdC, SqCC and large cell squamous carcinoma) along with non-tumourigenic 
immortalised bronchial epithelial cells (HBEC-3kt and its isogenic derivatives which are 
KRAS mutants, p53 knockouts, and cells with both aberrations). mRNA expression 
profiling of the gene penal (except AURKC transcripts) was significantly higher than that 
in HBEC-3kt in all of these cell lines except CKAP5 mRNA expression in only Calu-3 cell 
line. (Figures 5.4.1-4).  
In order to expand the sample size of cell lines, the mRNA expression profiling of the 
studied genes in  a panel of thirteen HNSCC cell lines (BHY, HN5, PE/CA-PJ15, PE/CA-
PJ41, UM-SCC-104, UM-SCC-12, UM-SCC-17as, UM-SCC-19, UM-SCC-4, UM-SCC-47, UM-
SCC-5, UM-SCC-81b and UPCI-SCC-090) in addition to primary HNSCC cells Liv7K (gift of 
Dr. Janet Risk) (Chapter 2, Table 2.1).  Similar to the trend already shown in lung cell 
lines, mRNA expression profiling of HNSCC showed  variable expression levels of gene 
transcripts, but in most cases was higher than that of the calibrator cell line HBEC-3KT 
(Figures 5.5.1-4).  
MTT analysis was used to measure cellular response to the taxanes after treatment of 
HNSCC cell lines with (0 -35 nM) of paclitaxel and docetaxel. This showed a similar trend 
to that seen in lung cancer cells of that docetaxel was superior in its inhibition of 
cancerous cells with few exceptions (Figures 5.6.1-7). Docetaxel IC50s values at 95% 
confidence intervals in most cell lines were lower than that of paclitaxel except for 
UMSCC-17as, UMSCC-104 and UPCI-SCC-090 (Figures 5.6.3 (F), 5.6.4 (H) and 5.6.7 (N)).   
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Figure 5.4.1: mRNA expression of AURKC (A), and CKAP5 (B) in human bronchial epithelial 
cells (HBEC) and lung cancer cell lines. Bars represent mean values for four independent 
repeats and error bars represent 95% confidence intervals. 
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Figure 5.4.2: mRNA expression of DLGAP5 (C) and KIF11 (D) in human bronchial epithelial 
cells (HBEC) and lung cancer cell lines. Bars represent mean values for four independent 
repeats and error bars represent 95% confidence intervals. 
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Figure 5.4.3: mRNA expression of TPX2 (E) and TTK (F) in human bronchial epithelial 
cells (HBEC) and lung cancer cell lines. Bars represent mean values for four independent 
repeats and error bars represent 95% confidence intervals. 
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Figure 5.4.4: mRNA expression of TUBB (G) and TUBB3 (H) in human bronchial epithelial 
cells (HBEC) and lung cancer cell lines. Bars represent mean values for four independent 
repeats and error bars represent 95% confidence intervals. 
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Figure 5.5.1:  mRNA expression of AURKC (A) and CKAP5 (B) in HNSCC cell lines. The 
expression was variable among the cell lines.  Bars represent mean values for four 
independent repeats and error bars represent standard error of the mean. Human 
bronchial epithelial cell line (HBEC-3KT) was used as a technical calibrator. 
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Figure 5.5.2:  mRNA expression of DLGAP5 (C) and KIF11 (D) in HNSCC cell lines and human 
bronchial epithelial cells (HBEC-3KT). mRNA expression of both gene was variable among 
the cell lines.  Bars represent mean values for four independent repeats and error bars 
represent standard error of the mean. Human bronchial epithelial cell line (HBEC-3KT) was 
used as a technical calibrator. 
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Figure 5.5.3:  mRNA expression of TPX2 (E) and TTK (F) in HNSCC cell lines and human 
bronchial epithelial cells (HBEC-3KT). mRNA expression of both gene was variable 
among the cell lines.  Bars represent mean values for four independent repeats and 
error bars represent standard error of the mean. Human bronchial epithelial cell line 
(HBEC-3KT) was used as a technical calibrator. 
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Figure 5.5.4:  mRNA expression of TUBB (G) and TUBB3 (H) in HNSCC cell lines and human 
bronchial epithelial cells (HBEC-3KT). mRNA expression of both gene was variable among 
the cell lines.  Bars represent mean values for four independent repeats and error bars 
represent standard error of the mean. Human bronchial epithelial cell line (HBEC-3KT) 
was used as a technical calibrator. 
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Figure 5.6.1: Taxane response of Head and Neck cancer cell lines (A) primary HNSCC 
cell line Liv-7K (B) BHY. Among all of studied cell lines (NSCLC, HNSCC and HBEC 
cells), Liv-7K primary cell line was the most sensitive one to both taxanes. BHY cell 
line was the 2nd most resistant among HNSCC cells. Generally, both cell lines are 
more sensitive to docetaxel than paclitaxel. The mean and error values are for six 
technical replicates and that one of two independent experiments is shown. Error 
bars in both line graphs represent 95% confidence intervals. 
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Figure 5.6.2: Taxane response of Head and Neck cancer cell lines (C) PE/CA-PJ15 (D) 
PE/CA-PJ41. Although PE/CA-PJ15 represents the 2nd most sensitive cell line 
docetaxel and paclitaxel and PE/CA-PJ41 is the 3rd one among all of studied cell 
lines, they are similar in their response to both taxanes. Generally, both cell lines 
are more sensitive to docetaxel than paclitaxel. The mean and error values are for 
six technical replicates and that one of two independent experiments is shown. 
Error bars in both line graphs represent 95% confidence intervals. 
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Figure 5.6.3: Taxane response of Head and Neck cancer cell lines (E) HN5 (F) 
UMSCC-104. While HN5 cell line more sensitive to docetaxel than paclitaxel as same 
as most other cell lines, UMSCC-104 has opposite trend, as it is more sensitive to 
paclitaxel than docetaxel. The mean and error values are for six technical replicates 
and that one of two independent experiments is shown. Error bars in both line 
graphs represent 95% confidence intervals. 
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Figure 5.6.4: Taxane response of Head and Neck cancer cell lines (G) UMSCC-12 (H) 
UMSCC-17. UMSCC-12 cells are more sensitive to docetaxel than paclitaxel similar 
to most other cell lines. In contrast, UMSCC-17 is more sensitive to paclitaxel than 
docetaxel. The mean and error values are for six technical replicates and that one of 
two independent experiments is shown. Error bars in both line graphs represent 
95% confidence intervals. 
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Figure 5.6.5: Taxane response of Head and Neck cancer cell lines (I) UMSCC-19 (J) 
UMSCC-4. In general, both cell lines are more sensitive to docetaxel than paclitaxel 
although taxane survival line graphs of UMSCC-4 cells show some overlapping in 
both taxane concentrations higher than 7.5 nM. The mean and error values are for 
six technical replicates and that one of two independent experiments is shown. 
Error bars in both line graphs represent 95% confidence intervals. 
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Figure 5.6.6: Taxane response of Head and Neck cancer cell lines (K) UMSCC-47 (L) 
UMSCC-5. The line graphs show the higher resistance of UMSCC-47 cell line to both 
taxanes. Generally, both cell lines are more sensitive to docetaxel than paclitaxel 
although taxane survival line graphs of UMSCC-47 cell line demonstrated some 
overlapping in response to both taxane at concentrations lower than 12.5 nM. The 
mean and error values are for six technical replicates and that one of two 
independent experiments is shown. Error bars in both line graphs represent 95% 
confidence intervals. 
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Figure 5.6.7: Taxane response of Head and Neck cancer cell lines (M) UMSCC-81B 
(N) UPCI-SCC-090. Similar with most other cell line, UMSCC-81B cell line is more 
sensitive to docetaxel than paclitaxel. However, UPCI-SCC-090 is the 3rd cell line that 
showing more sensitivity to paclitaxel than docetaxel in HNSCC group. The mean 
and error values are for six technical replicates and that one of two independent 
experiments is shown.  error bars in both line graphs represent 95%CI. 
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The MTT analysis demonstrated that the most resistant cell line among all of examined 
RTCs cells was UMSCC-47 with IC50 values 32.9nM and 17.1nM for paclitaxel and 
docetaxel respectively, while the primary cell line Liv-7K was the most sensitive one,  
with IC50 values of 0.1nM for docetaxel and 0.6nM for paclitaxel (Table 5.3). 
Based on a significant correlation observed between the expression of TPX2 and the 
doxetaxal IC50s of tested cell lines (Spearman’s test, rho=- 0.78, p=0.013), the effect of 
modulation of TPX2 mRNA expression on doxetaxal sensitivity in CALU6 cell line was 
analysed. The data obtained from performing TPX2 mRNA knock down showed that 
TPX2 down regulation has a lethal effect in these cells (Figure 5.7). Therefore, I was not 
been able to perform further investigation regarding the effect of TPX2 knock down. The 
lethal effect of TPX2 knockdown was confirmed through informal communication with 
Dr Linardopoulos at ICR London.  
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Table 5.3: Data demonstrating the IC50 values with their respective 95% confidence 
intervals. The data showed that the HNSCC cells are ranged in their response both 
taxanes from the most sensitive cell line (Liv-7K) in green to the most resistant one 
(UMSCC-47) in red. In general, most cell lines were more sensitive to docetaxel than 
paclitaxel with three exceptions (UMSCC-104, UMSCC-17as and UPCI-SCC-090) where 
they were more sensitive to paclitaxel than docetaxel.   
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Figure 5.7: Microscopic pictures depicting a clone derived from TPX2 shRNA-transfected CALU6 cells at different growth stages; (A) successful 
grown transfected single cell after 1 week of transfection. (B) first mitotic cell division of derived clone at week 2 (C) cell migration at week 3 
(D) nuclear division of divided clones at week 4 (E) multi nuclear division with failing in cytoplasmic division at week 5 (F) poly-nucleation and 
failing in completing mitosis at week 6(G) cell death after 7-8 weeks. The magnification was 200m for A, B and C, While 100m for D, E, F and 
G. 
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In summary, the findings of the present study showed that of the 10 genes examined, 
only AURKA was significantly associated with prognosis in NSCLC. Multivariate Cox 
regression analysis showed that AURKA mRNA expression (Hazard Ratio (HR), 1.81; 
95%CI 1.16-2.84, P = 0.009), age (HR 1.03; 95%CI 1.00-1.06, P = 0.020), pathological 
stage 2 (HR 2.43; 95%CI 1.16-5.10, P = 0.019), and involvement of distal nodes (pN2) (HR 
3.14; 95% CI 1.24-7.99, P =0.016) were independent predictors of poor prognosis in 
patients with NSCLC. Poor prognosis of those patients with high AURKA expression 
suggests they may benefit from therapy with AURKA inhibitors. TPX2 mRNA expression 
was associated with docetaxel IC50 values of tested cell lines (Spearman’s test, rho=0.7, 
p=0.036).  
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Chapter 6: Epigenetic sensitization of 
respiratory tract cancer cells to paclitaxel 
As epigenetic therapies have already been introduced into clinical cancer management 
(256), (257). I examined the potential sensitisation of lung and head and neck cancer cells 
to paclitaxel by two well-known epigenetic modifiers; the DNA methyltransferase (DNMT) 
inhibitor Decidabine and histone deacetylase (HDAC) class I inhibitor Valproic acid (VPA). 
These epigenetic modifiers can alter the response of cancer cells to paclitaxel treatment. 
Previous evidence suggested that VPA enhances paclitaxel cytotoxic effects in cancerous 
cells (258) due to HDAC6 deactivation, which results in tubulin hyperacetylation (259) and 
sensitises lung cancer cells to apoptosis (260). The combinatory effect of VPA-paclitaxel 
was also tested in HNSCC tumours (261). Aurora kinases also play a transcriptional 
regulatory role in HDAC inhibitors- mediated cytotoxicity in lung cancer cells (262). Recent 
reported data showed that enhancing p53 acetylation due to HDAC inhibition leads to 
enhance paclitaxel-induced apoptosis (263). In addition, a combination of VPA and 
decitabin has been introduced in clinical trials to treat NSCLC patients (256), (257). Based 
on aforementioned reported data, I investigated the epigenetic role of both the histone 
acetylator (VPA) and DNA methylator (decitabin) in sensitising RTC cells to paclitaxel.  
I next examined the cellular response to VPA alone in order to select the concentrations 
below IC50 for further investigation of VPA ability to sensitise cancerous cells to taxanes. 
MTT analysis of VPA exposure of lung cell lines (A549 and SKLU1) and the 2nd most 
paclitaxel resistant oral cancer cell line (BHY) demonstrated that these cells are resistant 
to very high VPA micro-molar concentrations (Figure 6.1) with IC50s of 6.63 mM of A549, 
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20 mM of SKLU1 and 2.1 mM of BHY) (Table 6.1) at 95% CI. In order to examine the ability 
of valproate to potentiate the anti-tumour efficacy of paclitaxel in controlling cellular 
viability, I used two different doses of valproate 0.5 mM and 1 mM that are below IC50s 
of all of these three cell lines. I utilised a fixed dose of paclitaxel (10 nM) which was also 
under the IC50s of the studied cell lines; 13.6 nM of A549, 16.7 nM of SKLU1 (Chapter 3, 
Table 3.2) and 14 nM of BHY (Table 6.1). The growth inhibitory effects of 1 mM VPA and 
10 nM paclitaxel were determined as optimal doses utilised either in combination or as 
successive treatments of the cell lines, A549, SKLU1 and BHY. The synchronous treatment 
of VPA and paclitaxel produced only a minor additive effect (Data not shown). In contrast, 
when VPA used to treat the cell for 48 hours prior to paclitaxel addition, a significant 
increase of the paclitaxel toxicity was observed in the subsequent 72 hours (Figure 6.2).   
Interestingly, mRNA expression of AURKA in BHY cell line was significantly reduced to 
around 65% after treatment with 1 mM VPA for 48 h (Figure 6.3). I also examined how the 
status of tumour suppressor gene p53 could affect the paclitaxel sensitisation of HBEC cell 
lines to paclitaxel. The results demonstrated that the VPA exhibited more efficiency in 
sensitising p53 wild type HBEC cells to paclitaxel than that exhibited in sensitising p53 
knockouts and thus p53 expression seems to increase the cytotoxic effect of paclitaxel 
after course exposure to 0.5 mM VPA although pre-treatment of HBECs with 1 mM VPA 
shows different trend (Figure 6.4). The efficiency of decitabine treatment of A549 was 
determined at different concentrations (50, 100 and 200 M) by measuring the global 
methylation levels (LINE1 element) (Figure 6.5). This agent showed a dose-dependent 
efficiency to demethylate A549 cellular DNA (Figure 6.6). Although decitabine was 
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Figure 6.1: MTT line ghraph showing the cellular survival rates of lung (A549 and 
SKLU1) and HNSCC (BHY)  cell lines to VPA. Error bars were represent 95% 
confidence intervals. 
 
 
Table 6.1: The data demonstrating the IC50 values of VPA in A549, SKLU1 and BHY 
cell lines and their respective 95% CI. The results demonstrate that SKLU1 cell line is 
the most resistant to VPA with IC50 value 20 mM VPA, while BHY is the most 
sensitive one IC50 value 2.1 mM VPA. 
 
 
Chapter 6 
 190 
 
Figure 6.2: Bar charts of cytotoxic effects of 48-hour treatment with 1 mM VPA flowed 
by 72 hours of 10 nM paclitaxel on A549 (A), BHY (B) and SKLU1 (C) cell lines. 
Interestingly, SKLU1 cell line exhibited more response to paclitaxel after 48hr exposure 
to VPA. BHY showed different trend of response to treatment of VPA and paclitaxel 
separately compared to A549 and SKLU1 cell lines. Error bars represent 95% confidence 
intervals. 
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Figure 6.3: AURKA mRNA expression in VPA-treated BHY cells with 1mM 
concentration compared with non-treated in comparison with HBEC-3KT control. 
VPA treatment seems to reduce AURKA expression to around 65%. Error bars were 
represented 95% confidence intervals.   
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Figure 6.4: Bar charts of cytotoxic effects of 48-hour treatment with 1 and 0.5 mM VPA 
flowed by 72 hours of 10 nM paclitaxel on HBEC-3KT (A) and HBEC-3KT-p53 (B) cell lines. 
P53 wild type HBEC cells showed more response to 10nM paclitaxel after 48 hr exposure 
to 0.5 mM VPA compared to p53 knockouts. However, increasing VPA concentration to 
1mM no more effect in HBEC-3KT as opposed to more effect in HBEC-3KT-p53. Error 
bars were represented 95% confidence intervals. 
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Figure 6.5: Pyrograms of LINE1 global methylation analysis demonstrating the cellular 
DNA methylation status of A549 cell line  in the absence (A) and presence (B) of 
decitabine at 200 mM. 
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Figure 6.6: The bar chart demonstrating the change in the methylation status of 
LINE-1 following treatment of A549 with the demethylating agent decitabine at 
different concentration (0, 50, 100 and 200) M. The results showed that reduction 
of the methylation level correlated with increasing decitabine dose. Error bars 
represent standard error of the mean. 
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efficient in reducing global LINE methylation, it did not sensitise any of the cell lines to 
paclitaxel when used either in a synchronous (Figure 6.7) or in a preceding manner (data 
not shown). In order to provide insight into the inability of decitabine to sensitise cell 
lines to paclitaxel, I investigated the methylation status of the different gene promoters 
tested in this study. The pyrosequencing analysis demonstrated that none of the gene 
promoters examined in this study demonstrated altered methylation status; in fact, all of 
promoters were unmethylated in all of tumour and normal tissues tested (Figures 6.8). 
In summary, VPA was an effective epigenetic sensitizer for treating lung and head and 
neck cancerous cells (A549, SKLU1 and BHY). 48 hours prior to paclitaxel addition, a 
significant increase of the paclitaxel toxicity was observed when the cancer cells pre-
treated with VPA for 48hr and subsequently with paxlitaxel for 72 hours.  Interestingly, 
mRNA expression of AURKA was reduced by VPA treatment. The result also demonstrated 
that p53 status was involved in VPA- mediated paclitaxel sensitisation of HBEC cell lines to 
paclitaxel. VPA seems to potentiate p53 wild type cells (HBEC-3KT) to paclitaxel, while p53 
HBEC knockouts showed less cytotoxic effect of paclitaxel after exposure to 0.5 mM VPA.  
On the other hand, decitabin was not efficient to sensitise any of the cell lines to 
paclitaxel when used in either a synchronous or a preceding manner. In addition, the 
pyrosequencing analysis of the methylation status of the different gene promoters in the 
lung tumour and normal tissues showed that all of the promoters were unmethylated. 
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Figure 6.7: MTT line graphs showing the sensitivity of A549 (a), SKLU1 (b) and (c) SKMES1 cell lines to paclitaxel in the presence of differing 
concentrations of decitabine (0, 50 and 100 M. The data of showed no significant difference in cellular response to treatment with 
paclitaxel alone or in combination with decitabine. Error bars were represented 95% confidence intervals. 
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Figure 6.8: representative programs showing DNA methylation status of KIF11 gene 
promoter in (A) tumour and (B) normal lung samples. The figures show that the gene 
promoters were unmethylated in both malignant and normal tissues of the lung. 
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Chapter 7: Discussion 
Mitotic spindle formation and spindle checkpoint are extremely important for the 
maintenance of correct cell division. The accurate chromosome alignment and their proper 
attachment to the mitotic spindle are ensured by spindle checkpoint, prior to chromosome 
segregation (183), (184). Taxanes are anti-mitotic agents, commonly used in a variety of 
human cancers including those of the lung (138) and head and neck (139). Their limited 
clinical success is largely due to development of resistance by the neoplastic cells. 
However, despite the clinical use of taxanes for almost two decades in cancer therapeutics, 
little is still known about the mechanisms contributing to this resistance and thus potential 
response predictors to taxane-based regimens. The present study demonstrated that both 
AURKA and AURKB are potential modulators for taxane resistance in RTCs cells, despite 
their reciprocal prediction to these antimitotic agents. The findings collectively 
demonstrated a high potential for further exploitation of the spindle assembly associated 
genes in developing prediction biomarkers for clinical use. 
7.1 Aurora kinase A involvement in docetaxel resistance in NSCLC 
Aurora kinase A is frequently upregulated in many malignancies and its oncogenic activity 
implicated in malignancy transformation of cancerous tissues (196). This study 
demonstrated the frequent mRNA over-expression of AURKA in NSCLC cells and tissues 
compared with normal ones. My findings confirmed the previously reported data of AURKA 
overexpression of in NSCLC (264), and similar to other findings (209). AURKA mRNA 
overexpression was more evident in SqCC than AdC. However, the information on the 
prognostic value of AURKA in this tumour type remains to be examined.  In present study a 
significant correlation was established between the elevated levels of AURKA transcripts 
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and shortened overall survival in NSCLC patients. In contrast to data from (265), the 
negative prognostic significance of AURKA expression in my data holds true for both 
histological subtypes. A consensus on this issue is missing, with some groups reporting that 
levels of Aurora A are associated with poor prognosis in SqCC (210), while others do not 
(209). Furthermore, perimembrane IHC staining was shown as a strong predictor of poor 
prognosis in SqCC, but not in AdC patients (206), while recent microarray data analysis 
demonstrated that AURKA mRNA overexpression is associated with poor prognosis in AdC 
but not SqCC (265). Therefore, recent published data demonstrates the inconsistencies in 
the field, probably due to differences in the study designs, methodology of Aurora A 
expression assessment and the occasional inclusion of therapy stratification in the survival 
outcome. However, in my study, mRNA levels of AURKA were associated, and thus may be 
considered as a candidate prognostic biomarker, in both histological subtypes.  
The functional part of this study has clearly demonstrated that suppression of AURKA 
mRNA expression, using shRNA-specific knock down, increased docetaxel response in 
NSCLC cells. AURKA suppression dependent differential docetaxel cytotoxicity has been 
previously shown in esophageal squamous cell carcinoma (ESCC) (266), prostate cancer 
cells in vitro (267) and in vivo  (268), renal cell carcinoma (RCC) cells (269) and breast 
cancer cells (270), however this is the first such report to my knowledge on lung cancer 
cells. The present study is also in agreement with previously reported data, which showed 
that combined docetaxel with alisertib-based AURKA deactivation resulted in increased 
docetaxel anti-tumour activity in upper gastrointestinal adenocarcinomas (271), breast 
cancer (272) and mantle cell lymphoma (273). It was also reported that co-treatment with 
docetaxel and MK-5108, another selective Aurora A kinase inhibitor, in NSCLC cell lines, 
(274) and HeLa cells in in vitro and in vivo (275) enhanced cytotoxic effect of docetaxel. 
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AURKA suppression induces aneuploidy, polyploidy, and mitotic perturbation in cells and 
thus cancerous cells exposure to alisertib increases proportion of polyploidy cells leading to 
mitotic catastrophe (271). Docetaxel perturbs spindle assembly and function due to 
microtubule stabilisation and activates SAC. It induces either aberrant mitosis then 
aneuploidy at low concentration or sustained mitotic arrest then mitotic slippage at higher 
concentrations forming polyploidy cells (276). AURKA overexpression enables the 
polyploidy cells to abrogate the SAC and confer resistance to taxanes (277). Cellular 
exposure to docetaxel accumulates cells in the G1 cell cycle stage, activating SAC and then 
apoptotic pathways (276) accompanying the p53 induction (269). AURKA-overexpressing 
cells can easily override a transient and weak SAC activation induced by low docetaxel 
concentrations (278). However, AURKA suppression leads to prolonged activation of 
docetaxel-induced SAC that subsequently accelerates mitotic exit due to mitotic slippage. 
These cells re-enter G1 phase with a tetraploid genome and multinucleated phenotype 
(279). These cells then undergo endoreduplication process due to hyper-karyokinesis 
forming polyploidy cells   (272) And this eventually leads to apoptosis due to induction p53 
and its target bax (267). This mechanism was described in NSCLC cell lines as a result to 
integration of docetaxel treatment and selective Aurora A kinase inhibition by MK-5108 
(274). 
Despite the fact that the previous studies employed either shRNA-based suppression of 
AURKA mRNA or alisertib-mediated deactivation of Aurora A kinase in enhancement of 
docetaxel antitumor activity in a number of cancers, employing of which method in 
sensitising NSCLC cells to docetaxel has not yet been examined. This study, therefore, 
provide functional evidence demonstrating the AURKA involvement in the efficiency of 
docetaxel. These results suggest that AURKA could be used two-fold in the clinical 
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management of lung cancer: (a) as response prediction biomarker for paclitaxel based 
therapy for NSCLC cancer and (b) by using AURKA selective inhibitors to sensitise tumours 
to docetaxel treatment. Docetaxel was clinically approved for NSCLC therapy since last 
decade, (280), while alisertib has very recently clinically approved in treatment of RTC 
including NSCLC and HNSCC (281). Assuming that my findings in modulation of cellular 
response to taxanes could be reproduced in NSCLC cases, then a potential scheme of 
stratifying those patients to taxane-involving schemes could be explained as a scatter plot 
model (Figure 7.1).  As shown in this model, most cases could potentially benefit from 
integrative therapy of both docetaxel-alisertib combination and paclitaxel-based therapy as 
an effective therapeutic manoeuvre could apply on NSCLC patients whom tumours 
overexpressed AURKA. This may also give good prognostic outcome. While additional 
preclinical work can provide further support, alisertib has already gained FDA approval, 
therefore clinical trials can simultaneously start being designed. 
7.2 Aurora kinase B expression can predict response of NSCLC to paclitaxel 
Aurora kinase B is an important contributor to the mitotic spindle assembly and its 
overexpression in human cancer has been frequently reported (282), (283), (284), 
therefore attracting the interest both in cancer biology and cancer therapeutics fields. In 
this study, it is hypothesized that Aurora B activity may be implicated in modulating cellular 
response to taxanes, due to its function in microtubule stabilisation. mRNA profiling of the 
surgical non-small cell lung tumour cohort confirmed the extensive overexpression of this 
gene, which has previously reported  (207), (211), (212). In contrast to Vischioni et al and 
Takeshita et al, who profiled NSCLC tumour for Aurora B protein by IHC, I did not observe 
significant associations between AURKB expression and clinicopathological factors (211), 
(207). This may suggest that post translational regulation may contribute to this difference, 
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as it is probable that the protein expression may not accurately reflect the level of mRNA 
expression for a particular gene. Nevertheless, two other studies attempted to correlate 
AURKB mRNA expression with the clinicopathological data; one has not found a significant 
association between these data and the mRNA expression (212), while the second 
conducted this correlation by testing more than one cohort; one cohort showed a clear link 
while the second, however, has not revealed that marked link  (213). 
I also analysed AURKB mRNA expression profiling in nine NSCLC cell lines from different 
histologic subtypes; SqCCL, LAdC and Large cell lung carcinoma in addition to HNSCC cell 
lines. This screening intended to confirm the expression patterns identified in primary lung 
cancer tissues earlier, as well as to investigate the potential involvement of AURKB in 
cellular resistance to taxanes. In consistence with previously reported data (285), the 
present study demonstrated that AURKB is frequently overexpressed in lung cancer cells in 
comparison with immortalised non-tumorigenic HBECs. This may reflect the potency of 
upregulated Aurora B in overriding mitotic spindle checkpoint and its overexpression 
seems to be the driving power behind aneuploidy formation during cancer progression via 
augmented mitotic phosphorylation of histone H3 at Serine-10 (286). 
The outcome of taxane response in most RTCs cells showed that the IC50 values for 
docetaxel were consistently lower to those of paclitaxel except SKLU1 from NSCLC cells and 
UMSCC-17as, UMSCC-104 and UPCI-SCC-090 from HNSCC cells. These results are in 
agreement with previously reported data in in vitro, ex vivo and in vivo study (175) as well 
as randomized phase III clinical study (176).  Regarding the HNSCC cell lines (UMSCC-17as, 
UMSCC-104 and UPCI-SCC-090), the possible explanation for this difference may due to the 
difference in HPV status in these cell lines. It has been recently investigated HPV status in 
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these HNSCC cell lines and reported that most of the cells are HPV negative except UPCI-
SCC090 and UMSCC-104 (287), (288)  but also UMSCC-47. In addition, HPV status of 
UMSCC-17as is not reported. Therefore, this may partially explain the results and further 
investigation is warranted in this regard.   
The findings have also provided clear evidence of correlation between the AURKB 
overexpression of NSCLC cell lines with response to paclitaxel. However, there was no 
correlation detected between the expression and taxane response in HNSCC. This may due 
to the difference in the origin of both cell types. Interestingly, low levels of mRNA 
expression of AURKB in NSCLC cell lines were observed to correlate with resistance to both 
taxanes. However, functional experiments involving knockdown and chemical inhibition of 
AURKB demonstrated a stronger involvement of AURKB in paclitaxel rather than docetaxel 
cytotoxicity. This may support my hypothesis that AURKB is a potential predictor for 
paclitaxel-based regimen for treating lung cancer. Docetaxel induced-apoptosis occurs at 
100 fold lower concentrations than that of paclitaxel (179) with higher affinity for β-tubulin 
(180), and broader cell cycle effectiveness in three phases (S/G2/M) compared with two 
(G2/M) for paclitaxel. However, paclitaxel, occasionally, manifests more anti-tumour 
activity (177). The reason behind this variation is not fully understood. Docetaxel mainly 
targets centrosome organization leading to incomplete mitosis and cell damage in S phase 
with partial toxic effect during mitosis. It is known that AURKA is mainly involved in 
centrosome maturation (214), (196), whereas paclitaxel affects the mitotic spindle causing 
cell death (182). This difference in site of action may explain some difference in their 
efficacy in killing cancer cells and may also give insight on my finding of that the substantial 
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difference of both Aurora A and B down regulation involvement in taxane-based 
treatment.    
In order to functionally test the hypothesis in this chapter, two different approaches were 
followed, the cell sensitivity to paclitaxel was first measured after establishing AURKB 
knockout derivative clones from A549 and SK-MES1 employing multiple shRNA constructs. I 
then went on to inhibit Aurora B protein activity in these cell lines along with SKLU1 using 
highly selective Aurora B inhibitor (Barasertib). Similarly to cellular inhibitory effects of 
other selective Aurora B inhibitors such as Hesperadin (169) and ZM447439 (170), very low 
levels of barasertib resulted in significant cytotoxicity to lung cancer cells (IC50 0.9-2.3 nM). 
Barasertib treated cells may undergo failed mitotic cell division and endoreplication leading 
to polyploidy due to blocking of Histone H3 phosphorylation on serine 10, the most 
important substrate of Aurora B (254) , (253). The key role of mitotic spindle checkpoint is 
to ensure that the metaphase-to-anaphase transition is not occurred until an accurate 
attachment of sister kinetochores to spindle microtubules is happened in correct 
biorientation (289). This amphitelic attachment is promoting by Aurora kinase B that 
localises in the inner centromeric gap/region, midway between kinetochore pairs, during 
mitosis.  
Aurora B mutation (290), inhibition using small-molecule inhibitor, or depletion using small 
inhibitory RNA (169) leads to chromosomal missegregation due to increasing synthetic 
attachment of microtubules with kinetochore pairs, in spite of remaining a full capability of 
mitotic spindle to attach to sister kinetochores and pull them on (169), (291). 
It was reported that depletion of Aurora B selectively using Hesperadin in presence of 
paclitaxel leads to abrogating this checkpoint (169). It was also reported that Aurora kinase 
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B inhibition using AT9283 could be targeted to increase cellular response to antimitotic 
agents. This kinase inhibition causes slowing or arrest of the cell growth during mitosis 
when co-treating either with paclitaxel (292) or with docetaxel (293). AT9283, however, is a 
dual kinase inhibitor of both Aurora A & B. This combinatory effect could be due to 
inhibitory effect of AT9283 on both kinases. While Curry et al do not consider the 
possibility of Aurora A inhibition by AT9283 and suggest employing Aurora B inhibition to 
potentiate paclitaxel’s effect, Qi et al referred to a possible role for Aurora A inhibitory 
effect of AT9283 in sensitising cells to docetaxel. Likewise, I could argue that (294) study of 
depicting the enhancing of taxane antitumor activity by AMG 900, the pan Aurora kinase 
inhibitor, was merely caused by inhibiting Aurora B kinase activity.  In addition, all of the 
three aforementioned studies lack of supporting evidence that could further prove their 
explanation in favour of Aurora B, for instance using specific Aurora B-RNA interference 
(RNAi) to gain that evidence. Therefore, identifying ATP competitive molecules that inhibit 
Aurora B selectively may make the high homology degree among Aurora kinases (295) less 
challenging. 
The selective Aurora kinase B inhibitors, such as barasertib (254) Hesperadin (169) and 
ZM447439 (170), induce mitotic arrest and polyploidy leading to apoptosis in leukaemia 
cells. This occurs in the same Aurora B inhibition dependent manner regardless of the 
Aurora B expression level. The kinase inhibitory effect of each selective inhibitor is 
different, for example the inhibitory effect of barasertib is higher than that of ZM447439 
(296). Supporting evidence from (169) and (170) studies can assist interpretation of my 
findings, i.e. that both AURKB down-regulated clones and barasertib-treated cells 
demonstrated resistance to paclitaxel. Paclitaxel arrests cells by activating mitotic spindle 
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checkpoint in the presence of Aurora b activity, which maintains a dynamic rhythm 
between attached kinetochore with those unattached (169), (170).  Anaphase onset is 
initiated by activating anaphase-promoting complex (APC). This activated complex is 
supressed by the mitotic spindle checkpoint if any sister kinetochore is incorrectly attached 
with spindle microtubules. This improper attachment recruits mitotic spindle checkpoint 
components, such as kinetochore-associated protein Mad2, to deactivate APC (169). Like 
other spindle checkpoint regulators, Mad2 localises to unattached kinetochores and this 
localisation is indispensable for spindle assembly checkpoint signalling (221), Although 
Aurora B inhibition reduces high proportion of kinetochore-associated protein Mad2 (297), 
the residual attached protein may be sufficient to maintain the mitotic checkpoint in 
absence of  kinetochore–microtubule interactions and/or tension. If microtubule 
occupancy is adequate for unattached kinetochore then this could inactivate MSC and, in 
turn, activate APC to promote anaphase onset (170).  
Accordingly, the possible explanation of why paclitaxel-treated cells cannot be arrested in 
the absence of Aurora B function could be that the stabilising syntelic kinetochore, and 
may be monotelic, attachments increase the possibility of inhibiting mitotic checkpoint 
signalling in paclitaxel-exposed cells caused by Aurora b deactivation using Barasertib. This 
is possibly because all kinetochores gradually accumulate depolymerized attached 
microtubules (298). Therefore, no free-attached Mad2 that could inhibit APC by the mitotic 
checkpoint thus co-treated cells enter anaphase and, eventually, exit mitosis. 
In addition to the qualitative Aurora B inhibition that could results in abolishing the spindle 
assembly checkpoint in paclitaxel-arrested cells, the findings clearly demonstrated the 
quantitative effect of this inhibition in paclitaxel efficacy. Lower levels of Aurora B 
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decreased response to paclitaxel in all of the three cell lines, but intermediate levels of 
Aurora B had an intermediate effect on paclitaxel resistance. Therefore, the response to 
paclitaxel seems to rely on the level of Aurora B activity. The outcomes are keeping with 
(90); this study reported that decreased Aurora B activity, using either selective inhibition 
or mutation, raised the cellular resistance to paclitaxel. Interestingly, when Aurora B 
activity is only slightly increased (in the kinase activation defective mutant compared to the 
kinase-binding defective mutant), it appears to intensify the response to low dose 
paclitaxel, but Aurora B activity is not necessary for response to high doses of paclitaxel 
(90). 
In conclusion, the results confirm previous reports on the significant overexpression of the 
AURKB in NSCLC tissue and its association with NSCLC patient survival, pointing to a 
potential exploitation for therapeutic stratification of NSCLC patients into taxane-involving 
regimens. I have shown that high AURKB expression is associated with sensitivity to 
paclitaxel and that AURKB inhibition or down-regulation leads to paclitaxel resistance.  
The important translational message from this study is that; while AURKA inhibitors could 
be utilised in combination with docetaxel to overcome the resistance demonstrated by 
many lung tumours that overexpress Aurora kinase A, AURKB inhibitors should be avoided 
if treating with paclitaxe. Nontheless, high AURKB expression could benefit as a candidate 
biomarker for stratification of lung cancer patients to paclitaxel therapy (Figure 7.1). The 
molecular basis of these interactions is described in my proposed model presented in 
Figure 7.2.  
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Figure 7.1: A scatter plot demonstrating potential taxane therapeutic scheme based on the coordinated mRNA 
expression of both AURKA and AURKB in the screened NSCLC tissues. The top left quartile represents the NSCLC tissues 
cases with high level of mRNA AURKB expression and low AURKA transcripts. These cases would benefit from paclitaxel 
only involving regimen. Most cases are located in the top right quartile. These tumours overexpress both kinases and 
may require simultaneous treatment with combination of docetaxel and alisertib. NSCLC cases at the bottom left 
quartile would not be eligible for neither taxane nor alisertib therapies. 
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Figure 7.2: Proposed model explaining the different roles of AURKA and AURKB in 
molecular modulation of docetaxel and paclitaxel cytotoxicity respectively in lung 
cancer cells: (A) Both AURKA inhibition by alisertib (or down-regulation by shRNA) and 
docetaxel treatment affect centrosome organisation in the S phase resulting in G2/M 
arrest and forming  tetraploid and polyploid cells that undergo apoptosis. Meanwhile, 
both paclitaxel and up-regulated AURKB activate mitotic spindle checkpoint in 
metaphase causing mitotic arrest and eventually apoptosis; (B) AURKA over 
expression overrides the mitotic spindle checkpoint activated by docetaxel leading to 
docetaxel-resistant tetraploid cells that continue to divide. On the other hand, AURKB 
inhibition by barasertib (or down-regulation by shRNA) results in MSC disassembly 
leading to cellular resistance to paclitaxel. 
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7.3 AURKA mRNA expression is an independent predictor of poor prognosis 
in patients with NSCLC 
Mitotic spindle formation is a key process for cell proliferation (199). It is well known that 
spindle assembly aberrations lead to aneuploidy and are heavily involved in cancer 
development (190). I thus hypothesised that the expression of genes related to this 
process may be indicative of the aggressiveness of a tumour and therefore might be used 
for prognostication.  
In the present study, the mRNA expression profiling of AURKA, AURKAB, AURKC, CKAP5, 
DLGAP5, KIF11, TPX2, TTK, TUBB and TUBB3 was investigated in a large cohort of human 
NSCLC and queried potential associations between expression profiles and 
clinicopathological characteristics including survival. All of the genes, except AURKC, were 
overexpressed in malignant tissues compared to normal adjacent ones. Taken together, 
my results suggest that up-regulation of mitotic spindle genes is a common abnormality in 
NSCLC and may explain its important contribution in lung tumour aggressiveness (196).  
Of the 10 genes examined, only AURKA overexpression was associated with poor 
prognosis. Multivariate Cox regression analysis showed that AURKA mRNA expression, age, 
pathological stage and involvement of distal nodes were independent predictors of poor 
prognosis in patients with NSCLC.  
AURKA overexpression may play an important role in cancer aggressiveness through a 
range of mechanisms. Elevated levels of AURKA perturb mitotic spindle formation and thus 
cytokinesis due to centrosome amplification, aneuploidy and chromosomal instability 
(214), (196). When overexpressed, AURKA also inactivates the activity of several tumour 
suppressor genes including p53 (215).  The association between AURKA overexpression 
and p53 mutation as well as high tumour grade and high cancer stage was also reported in 
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patients with hepatocellular carcinoma (216) and with clinically aggressive disease and 
reduced survival in ovarian cancer (217). These AURKA-related events, the perturbation of 
spindle formation and inactivation of tumour suppressor genes by elevated AURKA, may 
explain my established association between up-regulated AURKA and poor outcome of 
NSCLC patients. Nonetheless, the notion that up-regulated AURKA contributes to a poor 
outcome in lung cancer has been debated, presumably because NSCLC represents a set of 
heterogeneous malignancies (218), with differing outcomes, even amongst those with the 
same clinopathological features.  
The kinase activity of Aurora A is regulated by Targeting Protein for Xenopus kinesin-like 
protein 2 (TPX2) through their interaction during mitosis (240). At the end of mitotic cell 
division, both Aurora A (241) and TPX2 (242) are degraded by the anaphase promoting 
cyclosome/complex E3 ubiquitin ligase. TPX2 expression was differentially detected in 
cancerous lung tissues and not in normal lung tissue (243). Investigation of the distinctively 
higher expression of TPX2 in mitotic phases of cell cycle led to the suggestion it may serve 
as a biomarker for cancer prognosis (244). Several studies on TPX2 expression have 
demonstrated the potential prognostic value of this gene when overexpressed in lung 
cancer using different approaches either as independent marker by immunohistochemistry 
(245), or as a part of 5 gene cluster/ panel signature (P < 0.001, HR = 2.84) employing lung 
adenocarcinoma microarray data sets (69), (208). Nevertheless, TPX2 mRNA involvement 
in NSCLC prognosis has not been previously investigated independently in lung cancer 
cases. 
Aurora A recruits the interaction between the CKAP5 encoded protein, colonic and hepatic 
Tumour Over-expressed Gene (ch-TOG), and TACC3 to centrosomes and proximal spindle 
microtubules (229). ch-TOG up regulation in cancer was first demonstrated by Charrasse et 
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al 1995 in liver and colon tumours compared with the corresponding normal tissues (230). 
However, no reported data that show such association between CKAP5 expression and 
survival in cancer patients or could potentially prognosticate the disease outcome. 
Therefore, my results warrant further investigation of exporting the CKAP5 role in 
predicting survival in cancer patients including lung cases. 
DLGAP5, which reported as the most closely related to AURKA expression (233), was first 
described by Tsou et al 2003 as an up-regulated transcript in hepatocellular cancer and 
called Hepatoma Up Regulated Protein (HURP) (232). HURP is a kinetochore microtubule-
associated protein that mediates Ran-GTP-dependent mitotic spindle assembly, promoting 
microtubule polymerization and spindle formation, activating chromosome congregation 
and alignment during mitosis in normal and cancer cells (233). Increased expression levels 
of DLGAP5 are related to tumour aggressiveness in several cancers such as hepatocellular 
carcinoma (234), adrenocortical tumours (235), and meningioma (23). Up-regulation of 
DLGAP5, which is correlated with poor prognosis in liver (237) and prostate (238) cancers, 
showed a borderline trend (p=0.067) with poor outcome in lung cancer cases involved in 
my study. My data, therefore, may suggest further investigation of the potential 
prognostic value of DLGAP5-mRNA expression in lung cancer. 
In conclusion, Overexpression of AURKA, AURKB, CKAP5, DLGAP5 and TPX2 were 
associated with poor prognosis of NSCLC patients in different degrees. However, only 
AURKA mRNA overexpression can prognosticate the clinical outcome in NSCLC patients 
using univariate and multivariate models could be useful in the management of NSCLC. 
This may also have application for developing of targeted therapy for lung carcinoma; 
patients with high AURKA expression may benefit from therapy with AURKA inhibitors to 
have good prognosis. 
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7.4 Epigenetic sensitization of respiratory tract cancer cells to paclitaxel 
Epigenetic therapies and epigenetic sensitization of cancer cells to common 
chemotherapeutics have come to focus in the last decade (30), (176). As sensitization to 
taxanes was a major objective in my thesis, I examined the potential of modulating 
paclitaxel efficiency using two epigenetic modifiers; valproic acid to induce histone 
acetylation and decitabin to induce global DNA hypomethylation. Both epigenetic drugs in 
used as a combination treating patients with lung and head and neck in phase I clinical 
studies (256), (257) which demonstrated that decreased DNA methylation and induction of 
histone acetylation were associated with prolonged stable disease for 6 months as a 
median (4-12 months). 
This part of the study commenced later in year three and produced only pilot data that 
warrant further investigation. The data obtained demonstrated that pre-treatment of 
three different RTC cell lines with VPA sensitised these cells to paclitaxel, while decitabin 
has no such sensitising effect. The maximum concentration that has been used in this 
study was corresponded to levels in the plasma of patient treated for epilepsy that ranged 
from (30-111) mg/L as opposed to (0.2 – 0.8) mM and exhibited low risk side effects (299), 
while resulting in histone acetylation (300).  These findings are consistent with Chen et al, 
who established that VPA enhanced paclitaxel response in resistant human lung 
adenocarcinoma cells but in dose-dependent manner (218), but in contrast to Erlich et al, 
who could not deduce that VPA can potentiate the cytotoxic effect to paclitaxel in HNSCC 
cells (261). This inconsistency probably exists because the researchers did not try to pre-
treat the cells with VPA prior paclitaxel treatment rather they examined only the VPA-
paclitaxel combination. However, my finding demonstrated a minor effect of VPA and 
paclitaxel in RTC cells. This epigenetic sensitisation of cancer cells to paclitaxel might result 
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through induction of apoptosis due to enhancement of tubulin acetylation (259). Although 
paclitaxel–induced apoptosis in NSCLC is well documented and p53-independent, (301), 
(302), (303), (304), following the finding that VPA pre-treatment potentiates paclitaxel 
cytotoxic effect in RTC cell lines, I investigated whether VPA-mediated paclitaxel 
cytotoxicity is associated with p53 status. The results indicated that p53 status was a 
determinant of epigenetic sensitisation of HBEC cells to paclitaxel cytotoxicity. It was 
evident that 0.5 mM VPA enhanced paclitaxel activity in p53 wild type HBEC cells but to a 
lesser extent in the p53-knockout derivatives. However, increased VPA dose to 1mM 
showed similar paclitaxel sensitising effect in both p53 wild type and p53 null cells. Further 
investigation is required to provide compelling evidence on the exact mechanism of p53 
involvement on VPA-based sensitization of paclitaxel.  
The present study also demonstrated that VPA exposure of BHY cells led to the reduction 
of AURKA mRNA expression. This suggests that AURKA transcription is under epigenetic 
control (305). While the mechanism behind VPA-mediated sensitisation to paclitaxel is still 
unclear, the reduction of AURKA expression may be one of the mediators as thoroughly 
discussed in the previous chapters.  
In conclusion, the results indicate that HDAC inhibitors could be beneficial in sensitising 
RTC cells to paclitaxel, which is a very common and inexpensive chemotherapeutic agent. 
Such sensitisation could lead to lowering the effective dose of paclitaxel and subsequently 
reducing the adverse effects of this drug to the patient. Additional preclinical and clinical 
evidence is required to provide further support to my observation. The great advantage of 
VPA is that it is in routine clinical use for many years demonstrating minor side effects. 
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Further research is required to establish the exact molecular mechanisms modulating this 
epigenetic sensitisation of cancer cells to paclitaxel. 
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Appendices 
 
Appendix 1: Publication/communication material out of this study.  
1. A manuscript on AURKB modulation has been recently reviewed by the Journal of 
Thoracic Oncology and the comments are currently dealt with.    
2. Four posters have been presented in the following conferences: 
 A Al-Khafaji, P Pantazi, J Risk, R Shaw, J Field, T Liloglou. mRNA signature of the 
mitotic spindle gene members in predicting taxane response for non-small cell lung 
carcinomas. B14. NCRI Cancer Conference, 3-6 Nov 2013, Liverpool, UK. 
 P Pantazi, A Al-Khafaji, A Acha Sagredo, A Schache, T Liloglou. Upregulation of HURP 
gene expression in Head and Neck cancer and its clinical impact. v international 
symposium “advances in oral cancer”,  10-11 Jul 2014, Bilbao, Spain. 
 A Al-Khafaji, S Ali, J Field, T Liloglou. AURKA involvement in paclitaxel resistance in 
non-small cell lung cancer. B54. NCRI Cancer Conference, 2 - 5 Nov 2014, Liverpool, 
UK. 
 A Al-Khafaji, J Risk, R Shaw, J Field, T Liloglou. Epigenetic sensitization of respiratory 
tract cancer cells to paclitaxel. 627. EAS2015 conference, 20-23 Jun 2015, Florence, 
Italy.
Appendices 
 240 
Appendix 2: Clinicopathological characteristics of the patients included 
in this study. 
 
No. Sex Age Histology pT pN Clinical stage 
1 Female 70 AdC 1 0 IA 
2 Male 50 AdC 1 0 IA 
3 Male 67 AdC 1 0 IA 
4 Female 77 AdC 1 0 IA 
5 Female 80 AdC 1 0 IA 
6 Female 77 AdC 1 0 IA 
7 Female 79 AdC 1 0 IA 
8 Female 63 AdC 1 0 IA 
9 Male 67 AdC 2 0 IB 
10 Female 66 AdC 2 0 IB 
11 Female 65 AdC 2 0 IB 
12 Female 67 AdC 2 0 IB 
13 Female 69 AdC 2 0 IB 
14 Female 71 AdC 2 0 IB 
15 Male 49 AdC 2 0 IB 
16 Male 54 AdC 2 0 IB 
17 Male 76 AdC 2 0 IB 
18 Male 73 AdC 2 0 IB 
19 Female 69 AdC 2 0 IB 
20 Male 76 AdC 2 0 IB 
21 Male 74 AdC 2 0 IB 
22 Female 74 AdC 2 0 IB 
23 Female 74 AdC 2 0 IB 
24 Male 74 AdC 2 0 IB 
25 Male 75 AdC 2 0 IB 
26 Female 75 AdC 2 0 IB 
27 Female 78 AdC 2 0 IB 
28 Female 49 AdC 2 0 IB 
29 Female 55 AdC 2 0 IB 
30 Male 62 AdC 2 0 IB 
31 Male 68 AdC 2 0 IB 
32 Female 61 AdC 1 1 IIA 
33 Male 73 AdC 2 1 IIA 
34 Male 60 AdC 2 1 IIB 
35 Female 61 AdC 2 1 IIB 
36 Female 60 AdC 2 1 IIB 
37 Female 66 AdC 2 1 IIB 
38 Male 70 AdC 2 1 IIB 
39 Female 73 AdC 2 1 IIB 
40 Male 63 AdC 2 1 IIB 
41 Male 67 AdC 2 1 IIB 
Appendices 
 241 
42 Male 78 AdC 2 1 IIB 
43 Female 68 AdC 2 1 IIB 
44 Male 64 AdC 3 0 IIB 
45 Male 70 AdC 2 1 IIB 
46 Male 70 AdC 2 2 IIIA 
47 Male 67 AdC 3 1 IIIA 
48 Female 66 AdC 2 2 IIIA 
49 Male 71 AdC 3 2 IIIA 
50 Male 47 AdC 2 2 IIIA 
51 Male 67 AdC 2 2 IIIA 
52 Female 60 AdC 3 2 IIIA 
53 Female 73 AdC 2 2 IIIA 
54 Female 68 AdC 3 2 IIIA 
55 Male 68 AdC 4 2 IIIB 
56 Female 71 AdC 2 1 IIIB 
57 Female 69 SqCCL 1 0 IA 
58 Male 54 SqCCL 1 0 IA 
59 Male 55 SqCCL 1 0 IA 
60 Male 77 SqCCL 1 0 IA 
61 Male 57 SqCCL 1 0 IA 
62 Male 73 SqCCL 1 0 IA 
63 Female 73 SqCCL 1 0 IA 
64 Female 58 SqCCL 2 0 IB 
65 Female 79 SqCCL 2 0 IB 
66 Male 70 SqCCL 2 0 IB 
67 Female 69 SqCCL 2 0 IB 
68 Female 71 SqCCL 2 0 IB 
69 Male 66 SqCCL 2 0 IB 
70 Male 63 SqCCL 2 0 IB 
71 Male 57 SqCCL 2 0 IB 
72 Male 69 SqCCL 2 0 IB 
73 Male 74 SqCCL 2 0 IB 
74 Male 73 SqCCL 2 0 IB 
75 Female 56 SqCCL 2 0 IB 
76 Male 73 SqCCL 2 0 IB 
77 Female 50 SqCCL 2 0 IB 
78 Male 66 SqCCL 2 0 IB 
79 Male 71 SqCCL 2 0 IB 
80 Male 76 SqCCL 2 0 IB 
81 Female 61 SqCCL 2 0 IB 
82 Male 77 SqCCL 2 0 IB 
83 Male 80 SqCCL 2 0 IB 
84 Male 71 SqCCL 2 0 IB 
85 Male 54 SqCCL 2 0 IB 
86 Female 71 SqCCL 2 0 IB 
87 Male 77 SqCCL 2 0 IB 
88 Female 70 SqCCL 2 0 IB 
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89 Female 71 SqCCL 2 0 IB 
90 Male 76 SqCCL 2 0 IB 
91 Male 75 SqCCL 2 0 IB 
92 Female 78 SqCCL 2 0 IB 
93 Male 63 SqCCL 2 0 IB 
94 Male 76 SqCCL 2 0 IB 
95 Male 70 SqCCL 2 0 IB 
96 Male 60 SqCCL 2 0 IB 
97 Male 65 SqCCL 2 0 IB 
98 Male 75 SqCCL 1 1 IIA 
99 Female 54 SqCCL 1 1 IIA 
100 Male 46 SqCCL 1 1 IIA 
101 Female 51 SqCCL 2 1 IIB 
102 Female 60 SqCCL 2 1 IIB 
103 Female 50 SqCCL 2 1 IIB 
104 Male 70 SqCCL 2 1 IIB 
105 Male 79 SqCCL 2 1 IIB 
106 Male 74 SqCCL 2 1 IIB 
107 Male 70 SqCCL 2 1 IIB 
108 Female 70 SqCCL 2 1 IIB 
109 Male 56 SqCCL 2 1 IIB 
110 Male 69 SqCCL 3 0 IIB 
111 Female 45 SqCCL 2 1 IIB 
112 Male 73 SqCCL 2 1 IIB 
113 Female 60 SqCCL 2 1 IIB 
114 Male 68 SqCCL 2 1 IIB 
115 Male 59 SqCCL 2 1 IIB 
116 Female 73 SqCCL 2 1 IIB 
117 Male 82 SqCCL 2 1 IIB 
118 Male 58 SqCCL 2 1 IIB 
119 Female 66 SqCCL 2 1 IIB 
120 Female 63 SqCCL 2 1 IIB 
121 Female 77 SqCCL 2 1 IIB 
122 Male 51 SqCCL 2 1 IIB 
123 Male 64 SqCCL 2 2 IIIA 
124 Male 69 SqCCL 3 1 IIIA 
125 Male 62 SqCCL 3 2 IIIA 
126 Male 63 SqCCL 3 2 IIIA 
127 Female 66 SqCCL 3 2 IIIA 
128 Male 50 SqCCL 2 2 IIIA 
129 Male 74 SqCCL 2 2 IIIA 
130 Female 58 SqCCL 3 2 IIIA 
131 Male 68 SqCCL 2 2 IIIA 
132 Female 71 SqCCL 2 2 IIIA 
 
MPI: master patient index, AdC: adenocarcinoma of the lung, SqCCL: squamous cell 
carcinoma of the lung. 
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Appendix 3: Representative data of cell line authentication determined by DNA fragmentation analysis using  
GenePrint 10 System 
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Appendix 4: Representative pyrosequencing assay design and its analysis 
report for detection methylation status of KIF11 gene promoter. The forward 
biontinylated (Fb), reverse (R) and Sequencing (S) primers were designed 
using PyroMark assay design 2.0 software. 
 
 
Appendices 
 245 
Appendix 5 (A): The sequencing confirmation of AURKB cDNA sequence on pCMV6-XL4-AURKB/Bsd recombinant 
plasmid analysed on 3130 Genetic Analyzer. 
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Appendix 5 (B): The map of genetically engineered plasmid pCMV6-XL4-
AURKB-Bsd highlighting the insertion site of BSD gene. 
GGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGG
AACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATGGGAATTCAGACATGATAAGATACATTGATGAGTTTGGACAA
ACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTG
CAATAAACAAGTTTCGAGGTCGAGTGTCAGTCCTGCTCCTCGGCCACGAAGTGCTTAGCCCTCCCACACATAACCAGAGGGCA
GCAATTCACGAATCCCAACTGCCGTCGGCTGTCCATCACTGTCCTTCACTATGGCTTTGATCCCAGGATGCAGATCGAGAAGC
ACCTGTCGGCACCGTCCGCAGGGGCTCAAGATGCCCCTGTTCTCATTTCCGATCGCGACGATACAAGTCAGGTTGCCAGCTGC
CGCAGCAGCAGCAGTGCCCAGCACCACGAGTTCTGCACAAGGTCCCCCAGTAAAATGATATACATTGACACCAGTGAAGATGC
GGCCGTCGCTAGAGAGAGCTGCGCTGGCGACGCTGTAGTCTTCAGAGATGGGGATGCTGTTGATTGTAGCCGTTGCTCTTTCA
ATGAGGGTGGATTCTTCTTGAGACAAAGGCTTGGCCATGGTTTAGTTCCTCACCTTGTCGTATTATACTATGCCGATATACTA
TGCCGATGATTAATTGTCAACACGGTCCGTTCCAATGCACCGTTCCCGGCCGCGGAGGCTGGATCGGTCCCGGTGTCTTCTAT
GGAGGTCAAAACAGCGTGGATGGCGTCTCCAGGCGATCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGT
ACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAA
ACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAA
ACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCA
TAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTG
GGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTG
ACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGGACCTCGAGCTAGCGATA
TAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATT 
 
The inserted sequence above include CMV promoter, EM7 promoter, BSD gene SV40 
polyadenylation signal sequences. BSD gene carries the blasticidin resistant characteristic as 
a selective marker that employed to select AURKB overexpressed clones derived from 
transfected parental Calu-3 cell line. The map was build using SnapGene Viewer software. 
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Appendix 6: AURKB mRNA expression of Calu-3 cell line and its derivative overexpressed clones (A) in relation to 
their response to both taxanes (B). 
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Appendix 7: mRNA expression of AURKC, CKAP5 and TUBB3 in lung cancer tissues. 
 
Boxplots demonstrating mRNA expressions of AURKC (A), CKAP5 (B) and TUBB3 (C) genes in squamous cell carcinomas 
(sqCCL) and adenocarcinomas (AdC) of the lung. 
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Appendix 8(A): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients 
dichotomised by median AURKB mRNA expression. The p value was derived from Log Rank 
(Mantel-Cox) test. 
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Appendix 8(B): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by 
median AURKC mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(C): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median CKAP5 
mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(D):  Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median 
DLGAP5 mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(E):   Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median KIF11 
mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(F): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median TTK 
mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(G): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median TUBB 
mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
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Appendix 8(H): Kaplan-Meier analysis of overall survival (OS) of NSCLC cancer patients dichotomised by median TUBB3 
mRNA expression. The p value was derived from Log Rank (Mantel-Cox) test. 
 
 
